TWI583692B - Nucleoside phosphoramidates - Google Patents

Nucleoside phosphoramidates Download PDF

Info

Publication number
TWI583692B
TWI583692B TW104102544A TW104102544A TWI583692B TW I583692 B TWI583692 B TW I583692B TW 104102544 A TW104102544 A TW 104102544A TW 104102544 A TW104102544 A TW 104102544A TW I583692 B TWI583692 B TW I583692B
Authority
TW
Taiwan
Prior art keywords
ml
1h
mixture
solution
mmol
Prior art date
Application number
TW104102544A
Other languages
Chinese (zh)
Other versions
TW201518313A (en
Inventor
布魯斯S 羅斯
麥克J 索菲亞
加那佩堤R 帕穆拉佩堤
蘇古納 拉查肯達
張海仁
千炳權
王培源
Original Assignee
基利法瑪席特有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US17992309P priority Critical
Priority to US31951310P priority
Application filed by 基利法瑪席特有限責任公司 filed Critical 基利法瑪席特有限責任公司
Publication of TW201518313A publication Critical patent/TW201518313A/en
Application granted granted Critical
Publication of TWI583692B publication Critical patent/TWI583692B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI583692(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/242Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/55Synthetic design, e.g. reducing the use of auxiliary or protecting groups

Description

Nucleoside phosphoniumamine Field of invention

The present application claims priority to U.S. Provisional Patent Application No. 61/179,923, filed on May 20, 2009, and the priority of U.S. Provisional Patent Application No. 61/319,513, filed on The content is incorporated for reference.

Disclosed herein are nucleoside amino phosphates and their use as agents for the treatment of viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are effective as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication, and for the treatment of hepatitis C infection in mammals.

Background of the invention

Hepatitis C virus (HCV) infection is a major health problem that results in chronic liver disease such as cirrhosis and hepatocellular carcinoma in a large number of infected individuals estimated to be 2-15% of the world's population. According to the US Centers for Disease Control, there are an estimated 4.5 million infected people in the United States alone. According to the World Health Organization, there are more than 200 million infected individuals in the world, and at least 3 to 4 million people are infected each year. Once infected, about 20% of people will clear it The virus, but the rest of the population may have HCV for the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop cirrhosis or cancer that destroys the liver. The viral disease is transmitted from contaminated blood and blood products by gastrointestinal infections, contaminated needles, or sexually transmitted infections, and to the offspring of infected mothers or mothers of the original. Current treatment for HCV infection is limited to immunotherapy with recombinant interferon alpha alone or with the riboside analog ribavirin, which has limited clinical benefit. In addition, there are no established vaccines for HCV. Therefore, there is an urgent need for an improved therapeutic agent that is effective against chronic HCV infection.

The HCV virion is a set of membrane positive-strand RNA viruses having a single-stranded oligoribonucleotide gene sequence of about 9600 bases encoding a polyprotein of about 3,010 amino acids. The protein product of the HCV gene consists of structural proteins C, E1 and E2 as well as the non-structural proteins NS2, NS3, NS4A and NS4B, and NS5A and NS5B. Non-structural (NS) proteins are believed to provide catalytic mechanisms for viral replication. The NS3 protease releases NS5B, which is an RNA-dependent RNA polymerase from the polyprotein chain. HCV NS5B polymerase is required for the synthesis of double-stranded RNA from single-stranded viral RNA, which serves as a template in the HCV replication cycle. Therefore, NS5B polymerase is considered to be an essential component in HCV replication complexes (K. Ishi, et al, Heptology , 1999, 29 : 1227-1235; V. Lohmann, et al., Virology , 1998, 249: 108). -118). Inhibition of HCV NS5B polymerase prevents the formation of double-stranded HCV RNA and thus constitutes an attractive pathway for the development of HCV-specific antiviral therapy.

HCV belongs to a larger family of viruses with many common features.

Flaviviridae Viruses

The yellow fever virus includes at least three different genera: pestiviruses , which cause disease in cattle and pigs; flavivruses , which are major virulence factors such as dengue and yellow fever; Hepaciviruses , whose main member is HCV. The yellow fever virus genus includes more than 68 members, which are divided into groups based on serological associations (Calisher et al., J. Gen. Virol , 1993, 70, 37-43). Clinical symptoms vary and include fever, encephalitis, and hemorrhagic fever ( Fields Virology , Editors: Fields, BN, Knipe, DM, and Howley, PM, Lippincott-Raven Publishers, Philadelphia, PA, 1996, Chapter 31, 931-959). The worldwide concern for yellow fever viruses associated with human diseases includes dengue hemorrhagic fever virus (DHF), yellow fever virus, shock syndrome, and Japanese encephalitis virus (Halstead, SB, Rev. Infect. Dis. , 1984, 6, 251-264). Halstead, SB, Science , 239:476-481, 1988; Monath, TP, New Eng . J. Med , 1988, 319 , 641-643).

Plague virus genus includes bovine viral sputum virus (BVDV), typical swine fever virus (CSFV, also known as swine cholera virus), and sheep border disease virus (BDV) (Moennig, V.et Al. Adv. Vir. Res. 1992, 41, 53-98). The plague virus infection of domesticated livestock (bovine, pig and sheep) has caused enormous economic losses worldwide. BVDV causes bovine mucosal disease and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, HJ, Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir .Res. 1992, 41, 53-98). Human plague virus is not as broad as animal plague virus. However, serological surveys indicate that a significant number of plague viruses are exposed to humans.

In the yellow fever virus family, the plague virus and the hepatitis virus are closely related virus groups. Other closely related viruses in this family include GB virus A, GB virus A analog, GB virus-B, and GB virus-C (also known as hepatitis G virus, HGV). The hepatitis virus group (hepatitis C virus; HCV) consists of a number of closely related but genotypically different, human-infected viruses. There are at least 6 HCV genotypes and more than 50 seed types. Due to the similarity between plague virus and hepatitis virus, and the poor ability of hepatitis virus to grow efficiently in cell culture, bovine viral sputum virus (BVDV) is often used as a substitute for studying HCV virus.

The genetic structures of the plague virus and the hepatitis virus are very similar. These positive-stranded RNA viruses have a single large open reading frame (ORF) that encodes all viral proteins required for viral replication. These proteins are expressed as a polyprotein that is co-translated and post-translated by proteases encoded by both cells and viruses to produce mature viral proteins. The viral protein responsible for the replication of viral genomic RNA is located approximately within the carboxy terminus. Two-thirds of this ORF is referred to as a non-structural (NS) protein. The genetic structure of the non-structural protein portion of the plague virus and the ORF of the hepatitis virus and the multiprotein treatment are very similar. For both plague and hepatitis viruses, the mature non-structural (NS) protein, from the amine end of the non-structural protein coding region to the carboxy terminus of the ORF, consists of p7, NS2, NS3, NS4A, NS4B , NS5A and NS5B.

The plague virus and the NS protein of the hepatitis virus share a sequence region with specific protein functional features. For example, the NS3 protein of the virus in both groups has the motif of the amino acid sequence of the serine protease and the helicase (Gorbalenya et al., Nature, 1988 , 333 , 22; Bazan and Fletterick). Virology , 1989, 171, 637-639; Gorbalenya et al., Nucleic Acid Res., 1989 , 17 , 3889-3897). Similarly, the plague virus and the NS5B protein of hepatitis virus have the modularity of RNA-directed RNA polymerase (Koonin, EV and Dolja, VV, Crir. Rev. Biochem. Molec. Biol. 1993, 28, 375-430).

The actual roles and functions of the plague virus and the NS protein of the hepatitis virus in the viral life cycle are directly similar. In both examples, the NS3 serine protease is responsible for all proteolytic processing of the polyprotein precursor downstream of its position in the ORF (Wiskerchen and Collett, Virology , 1991, 184, 341-350; Bartenschlager et al., J. Virol. 1993, 67, 3835-3844; Eckart et al. Biochem . Biophys . Res. Comm . 1993, 192, 399-406; Grakoui et al., J. Virol. 1993, 67, 2832-2843; Grakoui et al., Proc. Natl. Acad Sci. USA 1993, 90, 10583-10587; Hijikata et al., J. Virol. 1993, 67, 4665-4675; Tome et al., J. Virol. , 1993, 67, 4017-4026 ). In both cases, the NS4A protein acts as a cofactor for NS3 serine protease (Bartenschlager et al., J. Virol. 1994, 68, 5045-5055; Failla et al., J. Virol. 1994, 68, 3753-3760; Xu et al., J. Virol. , 1997, 71: 5312-5322). The NS3 proteins of both viruses also act as helicases (Kim et al., Biochem. Biophys. Res. Comm . , 1995, 215, 160-166; Jin and Peterson, Arch. Biochem. Biophys. , 1995, 323, 47). -53; Warrener and Collett, J. Virol. 1995, 69, 1720-1726). Finally, the NS5B protein of plague virus and hepatitis virus has predicted RNA-guided RNA polymerase activity (Behrens et al., EMBO, 1996, 15, 12-22; Lechmann et al., J. Virol. , 1997, 71, 8416-8428; Yuan et al., Biochem. Biophys. Res. Comm . 1997, 232, 231-235; Hagedorn, PCT WO 97/12033; Zhong et al, J. Virol., 1998 , 72 , 9365-9369).

Currently, there are limited treatment options for individuals infected with the hepatitis C virus. The current improved medical option is the use of recombinant interferon alpha alone or immunotherapy using the nucleoside analog ribavirin. This therapy is limited by its clinical efficacy and only 50% of the patients treated respond to the therapy. Therefore, there is a significant need for more effective and innovative treatments to address the unmet medical needs caused by HCV infection.

Some potential molecular targets for the development of antiviral drugs that are directly active against HCV therapy have been identified, including but not limited to NS2-NS3 autoprotease, N3 protease, N3 helicase, and NS5B polymerase. . RNA-dependent RNA polymerase is absolutely essential for single-stranded RNA genomic replication, and this enzyme has attracted significant attention among pharmaceutical chemists.

HCV NS5B inhibitors, a potential therapy for HCV infection, have been revisited: Tan, S.-L., et al., Nature Rev. Drug Discov. , 2002, 1, 867-881; Walker, MP et al., Exp . Opin .Investigational Drugs , 2003, 12, 1269-1280 ; Ni, ZJ., et al., Current Opinion in Drug Discovery and Development , 2004, 7, 446-459; Beaulieu, PL, et al., Current Opinion in Investigational Drugs , 2004 , 5, 838-850; Wu, J., et al., Current Drug Targets-Infectious Disorders , 2003, 3, 207-219; Griffith, RC, et al, Annual Reports in Medicinal Chemistry , 2004, 39, 223-237; Carrol, S. , et al., Infectious Disorders-Drug Targets , 2006, 6, 17-29. The potential for emergence of drug-resistant HCV strains and the need to identify reagents with broad genotype coverage supports the ongoing need to identify new and more potent nucleosides as HCV NS5B inhibitors.

A nucleoside inhibitor of NS5B polymerase can act as either a non-natural substrate or as a competitive inhibitor, a non-native matrix leads to a chain termination, a competitive inhibitor and a binding to the polymerase. Nucleotide competition. To function as a linked terminator, the nucleoside analog must be taken up by the cell and converted to a triphosphate in vivo to compete for binding of the polymerase nucleotide. This conversion to triphosphate is generally mediated by cellular kinases that confer additional structural requirements on potential nucleoside polymerase inhibitors. Unfortunately, this limits the direct assessment of nucleosides as inhibitors of HCV replication for cell-based assays that can be phosphorylated in situ.

In some instances, the biological activity of a nucleoside is pinned by its poor quality characteristics, which requires one or more kinases to be converted into an activated triphosphate form. The formation of monophosphates by a nucleoside kinase is generally considered a rate limiting step for three phosphorylation events. To circumvent the need for nucleoside metabolism to the activated triphosphate analog during the initial phosphorylation step, the preparation of a stable phosphate precursor drug was published. Nucleoside phosphoramidate prodrugs have been shown to activate precursors of nucleoside triphosphates and inhibit viral replication when administered to whole cells infected with the virus (McGuigan, C., et al., J. Med. Chem. , 1996, 39, 1748-1753; Valette, G., et al., J. Med. Chem. , 1996, 39, 1981-1990; Balzarini, J., et al., Proc . National Acad Sci USA , 1996, 93, 7295-7299; Siddiqui, AQ, et al., J. Med. Chem. , 1999, 42, 4122-4128; Eisenberg, EJ, et al., Nucleosides, Nucleotides and Nucleic Acids , 2001, 20 , 1091-1098; Lee, WA, et al., Antimicrobial Agents and Chemotherapy , 2005, 49, 1898); US 2006/0241064 and WO 2007/095269.

Sometimes the poor physical and chemical properties of nucleosides also limit their use as a viable medical agent. These poor properties may limit intestinal absorption of the agent and limit uptake into the subject tissue or cells. In order to improve their properties, prodrugs of nucleosides have been used. It has been confirmed that the preparation of nucleoside aminophosphates improves the systemic absorption of nucleosides, and the aminophosphate blocks of these "nucleotide precursors" are more masked with neutral oleophilic groups to obtain a suitable partition coefficient. The partition coefficient optimizes uptake and transport into the cell as compared to administration of the parent nucleoside alone, greatly increasing the intracellular concentration of the nucleoside monophosphate analog. Enzymatic hydrolysis of the phosphate moiety produces a monophosphate nucleoside in which rate-limiting initial phosphorylation is not necessary. To this end, U.S. Patent Application Serial No. 12/053, 015, which is incorporated herein by reference in its entirety to the entire disclosure of the disclosure of Many of them demonstrate their activity in HCV assays. To obtain FDA approval, several compounds disclosed in US 2010/0016251 have been tested as a potential clinical candidate.

Summary of invention

One compound represented by the structural formula disclosed herein, 4, respectively, and by the formula S P - 4, and R P - phosphorus group represented by the 4 diastereomers.

High resolution XRD diffraction pattern of Fig. 1 .

Figure 2 is a high resolution XRD diffraction pattern of R P -4.

Figure 3 is a high resolution XRD diffraction pattern of S P -4 (Form 1).

Figure 4 is a high resolution XRD diffraction pattern of S P -4 (Form 1).

Figure 5 S P -4. High resolution XRD diffraction pattern of CH 2 Cl 2 (Form 2).

Figure 6 S P -4. High resolution XRD diffraction pattern of CHCl 3 (Form 3).

Figure 7 is a high resolution XRD diffraction pattern of S P -4 (Form 4).

Figure 8 is a high resolution XRD diffraction pattern of S P -4 (Form 5).

Figure 9 is a high resolution XRD diffraction pattern of S P -4 (amorphous).

Figure 10 is for the X-ray crystal structure of S P -4 (Form 1).

Figure 11 is for S P -4. X-ray crystal structure (isotropic) of CH 2 Cl 2 (Form 2).

Figure 12 for S P -4. X-ray crystal structure (isotropy) of CH 2 Cl 2 (Form 2).

Figure 13 is for S P -4. X-ray crystal structure of CHCl 3 (Form 3).

Figure 14 is an FT-IR spectrum of Figure 4.

Figure 15 is R P -4 FT-IR spectrum.

Figure 16 FT-IR spectrum of S P -4.

TGA and DSC analysis of Figure 17 Figure 4.

Figure 18 TGA and DSC analysis of R P -4.

Figure 19 TGA and DSC analysis of S P -4.

Figure 20A is for the X-ray crystal structure of 8 ( S P -isomer) (a molecule of asymmetric unit 1).

Figure 20B is for the X-ray crystal structure of 8 ( S P -isomer) (Asymmetric Unit No. 2 molecule).

Detailed description of the preferred embodiment definition

As used herein, the term "a (a)" or "an" is used. By one entity is meant one or more; for example, a compound means one or more compounds or at least one compound. For its part, the terms "a" or "an" or "at least one" are used interchangeably herein.

As used herein, the phrase "optional" or "optionally" means that a continuously described event or circumstance may, but does not necessarily, occur, and the description includes where the event or circumstance occurs. Examples and examples that do not occur. For example, "on-demand keying" means that the key may or may not be present, and the description includes single, double or triple keys.

The term "P*" means that the phosphorus atom is palm-like and has the corresponding "R" or "S" Cahn-Ingold-Prelog name, which has their acceptance Clear meaning.

As used herein, the term "purified" means the purity of a given compound. For example, when the given compound is a major component of the composition, the compound is "purified", i.e., at least 50% w/w pure. Thus, "purified" includes at least 50% w/w purity, at least 60% w/w purity, at least 70% purity, at least 80% purity, at least 85% purity, at least 90% purity, at least 92% purity, at least 94% purity, at least 96% purity, at least 97% purity, at least 98% purity, at least 99% purity, at least 99.5% purity, and at least 99.9% purity, wherein "substance" "Pure" includes at least 97% purity, at least 98% purity, at least 99% purity, at least 99.5% purity, and at least 99.9% purity.

As used herein, the term "metabolite" means a compound that is produced in vivo after administration to an individual in need thereof.

The term "about" (also denoted by ~) means that the recited value is part of a range that varies within standard experimental error.

The expression "substantially as shown in ..." a particular XRPD pattern means that the peak position displayed in the XRPD pattern is visually examined or by virtue of the selected peak list (±0.2. 2 θ ) The same is true. Those of ordinary skill in the art understand that the intensity can vary from sample to sample.

The phrase "substantially anhydrous" means that a substance comprises up to 10% by weight water, preferably up to 1% by weight water, more preferably up to 0.5% by weight water, and most preferably up to 0.1% by weight. Weight of water.

Solvents or antisolvents (such as those used in the reaction, crystallization or the like and lattices and/or adsorbed solvents) include C 1 to C 8 alcohols, C 2 to C 8 ethers, C 3 to C 7 Ketones, C 3 to C 7 esters, C 1 to C 2 chlorocarbons, C 2 to C 7 nitriles, a mixed solvent, C 5 to C 12 saturated hydrocarbons, C 6 to C At least one of 12 aromatic hydrocarbons.

The C 1 to C 8 alcohols mean straight/branched and/or cyclic/acyclic alcohols having such a number of carbon atoms. The C 1 to C 8 alcohols include, but are not limited to, methanol, ethanol, n-propanol, isopropanol, isobutanol, hexanol, and cyclohexanol.

The C 2 to C 8 ethers mean straight/branched and/or cyclic/acyclic ethers having such a number of carbon atoms. The C 2 to C 8 ethers include, but are not limited to, dimethyl ether, diethyl ether, di-isopropyl ether, di-n-butyl ether, methyl tert-butyl ether (MTBE), tetrahydrofuran, and dioxane. alkyl.

The C 3 to C 7 ketone means a linear/branched and/or cyclic/acyclic ketone having such a number of carbon atoms. The C 3 to C 7 ketones include, but are not limited to, dimethyl ketone, methyl ethyl ketone, propanone, butanone, methyl isobutyl ketone, methyl butyl ketone, and a ring. Hexanone.

The esters of C means a straight chain of 3 to C 7 / branched and / or cyclic / non-cyclic, has a number of such esters carbon atoms. The C 3 to C 7 esters include, but are not limited to, ethyl acetate, propyl acetate, n-butyl acetate, and the like.

The C 1 to C 2 chlorocarbon compound means a chlorocarbon compound having such a number of carbon atoms. The chlorocarbons C 1 to C 2 include, but are not limited to, chloroform, dichloromethane (DCM), dichloroethane and tetrachloroethane.

A C 2 to C 7 nitrile means a nitrile having such a number of carbon atoms. The C 2 to C 7 nitriles include, but are not limited to, acetonitrile, propionitrile, and the like.

A wide variety of solvents means solvents commonly used in organic chemistry, including but not limited to, diethylene glycol dimethyl ether, 1,2-dimethoxyethane, Dimethylformamide, dimethyl sulfoxide, ethylene glycol, glycerin, hexamethylphosphoniumamine, hexamethylphosphorium triame, N-methyl-2-pyrrolidone, nitromethane, pyridine, triethylamine And acetic acid.

The saturated hydrocarbon of the term C 5 to C 12 means a linear/branched and/or cyclic/acyclic hydrocarbon. The C 5 to C 12 saturated hydrocarbons include, but are not limited to, n-pentane, ligroin, n-hexane, n-heptane, cyclohexane, and cycloheptane.

The term C 6 to C 12 aromatic means a substituted and unsubstituted hydrocarbon having a phenyl group as their skeleton. Preferred hydrocarbons include benzene, xylene, toluene, chlorobenzene, o-xylene, m-xylene, p-xylene, xylene (s), with toluene being preferred.

As used herein, the term "halo" or "halogen" includes chlorine, bromine, iodine, and fluorine.

The term "barrier" means a chemical group that exhibits the following characteristics. The "group" is derived from "protective compounds". The group selected from the primary hydroxyl group to the secondary hydroxyl group can be placed in conformity with the stability of the amino phosphate (pH 2-8), and the resulting product is given substantially different physical properties such that the 3 The '-aminophosphate-5'-new group product is easily separated from the unreacted desired compound. The group must be selectively reacted in good yield to provide a protected substrate which is stable to the intended reaction (see Protective Groups in Organic Synthesis, 3 nd ed. TW Greene and PGM Wuts, John Wiley & Sons, New York, NY, 1999). Examples of such groups include, but are not limited to, benzamidine, ethenyl, benzhydryl substituted by phenyl, tetrahydropyran, trityl, DMT (4,4'-dimethoxy) Tritylmethyl), MMT (4-monomethoxytrityl), trimethoxytrityl, pixyl (9-phenyl) -9-yl) group, thio-based pixyl (9-phenyl sulfide) -9-yl) or 9-(p-methoxyphenyl)xanthene-9-yl (MOX), etc.; C(O)-alkyl, C(O)Ph, C(O)aryl, CH 2 O-alkyl, CH 2 O-aryl, SO 2 -alkyl, SO 2 -aryl, tert-butyldimethylindenyl, tert-butyldiphenylfluorenyl. Acetals such as MOM or THP and the like are considered to be possible groups. The fluorine-containing compound was also considered including, so that they may be connected to the compound and may be selectively removed by solid phase extraction through the intermediary of fluorine (FluoroFlash ®). Specific examples include a trityl analog of fluorine, a trityl analog 1-[4-(1 H , 1 H , 2 H , 2 H -perfluorodecyl)phenyl)-1,1 - Diphenylmethanol. Other triphenylmethyl fluoride analogs, BOC, FMOC, CBz, etc. are also contemplated. A sulfonium chloride such as p-toluenesulfonyl chloride can be selectively reacted at the 5' position. The esters may be selectively formed, for example, as acetate and benzoic acid. Dicarboxylic anhydrides such as succinic anhydride and its derivatives may be employed to form linkages of the ester to the free carboxylic acid, examples of which include, but are not limited to, sulfhydryl, propylene, butyl, pentane, pentane, Hexamethylene, heptyl, octane, fluorenyl, fluorenyl, fluorenyl, isodecyl, fluorenyl and the like. The free carboxylic acid dramatically increases polarity and can also be used as a treatment to extract the reaction product into a weakly alkaline aqueous phase such as a sodium bicarbonate solution. The amino phosphate group is relatively stable in an acidic medium, and therefore the group requires acidic reaction conditions, for example, tetrahydropyranyl group can also be used.

The term "protecting group" is derived from a "protecting compound" having its clear and general meaning that at least one protecting or blocking group is bonded to at least one functional group (eg, -OH, -NH 2 , etc.) Chemical modification of at least one other functional group is allowed. Examples of protecting groups include, but are not limited to, benzamidine, ethenyl, benzhydryl substituted by phenyl, tetrahydropyran, trityl, DMT (4,4'-dimethoxy) Benzyl), MMT (4-monomethoxytrityl), trimethoxytrityl, pixyl (9-phenyl) -9-yl) group, thio-based pixyl (9-phenyl sulfide) -9-yl) or 9-(p-methoxyphenyl)xanthene-9-yl (MOX), etc.; C(O)-alkyl, C(O)Ph, C(O)aryl, C (O)O (lower alkyl), C(O)O ((lower alkylene) aryl (eg, -C(O)OCH 2 Ph), C(O)O-aryl a group, a CH 2 O-alkyl group, a CH 2 O-aryl group, a SO 2 -alkyl group, a SO 2 -aryl group, a protecting group containing at least one halogen atom, for example, tert-butyldimethylmethyl group, tert-butyl group Bisphenylphenyl group, Si (lower alkyl group) 2 OSi (lower alkyl group) 2 OH (for example, -Si( i Pr) 2 OSi( i Pr) 2 OH).

As used herein and unless otherwise defined, the term "protecting compound" means a compound comprising a "protecting group" which is capable of reacting with a compound comprising a functional group which can be protected.

As used herein, the term "dissociative group" has the same meaning as the well-known skilled person (Advanced Organic Chemistry: reactions, mechanisms and structure-Fourth Edition by Jerry March, John Wiley and Sons Ed.; 1992, pp. 351-357). And representing a moiety that is part of a substrate molecule and attached to the substrate molecule; in the reaction of the matrix molecule undergoing a substitution reaction (eg, as a nucleophile), the leaving group is subsequently substituted . Examples of leaving groups include, but are not limited to, halogen (F, Cl, Br, and I), preferably Cl, Br, or I; tosylate, mesylate, triflate, acetate, camphor a sulfonic acid group, an aryloxy group, and an aryloxy group substituted with at least one electron withdrawing group (for example, p-nitrophenoxy, 2-chlorophenoxy, 4-chlorophenoxy, 2,4-dinitro) Phenoxy, pentafluorophenoxy, etc.), and the like. The term "electron-based" is given a clear meaning here. Examples of electron withdrawing groups include, but are not limited to, halogen, -NO 2 , -C(O) (lower alkyl), -C(O)(aryl), -C(O)O (lower level) Alkyl), -C(O)O(aryl) and the like.

As used herein, the term "alkaline agent" means a compound capable of deprotonating a monohydroxy group. Examples of alkaline agents include, but are not limited to, (lower alkyl) oxide ((lower alkyl) OM) in combination with an alcohol solvent, wherein (lower alkane) oxides include, but are not limited to, MeO - , EtO - , n PrO - , i PrO - , t BuO - , i AmO - (isopentoxide), etc., and wherein M is an alkali metal group metal cation such as Li + , Na + , K + , etc. Wait. The alcohol solvent includes (lower alkyl) OH such as, for example, MeOH, EtOH, n PrOH, i PrOH, t BuOH, i AmOH and the like. Non-alkoxy bases such as sodium hydride, sodium hexamethyldisodium sulphate, lithium hexamethyldiazepine, lithium diisopropylamide, calcium hydride, sodium carbonate, potassium carbonate, cesium carbonate, DBU, may also be used. DBN, Grignard reagents, such as (lower alkyl) Mg (halogen), including but not limited to MeMgCl, MeMgBr, t BuMgCl, t BuMgBr, and the like.

The term "base" includes the term "alkaline agent" and means a compound which is capable of deprotonating a proton-containing compound, i.e., a Bronsted base. In addition to the examples listed above, examples of further bases include, but are not limited to, pyridine, Colin base, 2,6-(lower alkane)-pyridine, dimethylaniline, imidazole, N- Methylimidazole, pyrazole, N-methylpyrazole, triethylamine, diisopropylethylamine, and the like.

The term "electron-based" is given a clear meaning here. Examples of electron withdrawing groups include, but are not limited to, halogen (F, Cl, Br or I), -NO 2 , -C(O) (lower alkyl), -C(O) (aryl), - C(O)O (lower alkyl), -C(O)O(aryl) and the like.

The term "cocrystals" includes co-crystals of 4 , R P - 4 or S P - 4 in combination with salts, including pharmaceutically acceptable salts.

As used herein, the term "salt" means a compound comprising a cation and an anion which can be produced by protonation of a proton accepting moiety and/or deprotonation of a proton donating moiety. . It should be noted that protonation of proton accepting motifs leads to the formation of cationic species in which the charge is balanced by the presence of physiological anions, and the deprotonation of the proton donor motif results in the formation of anion species, where the charge is Balanced by the presence of physiological cations.

The phrase "pharmaceutically acceptable salts" means that the salts are pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include, but are not limited to: (1) acid addition salts formed with, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or, for example, glycolic acid, Pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3-(4-hydroxybenzhydryl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, lauric sulfuric acid, gluconic acid, An acid addition salt formed from an organic acid such as glutamic acid, salicylic acid, muconic acid, or the like, or (2) a base addition salt formed from a conjugate base of any of the inorganic acids listed above, wherein the total The conjugate base comprises a cationic component selected from the group consisting of Na + , K + , Mg 2+ , Ca 2+ , NH g R''' 4-g + , wherein R''' is a C 1-3 alkyl group and g Is a number selected from 0, 1, 2, 3 or 4. It will be appreciated that all pharmaceutically acceptable salts as referred to herein include solvent addition forms (solvates) or crystalline forms (polymorphs) of the same acid addition salts.

The term "alkyl" means an unbranched or branched chain, saturated monovalent hydrocarbon residue containing from 1 to 30 carbon atoms. The phrase "C 1-M alkyl" means an alkyl group having 1 to M carbon atoms, wherein M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30. The phrase "C 1-4 alkyl" means an alkyl group having 1 to 4 carbon atoms. The term "lower alkyl" refers to a straight or branched hydrocarbon residue containing from 1 to 6 carbon atoms. As used herein, "C 1-20 alkyl" means an alkyl group containing from 1 to 20 carbon atoms. For example, "C 1 - 10 alkyl" as used herein means an alkyl group containing 1 to 10 carbon atoms. Examples of alkyl groups include, but are not limited to, lower alkyl groups, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl or pentyl, isopentyl, neopentyl Base, hexyl, heptyl and octyl. The term (aryl)alkyl or (heteroaryl)alkyl means that the alkyl group is optionally substituted by an aryl or heteroaryl group, respectively.

The term "alkenyl" means an unsubstituted hydrocarbon chain radical having 2 to 10 carbon atoms and having a double bond of one or two olefins, preferably a double bond of an olefin. . The term "C2 - Nalkenyl" means an alkenyl group containing 2 to N carbon atoms, wherein N is an integer having the following value: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C 2 -10 alkenyl" means an alkenyl group containing 2 to 10 carbon atoms. The term "C2-4"alkenyl" means an alkenyl group containing 2 to 4 carbon atoms. Examples include, but are not limited to, vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotonyl).

As used herein and unless otherwise specifically indicated, the term "aryl" means substituted or unsubstituted phenyl (Ph), biphenyl or naphthyl. Preferably, the term aryl means substituted. Or unsubstituted phenyl. Aryl group The group may be substituted by one or more motifs selected from the group consisting of hydroxyl, F, Cl, Br, I, amine, alkyl amine, aryl amine, alkoxy, aromatic Oxyl, nitro, cyano, sulfonate, sulphate, phosphonate, phosphate and phosphonic acid groups, as known to those skilled in the art, may be unprotected or protected when necessary For example, as taught by TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis," 3rd ed., John Wiley & Sons, 1999.

As used herein and unless otherwise indicated, the term "aryloxy" means substituted or unsubstituted phenoxy (PhO-), p-phenylphenoxy (p-Ph-PhO-) Or a naphthalene salt, preferably the term aryloxy means a substituted or unsubstituted phenoxy group. The aryloxy group may be substituted by one or more substituents selected from the group consisting of hydroxyl, F, Cl, Br, I, -C(O) (lower alkyl), -C(O)O (lower alkyl), amine, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonate, sulfate, phosphine Acid groups, phosphate groups, and phosphonic acid groups, as known to those skilled in the art, may be unprotected or protected when necessary, for example, as TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis," "3rd ed., taught by John Wiley & Sons, 1999.

The terms "formulation" or "dosage form" are intended to encompass both solid and liquid formulations of the active compound, and those of ordinary skill in the art will recognize that the active ingredient can be in accordance with its desired dosage and pharmacokinetic parameters. Present in different formulations.

The term "excipient" as used herein means A compound of a pharmaceutical composition which is generally safe, non-toxic and neither biologically nor otherwise undesirable, and which comprises veterinary use as well as excipients acceptable for human pharmaceutical use.

The term "crystalline" means a case where any solid sample of S P - 4 or R P - 4 has a crystalline characteristic when measured by X-ray powder diffraction or a single crystal X-ray technique.

The term "crystal-like" means a condition in which a solid sample of S P - 4 or R P - 4 has a crystalline character when measured by a method such as visual or by optical or polarizing microscopy, but when When measured by another method (for example, X-ray powder diffraction), it does not have a crystalline characteristic. Methods for visually determining the crystallinity of a solid sample by vision or by optical or polarizing microscopy are disclosed in USP <695> and <776>, both of which are incorporated by reference. A "crystal-like" solid sample of S P - 4 or R P - 4 can be crystallized under specific conditions, but may become amorphous when under other conditions.

The term "amorphous" means that any solid sample of S P - 4 or R P - 4 is neither crystalline nor crystalline.

Specific embodiment

The first embodiment is directed to a compound represented by Structural Formula 4: Where P* represents a palm phosphorus atom. Due to the palmitic phosphorus atom, the compound represented by Structural Formula 4 contains two non-image isomers designated as R P - 4 and S P - 4 . The compound represented by Structural Formula 4 may also be a solvent, a hydrate or a part of a mixed solvent/hydrate. The solvent is indicated as 4 . n S and the hydrate is labeled 4 . mH 2 O, wherein S is a lattice solvent, n is varied by an integer or a non-quantity of from about 0 to about 3, and m is varied by an integer or a non-quantity of from about 0 to about 5. Finally, one of the compounds represented by Structural Formula 4 may not be present as a solvent or hydrate, but has a particularly advantageous amount of adsorbent solvent ( S ) or water. In this case, the amount of S or water may vary from about 0 wt.% to about 10 wt.%, based on the weight of the compound represented by Structural Formula 4 . The compound represented by Structural Formula 4 , and a solvent thereof and a hydrate thereof are crystalline, crystalline or amorphous.

The second embodiment is directed to a compound represented by the structural formula R P - 4 : The compound represented by the structural formula R P - 4 may also be a solvent, a hydrate or a part of a mixed solvent/hydrate. This solvent is indicated as R P - 4 . n S , and the hydrate is labeled as S P - 4 . mH 2 O, wherein S is a lattice solvent, n is varied by an integer or a non-quantity of from about 0 to about 3, and m is varied by an integer or a non-quantity of from about 0 to about 5. Finally, the compound represented by the structural formula R P - 4 may not exist as a solvent, a hydrate or a mixed solvent/hydrate, but has a particularly advantageous amount of adsorbent solvent ( S ), water or S and water. By. In this case, the amount of S or water may vary from about 0 wt.% to about 10 wt.%, based on the weight of the compound represented by the structural formula R P -4 . The compound represented by the structural formula R P - 4 and its solvent and its hydrate are crystalline, crystalline or amorphous.

The first aspect of the second embodiment is directed to crystalline R P - 4 .

The second aspect of the second embodiment is directed to a crystalline R P - 4 having an XRPD 2θ-reflection angle (°) of about 6.6, 7.1, 9.0, 11.6, 17.9, 20.7, 24.1, 24.4, and 26.2.

The third aspect of the second embodiment is directed to having an XRPD 2θ-reflection angle (°) of about 6.6, 7.1, 9.0, 11.0, 11.6, 12.0, 16.0, 17.9, 19.6, 20.7, 21.0, 21.7, 21.9, 22.2, Crystalline R P - 4 of 23.1, 24.1, 24.4, 26.1, 27.3, 27.7 and 28.2.

The fourth aspect of the second embodiment is directed to a crystal R P - 4 having an XRPD diffraction pattern substantially as shown in Fig. 2.

The fifth aspect of the second embodiment is directed to R P - 4 having the following FT-IR peaks (cm -1 ): 1742, 1713, 1679, 1460, 1377, 1259, 1157, and 1079.

The sixth aspect of the second embodiment is directed to R P - 4 having an FT-IR spectrum substantially as shown in Fig. 15.

The seventh aspect of the second embodiment is directed to substantially purified R P - 4 .

The eighth aspect of the second embodiment is directed to substantially purified crystalline R P - 4 .

The ninth aspect of the second embodiment is directed to substantially purified amorphous R P - 4 .

A third embodiment is directed to a compound represented by the structural formula S P -4: The compound represented by the structural formula S P - 4 may also be a solvent, a hydrate or a part of a mixed solvent/hydrate. This solvent is indicated as S P - 4 . n S , and the hydrate is labeled as S P - 4 . mH 2 O, wherein S is a lattice solvent, n is varied by an integer or a non-quantity of from about 0 to about 3, and m is varied by an integer or a non-quantity of from about 0 to about 5. Finally, the compound represented by the structural formula S P - 4 may not be present as a solvent or a hydrate, but has a particularly advantageous amount of adsorbing solvent ( S ) or water. In this case, the amount of S or water may vary from about 0 wt.% to about 10 wt.%, based on the weight of the compound represented by the structural formula S P - 4 . The compound represented by the structural formula S P - 4 and its solvent and its hydrate are crystalline, crystalline or amorphous.

The first embodiment of the third aspect of the system for a specific embodiment the crystalline S P - 4.

The second aspect of the third embodiment is directed to monoclinic crystal S P - 4 , preferably having the following unit lattice parameters a~12.88Å, b~6.17Å, c~17.73Å, and β~92.05°.

The third aspect of the third embodiment is directed to monoclinic crystal S P - 4 , preferably having the following unit lattice parameters a~20.09Å, b~6.10Å, c~23.01Å, and β~112.29°.

The fourth aspect of the third embodiment is directed to monoclinic crystal S P - 4 , preferably having the following unit lattice parameters a~12.83Å, b~6.15Å, c~17.63Å, and β~91.75°.

A fifth aspect of the third embodiment of the system for a monoclinic crystal S P - 4, preferably has the following unit cell parameters a ~ 12.93Å, b ~ 6.18Å, c ~ 18.01Å and β ~ 96.40 °.

The sixth aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 5.2, 7.5, 9.6, 16.7, 18.3, 22.2.

The seventh aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 5.0, 7.3, 9.4, and 18.1.

The eighth aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 4.9, 6.9, 9.8, 19.8, 20.6, 24.7, and 26.1.

The ninth aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 6.9, 9.8, 19.7, 20.6, and 24.6.

The ninth aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 5.0, 6.8, 19.9, 20.6, 20.9, and 24.9.

The tenth aspect of the third embodiment is directed to crystalline S P - 4 having an XRPD 2θ-reflection angle (°) of about 5.2, 6.6, 7.1, 15.7, 19.1, and 25.0.

The eleventh aspect of the third embodiment is directed to a crystalline S P - 4 having an XRPD diffraction mode substantially as shown in any of Figures 3, 4, 5, 6, 7 and 8.

The twelfth aspect of the third embodiment is directed to S P - 4 having the following FT-IR peaks (cm -1 ) at about: 1743, 1713, 1688, 1454, 1378, 1208, and 1082.

The thirteenth aspect of the third embodiment is directed to S P - 4 having an FT-IR spectrum substantially as shown in Fig. 7.

The thirteenth aspect of the third embodiment is directed to S P - 4 having an FT-IR spectrum substantially as shown in Fig. 7.

The fifteenth aspect of the third embodiment is directed to substantially purified crystalline S P - 4 .

The sixteenth aspect of the third embodiment is directed to substantially purified amorphous S P - 4 .

Dosage, administration and use

The fourth embodiment is directed to a composition using any one of Compound 4 , R P - 4 or S P - 4 as a therapeutic and/or prophylactic agent for any virion. Possible viral lines include, but are not limited to, hepatitis C virus, hepatitis B virus, hepatitis A virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, poliovirus, bovine viral scorpion virus, Japanese encephalitis virus, or those belonging to the plague, hepatitis or yellow fever group.

An aspect of this particular embodiment is directed to a composition for treating any of the virions disclosed herein, the composition comprising a pharmaceutically acceptable medium selected from the group consisting of excipients, carriers, diluents, and equivalent media. And any one of the compound 4 , R P - 4 or S P - 4 , which is intended to include a hydrate thereof, a solvent, and any crystalline form of any of the compounds 4 , R P - 4 or S P - 4 , or Hydrate and its solvent.

Compound 4 , R P - 4 or S P - 4 can be formulated independently in a wide variety of oral dosage forms as well as carriers. Oral administration can be in the form of a troche, a film coat, a hard and soft gelatin capsule, a solution, an emulsion, a syrup or a suspension. In other routes of administration, Compound 4 , R P - 4 or S P - 4 is effective when administered by suppository administration. The most convenient mode of administration is usually oral administration using a convenient daily dose therapy, which can be adjusted depending on the severity of the disease and the patient's response to the antiviral drug.

Compound 4 , R P - 4 or S P - 4 may be co-incorporated with one or more conventional excipients, carriers or diluents in the form of the pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be combined with additional active compounds or additional active compounds in conventional compositions, and the unit dosage form may contain any suitable effective amount of active ingredient The ingredients are commensurate with the expected daily dose range to be used. The pharmaceutical composition can be used as a solid or a liquid, such as a tablet or a filled capsule, a semisolid, a powder, a sustained release formulation, a liquid such as a suspension, an emulsion, or a filled capsule for oral use; or for a rectum Or a suppository form for vaginal administration. A typical preparation will contain from about 5% to about 95% of one or more active compounds (w/w).

Compound 4, R P - 4 or S P - 4 may be administered separately, but usually in a mixture with one or more suitable pharmaceutical excipients, diluents or carriers, the pharmaceutical excipients The diluent or carrier is selected depending on the intended route of administration and standard pharmaceutical practice.

Solid form preparations include, for example, powders, lozenges, pills, capsules, Suppositories and dispersible granules. The solid carrier can be one or more substances which may also be employed as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents or encapsulating materials. In powders, the carrier is usually a finely divided solid which is a mixture with the finely divided active ingredient. In lozenges, the active ingredient is usually mixed in a suitable ratio with the carrier having the necessary binding ability and compressed in the desired shape and size. Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting waxes , cocoa butter and the like. In addition to the active ingredient, the solid form preparations may contain coloring agents, perfumes, stabilizers, buffers, artificial and natural sweeteners, dispersing agents, thickening agents, solubilizing agents, and the like. Examples of solid formulations are exemplified in EP 0524579; US 2002/0142050; US 2004/0224917; US 2005/0048116; US 2005/0058710; US 2006/0034937; US 2006/0057196; US 2006/0188570; US 2007/0026073 US 2007/0059360; US 2007/0077295; US 2007/0099902; US 2008/0014228; US 6,267,985; US 6,294,192; US 6,383,471; US 6,395,300; US 6,569,463; US 6,635,278; US 6,645,528; US 6,923,988; US 6,932,983; US 7,060,294 And each of US 7,462,608, each of which is incorporated herein by reference.

Liquid formulations are also suitable for oral administration with liquid formulations including emulsions, syrups, elixirs and aqueous suspensions. These include solid form preparations which are expected to be rapidly converted to liquid form preparations prior to use. Examples of liquid preparations are exemplified in the US patent number 3,994,974; 5,695,784 and 6,977,257. The emulsion may be prepared in a solution, for example, in an aqueous solution of polypropylene glycol, or may comprise an emulsifier such as a phospholipid, sorbitan monooleate or aramis. A suspension aqueous solution may be prepared by dispersing the finely divided active composition and the viscous material in water, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known Suspending agent.

The compound 4 , R P - 4 or S P - 4 can be administered separately as a suppository. The low melting wax, for example, one of a mixture of fatty acid glycerides or cocoa butter, is first melted and the active composition is homogeneously dispersed by, for example, stirring. The molten homogeneous mixture is then poured into a convenient size mold which is allowed to cool and solidify.

The compound 4 , R P - 4 or S P - 4 can be formulated separately for vaginal administration. In addition to the active ingredient, carriers such as pessary, tampon, cream, gel, cream, foam or spray are known in the art to be suitable. Some of these formulations may also be combined with condoms with or without spermicides.

Suitable formulations and pharmaceutical carriers, diluents and excipients are described in Remington: The Science and Practice of Pharmacy 1995, EW Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania, incorporated herein by reference. Scientists skilled in the art of formulation may modify the formulation in the teachings of this specification to provide numerous formulations for a particular route of administration without destabilizing or sacrificing their medical activity of the compositions comprising the compounds contemplated herein.

Additionally, purified compound 4 , R P -4 or S P - 4 can also be formulated separately in combination with liposomes or micelles. With respect to the liposome, it is contemplated that the purified compound can utilize U.S. Patent Nos. 4,797,285; 5,013,556; 5,077,056; 5,077,057; 5,154,930; 5,192,549; 5,213,804; 5,225,212; 5,277,914; 5,316,771; 5,376,380; 5,549,910; 5,567,434; 5,736,155; 5,827,533; 5,882,679; 5,891,468; 6,060,080; 6,132,763; 6,143,321; 6,180,134; 6,200,598; 6,214,375; 6,224,903; 6,296,870; 6,653,455; 6,680, 068; 6, 726, 925; With regard to micelles, it is contemplated that the purified compound can be formulated in the manner disclosed in U.S. Patent Nos. 5,145,684 and 5,091,188, the disclosure of each of each of each of

This fifth embodiment is directed to the use of any of Compound 4 , R P - 4 or S P - 4 in the manufacture of a medicament for the treatment of any symptoms caused by infection of any of the following viruses: Hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, poliovirus, hepatitis A virus, bovine viral sputum virus, and Japanese encephalitis virus.

The term "agent" means a substance used in a method of treating and/or preventing an individual in need thereof, wherein the substance includes, but is not limited to, any of the compounds 4 , R P - 4 or S P - 4 Compositions, formulations, dosage forms, and the like. To consider that the compounds 4, R P - 4 or S P - 4 in the manufacture of a medicament for the treatment of any symptoms of antiviral disclosed herein is the use of the individual compounds disclosed herein, or of another combination. The agent includes, but is not limited to, any of the compositions considered by the fourth embodiment disclosed herein.

A sixth embodiment is directed to a method of treating and/or preventing an individual in need thereof, the method comprising, in a therapeutically effective amount, any one of Compound 4 , R P - 4 or S P - 4 Administration to the individual.

An individual in need thereof is an individual having any of the symptoms caused by infection with any of the virions disclosed herein, including but not limited to hepatitis C virus, West Nile virus, yellow fever virus, dengue fever Virus, rhinovirus, poliovirus, hepatitis A virus, bovine viral sputum virus or Japanese encephalitis virus, yellow fever virus or plague virus or hepatitis virus or cause the disease to be equal to or comparable to any of the above listed viruses Viral.

The term "individual" means a mammal including, but not limited to, cow, pig, sheep, chicken, turkey, buffalo, llama, ostrich, dog, cat, and human, preferably the individual is a human. It is contemplated that any of the compounds contemplated herein may be in the method of treating an individual in a ninth embodiment, either alone or in combination with another compound disclosed herein.

As used herein, the term "medically effective amount" means the amount required to alleviate the symptoms of a disease in one body. This dose will be adjusted to the individual needs in each particular case. The dosage may vary within wide limits depending on a number of factors, such as the severity of the condition being treated, the age and general condition of the patient, the other agent being treated by the patient, the route and form of administration, and The preferences and experience of the medical practitioners involved. For oral administration, in monotherapy and/or combination therapy, daily about A daily dose of between 0.001 g and between about 10 g (including all values in between) should be appropriate, such as 0.001, 0.0025, 0.005, 0.0075, 0.01, 0.025, 0.050, 0.075, 0.1, 0.125, 0.150, 0.175, 0.2, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5. The particular daily dose is between about 0.01 g and about 1 g per day, including all increments of 0.01 g (i.e., 10 mg), preferably between about 0.01 g and about 0.8 g per day. More preferably, it is between about 0.01 g and about 0.6 g per day, and most preferably between about 0.01 g and about 0.25 g per day, with each increment including 0.01 g. In general, treatment begins with a larger initial "loading dose" to rapidly reduce or eliminate the virus, which is then reduced to a level sufficient to prevent recurrence of the infection. Those of ordinary skill in the art of treating the diseases described herein will be able to determine medical treatment of a compound of the invention for a given disease and patient without undue experimentation and relying on personal knowledge, experience, and disclosure in this application. Effective amount.

As used herein, the term "medically effective amount" means the amount required to alleviate the symptoms of a disease in one body. This dose will be adjusted to the individual needs in each particular case. The dosage may vary within wide limits depending on a number of factors, such as the severity of the condition being treated, the age and general condition of the patient, the other agent being treated by the patient, the route and form of administration, and The preferences and experience of the medical practitioners involved. For oral administration, in monotherapy and/or combination therapy, a daily dose of between about 0.001 g and about 10 g per day (including all values in between) should be appropriate, such as 0.001, 0.0025, 0.005. , 0.0075, 0.01, 0.025, 0.050, 0.075, 0.1, 0.125, 0.150, 0.175, 0.2, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9 and 9.5. The particular daily dose is between about 0.01 g and about 1 g per day, including all increments of 0.01 g (i.e., 10 mg), preferably between about 0.01 g and about 0.8 g per day. More preferably, it is between about 0.01 g and about 0.6 g per day, and most preferably between about 0.01 g and about 0.25 g per day, with each increment including 0.01 g. In general, treatment begins with a larger initial "loading dose" to rapidly reduce or eliminate the virus, which is then reduced to a level sufficient to prevent recurrence of the infection. Those of ordinary skill in the art of treating the diseases described herein will be able to determine medical treatment of a compound of the invention for a given disease and patient without undue experimentation and relying on personal knowledge, experience, and disclosure in this application. Effective amount.

A first aspect of the sixth embodiment is directed to a method of treatment and/or prevention of an individual in need thereof, the method comprising expressing a medically effective amount of Compound 4 , R P - 4 or S P - 4 Any compound and a medically effective amount of another antiviral agent are administered to the individual, wherein the administration is simultaneous or replacement. It is to be understood that the time between replacement administrations can range from 1 to 24 hours, including any subranges therebetween, including: 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23 hours.

Examples of "another antiviral agent" include, but are not limited to, HCV NS3 protease inhibitors (see EP 1881001, US 2003187018, US 2005267018, WO 2003006490, WO 200364456, WO 2004094452, WO 2005028502, WO 2005037214, WO 2005095403, WO 2007014920, WO 2007014921, WO 2007014922, WO 2007014925, WO 2007014926, WO 2007015824, WO 2008010921 and WO 2008010921); HCV NS5B inhibitors (see US 2004229840, US 2005154056, US 2005) -98125, US 20060194749, US 20060241064, US 20060293306, US 2006040890, US 2006040927, US 2006166964, US 2007275947, US 6784166, US 20072759300, WO 2002057287, WO 2002057425, WO 2003010141, WO 2003037895, WO 2003105770, WO 2004000858, WO 2004002940, WO 2004002944, WO 2004002977, WO 2004003138, WO 2004041201, WO 2004065367, WO 2004096210, WO 2005021568, WO 2005103045, WO 2005123087, WO 2006012078, WO 2006020082, WO 2006065335, WO 2006065590, WO 2006093801, WO 200702602, WO 2007039142, WO 2007039145 , WO 2007076034, WO 2007088148, WO 2007092000 and WO2007095269); HCV NS4 inhibitors (see WO 2005067900 and WO 2007070556); HCV NS5a inhibitors (see US 2006276511, WO 2006035061, WO 2006100310, WO 2006120) 251 and WO 2006120252); Toll-like receptor antagonists (see WO 2007093901); and other inhibitors (see WO 2000006529, WO 2003101993, WO 2004009020, WO 2004014313, WO 2004014852 and WO 2004035571); And the compounds disclosed in U.S. Patent Application Serial No. 12/053,015, the disclosure of which is incorporated herein by reference in its entirety in its entirety in PEGylated interferon-α, ribavirin, levovirin, viramidine, another nucleoside HCV polymerase inhibitor, HCV non-nucleoside polymerase inhibitor, HCV protease inhibitor , HCV helicase inhibitor or HCV fusion inhibitor.

When any one of Compound 4 , R P - 4 or S P - 4 is administered in combination with another antiviral agent, the activity may increase beyond the parent compound. When the treatment is a combination therapy, such administration of the nucleoside derivative can be simultaneous or continuous. Thus, as used herein, "simultaneous administration" includes administration of the agent at the same time or at different times. Simultaneous administration of two or more agents can be achieved by a single formulation comprising two or more active ingredients, or by continuously administering two or more dosage forms simultaneously with a single active agent. .

It will be appreciated that the treatments referred to herein extend to prophylactic methods as well as treatment of existing conditions. Moreover, as used herein, the term "treatment" of HCV infection includes the treatment or prevention of a disease or condition associated with or a vector of HCV infection or a clinical symptom thereof.

preparation

A seventh embodiment is directed to a process for the preparation of any of Compound 4 , R P - 4 or S P - 4 comprising: a) isopropyl-aluminum hydride ( A ), di-LG-phenyl phosphate Salt ( B ), 2'-deoxy-2'-fluoro-2'-C-methyluridine ( 3 ) and a base reaction to obtain at least one of S P - 4 and R P - 4 The first mixture.

Wherein X is a conjugate base of an acid, n is 0 or 1, and LG is a leaving group; b) the first mixture is reacted with a protecting compound to obtain a protected S P - 4 and a protected R a second mixture of at least one of P - 4 ; and c) optionally crystallizing, chromatographically or extracting the second mixture to obtain 4 , S P -4 or R P - 4 .

In a first aspect of the seventh embodiment, the aluminum isopropylhydride is present as its hydrochloride salt, which is preferably substantially anhydrous.

In a second aspect of the seventh embodiment, the base is N-methylimidazole.

In a third aspect of the seventh embodiment, the ratio A B ratio of 3 mole fraction of about 1.6 to 1.3 to 1.

In a fourth aspect of the seventh embodiment, the protecting compound is tert-butyldimethylchlorodecane.

The eighth embodiment is directed to a process for preparing S P -4 or R P - 4 comprising: a) isopropyl-aluminum hydride (A), di-LG-phenyl phosphate (B), 2'Deoxy-2'-fluoro-2'-C-methyluridine ( 3 ) and a base reaction to obtain a first mixture comprising at least one of S P -4 and R P -4 .

Wherein X is a conjugate base of an acid, n is 0 or 1, and LG is a leaving group; and b) optionally crystallization, chromatography or extraction of the second mixture to obtain purified S P - 4 or R P - 4 .

A first aspect of the eighth embodiment is for the additional preparation of R P - 4 , comprising further purifying the second mixture by dissolving or suspending the second mixture or the purified R P - 4 mixture in a solvent Or the purified R P - 4 ; optionally followed by crystallizing R P - 4 seeding; and adding sufficient anti-solvent to obtain crystalline R P - 4 .

A second aspect of the eighth embodiment is for the additional preparation of S P - 4 , comprising further purifying the second mixture or the purified S P - 4 by dissolving or suspending the second mixture or Purifying the S P - 4 in a solvent, followed by crystallizing the S P - 4 seed crystal at about room temperature; collecting the first solid containing a plurality of S P - 4 ; dissolving the first solid at a reflux temperature thereof A solid is in the solvent; and the anti-solvent is cooled or added to obtain a second solid.

A third aspect of the eighth embodiment is for the additional preparation of S P - 4 , comprising further purifying S P - 4 by d) dissolving or suspending the second mixture or the purified S P - 4 mixture In a solvent, an anti-solvent is then added to obtain a first composition, and the residual solvent/anti-solvent therein is removed by pouring to obtain a residue; the residue is treated with a solution containing the first solvent and the anti-solvent to generate a second composition, the first solid is provided by decompression; a second solvent is used to dissolve or suspend the first solid to obtain a third composition; and a seed crystal of S P - 4 is added to the third composition; Collecting a second solid; dissolving or suspending the second solid in a third solvent, optionally heating to a reflux temperature of the third solvent to obtain a fourth composition, and, if necessary, cooling the fourth composition A third solid comprising S P - 4 was obtained, which was collected by filtration.

The fourth aspect of the eighth embodiment for the preparation of S P - 4, S P - 4 by the second or purified mixture of S P - 4 is further purification, added to the silicone via the second d) a second mixture or the purified S P - 4 , followed by evaporation of the solvent to provide a dry slurry; the dry mud is agitated in the first solvent / anti-solvent combination to obtain a first wet mud; from the first Removing the first solvent/anti-solvent combination from the wet mud to obtain a second wet mud and a first composition; adding a second solvent/anti-solvent combination to the second wet mud followed by stirring; Removing the second solvent/anti-solvent combination from the second wet mud to obtain a third wet mud and a second composition; optionally repeating steps g)-h) to the triple wet mud Or an additional wet mud; evaporating the solvent from the second composition; and obtaining any additional composition, optionally in the optional step i), to obtain a first solid; dissolving or suspending the first solid a solution comprising a third solvent and optionally a fourth solvent , To obtain a third composition; optionally with added S P - the third seed crystal to the composition 4; comprising S P obtained from the composition of the third - the second solid 4; and with the use of a third solvent The second solid is selectively recrystallized to obtain a third solid comprising S P -4 .

Those skilled in the art will appreciate that the compounds are Separation by conventional extraction, conventional crystallization or conventional chromatographic techniques. Conventional chromatographic techniques include, but are not limited to, silica gel chromatography (using, for example, 3-5% methanol in DCM or 4-6% isopropanol in DCM) to produce one of the enhanced isomers (50 -100%) and crystallize again. Alternatively, one can use reverse phase chromatography (using a mobile phase such as 1-30% acetonitrile in water). Further, the compound can be isolated by supercritical fluid chromatography SFC using carbon dioxide as a main solvent and an alcohol such as methanol as a modifier, preferably using a suitable pair of palms. Medium, such as Daicel Chiralpack IA. Alternatively, SMB chromatography can be employed, using a suitable palmitic medium such as Daicel ChiralPack IA, using a solvent mixture such as hexane/isopropanol or a single solvent such as ethyl acetate.

A ninth embodiment is directed to a process for the preparation of S P - 4 comprising: a) isopropyl-propylamine mercapto-amino phosphate and 3'-O-protected or unprotected 3 and one The alkaline reagent is reacted to obtain a composition comprising protected or unprotected S P - 4 .

Wherein the isopropyl-alaninyl-amino phosphate comprises a mixture of non-image isomers represented by the following structural formula: The ratio of C : C' is about 1:1.

In a first aspect, the alkaline agent is t-butyl chloride, and the C: C 'of greater than or equal to about a ratio of 1: 1.

In a second aspect, the alkaline agent is t-butyl magnesium chloride and the ratio of C : C' is greater than about 1:1.

In a third aspect, the alkaline agent is t-butyl chloride, and the C: C 'the ratio is at least about 1.5: 1, about 2.3: 1, about 4: 1, about 5.7: 1, about 9: 1, Approximately 19:1, approximately 32.3:1, approximately 49:1 or approximately 99:1.

In a fourth aspect, LG' is p-nitrophenoxy, the alkaline reagent is t-butylmagnesium chloride, and the ratio of C : C' is at least about 1.5:1, about 2.3:1, about 4:1, about 5.7:1, about 9:1, about 19:1, about 32.3:1, about 49:1 or about 99:1.

A fifth aspect for preparing S P - 4, comprising of: a) isopropyl - propylamine acyl - phosphate group (C) and 3'-O- protected or unprotected, and a base 3 The reagent is reacted to obtain a composition comprising protected or unprotected S P - 4 .

Wherein Z is a protecting group or hydrogen; LG 'is a leaving group; and b) optionally with the obtained protected or unprotected of S P - 4 chromatography, extraction or crystallization reaction, to obtain purified by Protected or unprotected S P - 4 . In a subspecific embodiment, LG' is a tosylate group, a camphorsulfonate group or an aryloxy group substituted with at least one electron withdrawing group; preferably, LG' is selected from p-nitrophenoxy group, 2,4-Dinitrophenoxy and pentafluorophenoxy. In a further sub-embodiment, when S P - 4 is protected, i.e., Z is not hydrogen, the process of the ninth embodiment further deprotects the protected S P - 4 . In a further sub-specific embodiment, the reaction is carried out in a polar aprotic solvent, for example, tetrahydrofuran or another ether solvent, either alone or in combination with each other, or a C 2 to C 7 nitrile such as acetonitrile. .

The process of the ninth embodiment further comprises 1) making (LG')P(O)(LG) 2 (wherein the LG system is a detachment group independent of LG') and (i) isopropyl-aluminum hydride a first base reaction to obtain (LG')P(O)(LG)(Ala- i Pr), followed by (LG')P(O)(LG)(Ala- i Pr) with phenol and a first The dibasic reaction is carried out to obtain a mixture comprising C and C' ; and (ii) the phenol is reacted with a first base to obtain (LG')P(O)(LG)(OPh), followed by (LG') P(O)(LG)(OPh) is reacted with isopropyl-aluminum hydride and a second base to obtain a mixture comprising C and C' ; or (iii) combined with isopropyl-aluminum hydride, phenol and at least a base to obtain a mixture comprising C and C' ; or 2) to make (PhO)P(O)(LG) 2 (wherein LG' is a detachment independent of LG) and (i) isopropyl - aluminum hydride and a first base to obtain (PhO)P(O)(LG)(Ala- i Pr), followed by (PhO)P(O)(LG)(Ala- i Pr) with a leaving group The precursor and a second base are reacted to obtain a mixture comprising C and C' .

The mixture is subjected to chromatography or the mixture is crystallized to obtain C. In one aspect of the ninth embodiment, the isopropylaluminum hydride is present as its hydrochloride salt, wherein preferably it is substantially anhydrous.

A tenth embodiment is directed to a process for the preparation of R P -4 comprising: a) isopropyl-propylamine mercapto-amino phosphate and 3'-O-protected or unprotected 3 and one The alkaline reagent is reacted to obtain a composition comprising protected or unprotected R P - 4 .

Wherein the isopropyl-alaninyl-amino phosphate is composed of a mixture of non-image isomers represented by the following structural formula: The ratio of C' : C is about 1:1.

In the first aspect, the alkaline agent is t-butyl magnesium chloride, and the ratio of C' : C is greater than or equal to about 1:1.

In a second aspect, the alkaline agent is t-butyl magnesium chloride and the ratio of C' : C is greater than about 1:1.

In a third aspect, the alkaline agent is t-butyl magnesium chloride and the ratio of C' : C is at least about 1.5:1, about 2.3:1, about 4:1, about 5.7:1, about 9:1. Approximately 19:1, approximately 32.3:1, approximately 49:1 or approximately 99:1.

In a fourth aspect, LG' is p-nitrophenoxy, the alkaline reagent is t-butylmagnesium chloride, and the ratio of C' : C is at least about 1.5:1, about 2.3:1, about 4:1, about 5.7:1, about 9:1, about 19:1, about 32.3:1, about 49:1 or about 99:1.

The fifth aspect as the preparation of the R P -4 system comprises: a) isopropyl-propylamine mercapto-amino phosphate ( C' ) and 3'-O-protected or unprotected 3 and an alkaline The reagent is reacted to obtain a composition comprising protected or unprotected R P -4 .

Wherein Z is a protecting group or hydrogen; LG' is a leaving group; and b) optionally subjecting the obtained protected or unprotected R P - 4 to chromatography, extraction or crystallization to obtain a purified Protected or unprotected R P - 4 . In a subspecific embodiment, LG' is a tosylate group, a camphorsulfonate group or an aryloxy group substituted with at least one electron withdrawing group; more preferably, LG' is selected from p-nitrophenoxy group, 2,4-Dinitrophenoxy and pentafluorophenoxy. In another specific embodiment, the process of the ninth embodiment further deprotects the protected R P - 4 when R P - 4 is protected, i.e., Z is non-hydrogen. In another specific embodiment, the reaction is carried out in a polar aprotic solvent, for example, tetrahydrofuran or another ether solvent, either alone or in combination with each other, or a C 2 to C 7 nitrile, for example Acetonitrile.

The process of the tenth embodiment further comprises 1) making (LG')P(O)(LG) 2 (wherein LG is a leaving group independent of LG') and (i) isopropyl-aluminum hydride and a first base reaction to obtain (LG')P(O)(LG)(Ala- i Pr), followed by (LG')P(O)(LG)(Ala- i Pr) with phenol and a first The dibasic reaction is carried out to obtain a mixture comprising C and C' ; and (ii) the phenol is reacted with the first base to obtain (LG')P(O)(LG)(OPh), followed by (LG') P(O)(LG)(OPh) is accompanied by the reaction of isopropyl-aluminum hydride with a second base to obtain a mixture comprising C and C' ; or (iii) combining isopropyl-aluminum hydride, phenol and at least a base to obtain a mixture comprising C and C' ; or 2) to make (PhO)P(O)(LG) 2 (wherein LG' is a detachment independent of LG) and (i) isopropyl - aluminum hydride and a first base reaction to obtain (PhO)P(O)(LG)(Ala- i Pr), followed by (PhO)P(O)(LG)(Ala- i Pr) accompanied by a detachment The base precursor and a second base are reacted to obtain a mixture comprising C and C' .

The mixture is subjected to chromatography or the mixture is crystallized to obtain C' . In one aspect of the ninth embodiment, the isopropylaluminum hydride is present as its hydrochloride salt, wherein preferably it is substantially anhydrous.

The eleventh embodiment is directed to a composition obtained by the processes described in the seventh embodiment, the eighth embodiment, the ninth embodiment, or the tenth embodiment and their respective aspects. An aspect of the eleventh embodiment is directed to a composition obtained by any of the specific embodiments exemplified below. The composition thus obtained may be crystalline, crystalline, amorphous or a combination thereof.

The twelfth embodiment is directed to compound 3 , Wherein Z is a protecting group or hydrogen, which for the preparation of R P - 4 or S P - 4 useful. A first aspect of the twelfth embodiment is a compound selected from the group consisting of the following structural formula 3a: Z=-C(O)CH 2 CH 2 C(O)CH 3 3b: Z=-C(O)OCH 2 Ph 3c: Z=-Si(Me) 2 t Bu 3d: Z=-Si( i Pr) 2 OSi( i Pr) 2 OH.

A thirteenth embodiment is directed to a compound, a salt thereof, a hydrate, a solvent or a combination thereof, represented by the following structural formula Wherein LG' is a leaving group which is useful for the preparation of R P -4 or S P -4 .

In a first aspect of the thirteenth embodiment, LG' is a tosylate group, a camphorsulfonate group, an aryloxy group, or an aryloxy group substituted with at least one electron withdrawing group.

In a second aspect of the thirteenth embodiment, LG' is selected from the group consisting of p-nitrophenoxy, 2,4-dinitrophenoxy, and pentafluorophenoxy.

The fourteenth embodiment is directed to an isotopically labeled analog of R P -4 or S P -4 . The term "isotopically labeled" analog means an analog of R P - 4 or S P - 4 which is a "deuterated analog", " 13 C-labeled analogue" or "deuterated / 13 C - labeled analogues." The term "deuterated analog" means a compound described herein, which is substituted by a 1 H-isotope (i.e., hydrogen (H)) by a 2 H-isotope (i.e., deuterium (D)). The substitution of hydrazine can be partial or complete. Partial hydrazine substitution means that at least one hydrogen is replaced by at least one hydrazine. For example, for R P - 4 or S P - 4 , one of ordinary skill in the art can consider at least one of the following partially deuterated analogs (where " d n " represents n deuterium atoms, for example, for isopropyl That is, n = 1-7, and for phenyl, n = 1-5), and is described below.

Although the above-mentioned methyl groups are shown to be completely deuterated, one will recognize that partial deuteration changes are also possible, such as -CDH 2 and -CD 2 H. Isotopic labels are labeled on furanose, and bases are also considered. Similarly, the terms " 13 C-labeled analog" and "deuterated / 13 C-labeled analog" mean a compound described herein, by means of a carbon atom in increments of 13 C-isotopes, meaning The degree of increase exceeds the usual natural sufficiency of approximately 1.1%.

example

Without limiting the examples, the following examples serve as a better understanding of the disclosure.

Synthetic aspect

To prepare uridine, one can use in the synthesis of certain 3 3 ', 5'-acyl analogs (see below) trityl acylation of cytidine advanced intermediate product, the particular compound has It is synthesized efficiently on a trial scale (see WO 2006/031725 or US 2006/0122146, both of which are incorporated by reference in their entirety). The following methods were found to be scalable and cost effective.

3',5'-O-dibenzimidyl-2'-deoxy-2' is obtained by the method disclosed in WO 2006/031725 and WO 2008/045419, both incorporated herein by reference. -Fluoro-2'-C-methyl-N 4 -benzimidyl cytidine ( 1 ). Treatment with 1 % aqueous 70% acetic acid to give 3',5'-O-dibenzoylguanidino-2'-deoxy-2'-fluoro-2'-C-methyl-uridine ( 2 ). The benzamyl esters can also be hydrolyzed via several methods, such as alkoxides in alcoholic solvents, such as sodium methoxide in methanol, potassium carbonate in methanol or analogs in ethanol, alkylamines such as methanol. Methylamine, butylamine and so on. Methanol ammonia was selected as a larger scale work. From the tritylated cytidine ( 1 ), it can be purified via crystallization to obtain the uridine product ( 3 ) in 70% yield.

Several literature procedures detail the different routes and conditions for the preparation of amino phosphates using multiple equivalents of reagents. See, for example, McGuigan et al. J. Med . Chem. 2005, 48, 3504-3515 and McGuigan et al. J. Med. Chem. 2006, 49, 7215. There is currently only one known example for process scale work, which is disclosed in Lehsten et al., Org. Process Res. Dev . 2002, 6, 819-822 ("Lehsten"). In this reference, the authors introduce the concept of a "one-pot process" in which an amine hydrochloride and a phenyl dichlorophosphate are co-reacted with N-methylimidazole in dichloromethane. The nucleoside is added later to form the desired 5'-O-amino phosphate product, which in the present case will produce the compound represented by Structural Formula 4 . Unfortunately, the Lehsten program has encountered drawbacks. For example, the Lehsten program utilizes far more reagents than is required, which increases cost and increases the difficulty of chromatographic purification. Furthermore, Lehsten suggests that the selectivity of the reaction can be controlled at the 5'-hydroxy to 3'-hydroxyl group by using a lower temperature and slowly adding the nucleoside compared to the reference.

Using the procedure of Lehsten for the compounds disclosed herein, about 1-5% of the monosubstituted 3'-O-aminophosphate non-image isomer ( 5 ) and about 10-30% of the disubstituted product are provided ( 6 ). Since the polarity of the 3'-non-image isomer is very similar to the desired 5'-non-image isomer ( 4 ), chromatographic separation is very challenging. It is almost impossible to amplify the procedure without discarding most of the less polar 5'-non-image isomers ( 4 ) or not accepting the higher degree of 3'-non-image isomers ( 5 ). . In the initial 50g amplification, the resulting product contains about 3% of the 3'-non-image isomer ( 5 ) contamination, which is accompanied by a less polar 5'-non-image isomer ( 4 ) Proposed.

The reaction conditions disclosed herein use lesser amounts of reagents, and the selective removal of the impure 3'-O-aminophosphate non-image isomers ( 5 ) by a simpler chromatographic separation to provide the desired Higher purity 5'-O-amino phosphate non-image isomer ( 4 ).

For the chemometrics of reagents, studies have reported that it systematically alters the stoichiometry of the reagents and monitors the results as a phosphorous NMR as a Lehsten crude reaction. In a more successful operation, the yield and purity of the desired product separation are compared. It was observed that the primary 5'-hydroxyl group reacted at a faster rate than the secondary 3'-hydroxyl group. This creates a situation in which the reaction process that consumes all of the starting nucleosides competes with the conversion of the 5'- and 3'-monosubstituted products ( 4 and 5 ) to the 5',3'-disubstituted product ( 6 ). The 3'-monosubstituted product is converted to the disubstituted product at a rate that is faster than the 5'-monosubstituted product, thus potentially reducing the 3'-non-mirrored by further promoting the reaction to form a disubstituted product. The degree of contamination of the structure. However, with an efficient way to remove the 3'-non-image isomer, the reaction can be optimized without sacrificing so much conversion to the 5'-non-image isomer of the disubstituted product ( 6 ) Produce more of the required 5'-non-image isomers. The amine acid salt was also observed to be very sorbent. Since any moisture will consume an equivalent amount of the phenyldichlorophosphate reagent, care must be taken to keep the amino acid substantially anhydrous or should be substantially anhydrous prior to use. In short, Lehsten has reported an ideal ratio of amino acid to p-phenyl dichlorophosphate to nucleoside of 3.5:2.5:1. An ideal ratio of the amino acid to phenyldichlorophosphate to the nucleoside was found to be efficiently removed in the 3'-non-image isomer and when the amino acid hydrochloride was substantially anhydrous In the case of about 1.6, about 1.6 to about 1 is ideal. By using a smaller amount of reagent, it is understood that the cost savings are coupled to the simplification of chromatographic separation of the desired product from the reagent by-product and from the reduced degree of the dual non-image isomer.

In an alternative procedure, a 3'-hydroxyl-blocking derivative of 3 is prepared using a t-butyldimethylhydrazine blocker in two steps. It is then converted to its 5'-amino phosphate derivative. It is desirable that the alkyl group be removed and will not have a 3' isomer ( 5 ) or a 3',5'-diamino phosphate ( 6 ). A similar approach was verified by low molar yields of alkylamino phosphates by Borch and Fries (U.S. Patent No. 5,233,031).

Another alternative approach is to use direct synthesis using chemical methods and to assist in the 5'-4 from the desired impurities to distinguish the 3'-5 diastereomers and enantiomers of help separated. A group is required to selectively react with the free primary hydroxyl group of 3'-O-amino phosphate impurity 5 to the desired free secondary hydroxyl group of 5'-O-amino phosphate 4 . It is also desirable that the barrier be significantly altered from the desired 5'-O-aminophosphate 4 to form the polarity of the 5'-O-blocked 3'-O-amino phosphate product. Since the desired 5'-non-image isomer 4 will not be altered, no additional steps will be required to remove the barrier. The chemically altered 3'-non-image isomer will then facilitate separation of the chromatographic or separation via special scavenging support or via extraction.

Specifically, the barrier t-butyl dimethyl fluorenyl (Tbdms) meets these criteria and is the first one to be demonstrated and then used on a few kilograms. Under certain conditions, such as when pyridine is used as a solvent and a base, the tBDMS group is highly selectively reactive to the 3' secondary hydroxyl position at the primary hydroxyl position. The amino phosphate reaction uses N-methylimidazole (NMI) as a base. In the presence of NMI, this degeneration is less selective. Preferably, the amount of NMI should be reduced. This can be easily achieved by rinsing the reaction solution with 1 N hydrochloric acid after the reaction of the amino phosphate. The NMI and the remaining starting nucleosides are removed leaving a crude mixture of the single and disubstituted products with the by-products of the reagents. It was then dissolved in pyridine and treated with tert-butyldimethylmethyl chloride. The 3'-monosubstituted product 5 is converted to the 5'-O-tBDMS-3'-O-amino phosphate 7 in a few hours (or less). This experimental procedure can be monitored by HPLC. This deuterated product 7 is less polar than the bis-amino phosphate 6 and is easily removed by chromatography. Using this method, it is possible to reduce the 3'-monoaminophosphate 5 by at least 5'-product 4 by 0.1% (compared to 1-3%) without thiol treatment. Similarly, treatment with dimethoxytrityl chloride (DMT-Cl) under the same conditions can be done equally well. By TLC, it is also easier to identify the DMT reaction product when DMT containing a bright orange molecule is heated or exposed to an acid. As mentioned above, many other barriers are also contemplated.

Both the reaction conditions and elimination of the 3'-impurity are common methods and can be applied to most nucleoside amino phosphates having a free 3' hydroxyl group. The amino phosphate moiety can be a combination of any amino acid ester and an aromatic alcohol. The nucleoside motif can be any nucleoside whose 5' amino phosphate will result in 5'-monophosphate and can be further metabolized to the 5'-triphosphate form.

The following scheme is the main reaction scheme, illustrating the production of 2'-deoxy-2'-fluoro-2'-C-methyluridine isopropyl L-hydrogenated aluminum phenyl phosphate, accompanied by The main product is the desired 5'-O-amino phosphate ( 4 , two non-image isomers) and the lesser product is 3'-O-amino phosphate ( 5 , two non-image isomers) And 3',5'-bis-O-amino phosphate ( 6 , four non-image isomers). The reagent is added according to the stoichiometric ratio in the method described in the preparation paragraph. The reaction was allowed to proceed until about 5% of the starting material remained as determined by UV visualization on thin layer chromatography (TLC). UPLC/MS also showed that approximately 10% of the 3',5' bis-amino phosphate 6 was formed compared to the desired 5'-product. After quenching and the action of the acidic solution, the crude residue from the organic layer is prepared for deuteration. Under the described reaction conditions, the sulfhydryl group preferentially reacts with the free 5'-hydroxyl group of the 3'-O-amino phosphate to form 7 . The reaction was continued until the 3'-O-amino phosphate was no longer detectable via UPLC/MS.

After the deuteration reaction, the desired product was chromatographically chromatographed and eluted with a gradient of methanol (1-4%) in dichloromethane. Finally, the desired 5'-monoaminophosphate 4 is proposed.

Preparation Example 1. Preparation of 2'-deoxy-2'-fluoro-2'-C-methyluridine (3)

In a 10 L flask, 3',5'-O-dibenridinyl-2'-deoxy-2'-fluoro-2'-C-methyl-N 4 -benzimidyl cytidine ( 500 g, 0.874 mol) and 70% aqueous acetic acid (7.5 L). The solution was heated to reflux (110 ° C) for 20 hours. TLC indicated complete reaction (Rf 0.6 in 5% methanol in dichloromethane (DCM)). The mixture was cooled to a greenhouse and diluted with water (2 L). After stirring for 2 hours, the resulting precipitate was collected by filtration, rinsed with water (5 L) and dried in air at room temperature for 12 hours to afford 360 g (88%) of this solid. This benzhydryl uridine intermediate was used directly in the next step and was all added to freshly prepared methanolic ammonia (5.4 L, ca 25%) at 0 °C. This temperature was maintained for 3 hours and then allowed to warm to 15 ° C for 24 hours. TLC indicated complete reaction (Rf 0.4 to 10% methanol in DCM). The reaction mixture was filtered through a pad of celite and concentrated under reduced pressure to afford the crude product (216 g). The crude product was stirred with ethyl acetate (325 mL) at room temperature for 3 hr. The resulting solid was collected via filtration and washed with ethyl acetate (216 mL). The solid was dried under vacuum at room temperature for 4 hours to afford 160 g (78%) of desired product of HPLC. 1 H-NMR (DMSO- d 6 ) δ 11.44 (br s, 1H, NH), 7.95 (d, 1H, C-6H), 5.97 (d, 1H, C-1 'H), 5.64 (d, 1H) , C-5H), 3.84-3.77 (m, 3H, C-5'-Ha, C-3'HC-4'H), 3.63-3.60 (m, 1H, C5'-Hb), 1.23 (d, 3H, C-2'-CH 3 ). ES-MS M-1 259.

Example 2. Preparation of (S)-2-{[(1R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-(R )-Fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphonium}-propionic acid isopropyl ester (4)

Alias: 5'-O-(isopropyl-L-aluminum hydride, phenylphosphonium amide)-2'-deoxy-2'-fluoro-2'-C-methyl-uridine Mixture of substances.

A 5 L three-necked flask was fitted with a mechanical stir bar, a brine ice bath, an internal thermometer, and a nitrogen atmosphere. The flask was charged with L-alanine isopropyl ester hydrochloride (82.0 g, 0.490 moles) and anhydrous dichloromethane (0.80L). While stirring, a batch of phenyl dichlorophosphate (85.0 g, 0.40 moles) was added and stirred. While maintaining the internal temperature between -5 and 5 ° C, a solution of N-methylimidazole (NMI, 250 g, 3.07 moles) in dichloromethane (250 mL) was added over a period of half an hour. The solution was allowed to stir for 1 hour at this temperature range. 2'-Deoxy-2'-fluoro-2'-C-methyl-uridine ( 3 , 80.0 g, 0.307 moles) was added portionwise at 0 °C and then the flask was slowly warmed in a brine bath. The internal temperature rose to -2 ° C over 1 hour. TLC (5% methanol in DCM) at 1 hour showed that more than 50% of the nucleosides were consumed. The bath was removed and the reaction flask reached room temperature over 1 hour. A total of 95% of the starting nucleosides were consumed by TLC after 3 and 5 hours. The reaction mixture was quenched by the addition of methanol (100 mL) and the reaction was stirred for 5 min.

The reaction mixture was washed with 1N HCl (2×500 mL) then sat. The separated organic layer was dried over anhydrous sodium sulfate (50 g) and filtered. The solution was evaporated under reduced pressure and dried under high vacuum to afford crude (yield: 170 g) as a viscous oil. The NMRs ( 31 P and 1 H) of this crude product were obtained. The 31 P-NMR indicated that about 1% of all phosphorus was formed due to the presence of the 3' isomer 5 .

Anhydrous pyridine (1700 mL) was added to the crude product. The solvent is evaporated under reduced pressure and then the water content in the crude mixture is reduced by co-evaporation under high vacuum. The resulting oil was re-dissolved in anhydrous pyridine (500 mL) then excess t-butyl dimethyl decyl chloride (9.0 g, 60 mM). The reaction was stirred at room temperature. The reaction process was monitored by UPLC/MS. After 3 hours, the 3' impurity 5 was no longer detected and the reaction was quenched by the addition of methanol (50 mL).

The reaction was evaporated to an oil under reduced pressure. The residue was dissolved in ethyl acetate (1. 5 mL) and washed with EtOAc EtOAc. The organic layer was dried over anhydrous sodium sulfate (50 g).

The crude oil was diluted with the same volume of dichloromethane and loaded with 2.5 Kg of hydrazine in a radiation compression module at a pressure of 100 psi. A gradient pump was used at 60 psi and the flow rate was 400 mL/min, and the hydrazine was rinsed with dichloromethane (4 L) followed by a 1-4% gradient of methanol (48 L) in dichloromethane. The main impurity (di-(isopropylpropylamine hydrazide) phenyl phosphate, 3',5'-bis-amino phosphate ( 6 ), 3'-amino phosphate-5'-TBDMS adduct ( 7 Most of the)) is flushed with a gradient of ~3%. The desired product was flushed between 3 and 4% methanol. The product comprising a plurality of components is divided into two batches. The first batch contains a small amount of the upper impurity and is followed by a pure product. The first group of components contains a small amount of less polar impurities (upper impurities), such as the 3',5'-diamino phosphate and di-alanamine phenyl phosphate and most of the Rp non-image isomerism And a second column purification is required. (Relatively, the upper layer to the lower layer means the extraction of a normal phase of the rubber tube column, wherein the "upper layer isomer" means the first flushed isomer.) The second group of components does not have a significant amount Impurities - only the remaining R P and mostly S P non-image isomers. The components of the column are combined twice later. The solvent was evaporated under reduced pressure, and the resulting white foam was further dried (0.20 mmHg) for 1 hour to afford a crude portion of 42 g (4:1 upper layer to lower layer isomer based on &lt; 31 &gt; ) with a pure batch of 38g (1:3 upper layer to lower layer isomer). The impure batch was passed through the column in a similar manner to provide a 4:1 ratio of 3.8 g, 97% purity oversize (reserved component) and 36 g of pure product. The two main batches were dissolved in DCM, combined, evaporated under reduced pressure and dried (50 ° C, 0.2 mm Hg, 24 hr) to give a non-image isomer ratio of 74:51 of 74 g (45.7%) It is a white foamy pure product 4 with a melting point of about 75-85 °C.

To form the amorphous solid of the mixture of non-image isomers, 74 g of a white foam was stirred with t-butyl methyl ether (750 mL) to form a portion of the solution and residue of viscous solid. When stirring, heptane (750 mL) was slowly added and the suspension was mechanically stirred for 1 hour until most of the viscous material turned into a white solid. The solid was scraped off with a spatula and the resulting slurry was filtered. The solid was rinsed with heptane (4 x 50 mL) and dried under vacuum (50 ° C, 0.2 mm Hg, 24 hours) to afford a white amorphous powder with a broad melting range of ca 70-80 ° C ( 64g). 1 H and 31 P NMR were consistent with the structure, and HPLC showed a purity of 99.8% with a ratio of non-image isomers of 46:54 (also confirmed by 31 P NMR).

To form the amorphous solid of the mixture of non-image isomers, 74 g of a white foam was stirred with t-butyl methyl ether (750 mL) to form a portion of the solution and residue of viscous solid. When stirring, heptane (750 mL) was slowly added and the suspension was mechanically stirred for 1 hour until most of the viscous material turned into a white solid. The solid was scraped off with a spatula and the resulting slurry was filtered. The solid was rinsed with heptane (4 x 50 mL) and dried under vacuum (50 ° C, 0.2 mm Hg, 24 hours) to afford a white amorphous powder with a broad melting range of ca 70-80 ° C ( 64g). 1 H and 31 P NMR were consistent with the structure, and HPLC showed a purity of 99.8% with a ratio of non-image isomers of 46:54 (also confirmed by 31 P NMR).

Characterization of the mixture of the isomers ( 4 ): 1 H-NMR (CDCl 3 ) δ 10.05 (br s, 1H, NH, S P ), 10.00 (br s, 1H, NH, R P ), 7.49 (d , 1H, C6-H, S P ), 7.36 (m, 5H, C6-H, R P , aromatic), 7.23 - 7.14 (m, 6H, R P / S P , aromatic), 6.18 (br d , 2H, C1'-H, R P / S P ), 5.63 (d, 1H, C5-H, S P ), 5.58 (d, 1H, C5-H, R P ), 5.01 (m, 2H, C H -(CH 3 ) 2 , R P / S P ), 4.46-4.33 (m, 8H, C-5'-H 2 , ala-NH, C3'-OH, R P / S P ), 4.12 (m , 2 H, ala-C H -CH 3 , R P / S P ), 4.01-3.85 (m, 4H, C3'-H, C4'-H, R P / S P ), 1.39-1.22 (m, 12H, all CH 3 , R P / S P ).

31 P-NMR (CDCl 3 ) δ 3.60 ( R P ), 3.20 Sp at -17.80 ppm relative to triphenyl phosphate. ES-MS M+1 530.2. Elemental analysis: % calculated (including 0.29% water, as found by Karl Fisher analysis) C, 49.75; H, 5.54; N, 7.90, F, 3.58, P, 5.84. Found %: C, 49.50; H, 5.44; N, 7.85; F, 3.62; P, 6.05.

Discussion on the separation of isomers

Due to the palmarity on phosphorus, compound 4 consists of two non-image isomers, which are designated S P - 4 and R P - 4 . The stereochemical distribution was made according to the single crystal X-ray analysis of S P -4 . Both R P - 4 and S P - 4 form crystalline products. The procedure for crystallization is outlined below.

Example 3. R P -4 crystallization of isomers

The chromatographic fraction (3.8 g, purity 97%) containing the first flushed, lower polarity R P -4 isomer was dissolved in isopropanol (36 g) and diluted with heptane until turbid Shape (72g). The solution was seeded and stirred at room temperature for 5 hours. The resulting solid was collected via vacuum filtration, washed with heptane (2.times.20 mL) and dried (50[deg.] C. The HPLC purity of the resulting material was found to be 99.02%.

R P - 4 : 1 H-NMR (CDCl 3 ) δ 9.10 (br s, 1H, NH), 7.36 (m, 2H, o - aromatic), 7.26-7.16 (m, 4 H, C6-H, m , p - aromatic), 6.16 (br d, 1H, C1'-H), 5.58 (d, 1H, C5-H), 5.01 (sept, 1H, C H - (CH 3 ) 2 ), 4.52-4.47 (m, 2H, C-5'-H 2 ), 4.10 (d, 1H, C3'-H), 4.02-3.76 (m, 4H, ala-NH, C3'-OH, C4'-H, ala- C H -CH 3 ), 1.37-1.20 (m, 12H, all CH 3 ).

Example 4. S P -4 preparation and crystallization

Method 1: Direct precipitation from crude 4 : Dichlorophenyl phosphate (7.5 mL, 50 mmol) was added to isopropyl L-propyl propylamine hydrochloride (10.5 g, m. 61.5 mmol, azeotropically dried twice with 50 mL of toluene each time). The mixture was cooled to -10 ° C and a solution of NMI (30.5 mL, 38. After the addition was completed, the mixture was stirred at -10 and -15 ° C for 1 hour. A batch of 2'-deoxy-2'-fluoro-2'-C-methyluridine ( 3 ) (10 g, 38.4 mmol) was added to the above mixture and the mixture was stirred at -10 °C for 3 hours. And slowly let it warm to 20 ° C (6 hours). The mixture was stirred at this temperature overnight (15 hours) and then quenched with 10 mL of methanol. The solvent was evaporated and the residue was crystallised from EtOAc EtOAc. Water (100mL), 1N HCl (3 × 75mL), 2% NaHCO 3 solution (50mL) and brine (50mL) rinsing the EtOAc layer. Through the organic layer dried over Na 2 SO 4, filtered and concentrated. The residue was dried under high vacuum for 2 hours to afford a white foam (22 g).

The above foam was dissolved in 33 mL of DCM, then 65 mL of IPE (isopropyl ether) was added to give a saturated solution. The solution was filtered through a small pad of diatomaceous earth, and room temperature (about 22 ℃ - note will cause the crude oil product suspension was cooled to 0 deg.] C) to S P - 4 seeding the filtrate was stirred for 72 hours. The white solid was filtered to IPE (20mL) washed and dried to provide 4.58 g of (as measured by 31 P NMR, respectively, ~ 85: S 15 of P - 4: R P - 4 mixture) as a white powder. The above solid was suspended in 23 mL of DCM and then refluxed for 3 hr. The mixture was cooled to room temperature and stirred for 15 hours. The white solid was filtered, rinsed with cold 4.5mL of DCM and the height of 45 ℃ dried under vacuum to provide the pure S P - 4, m.p. 93.9-104.7 ℃, HPLC purity 99.74% (3.11g, 15.2% from the urinary Nucleoside).

S P - 4 1 H-NMR (CDCl 3 ) δ 8.63 (br s, 1H, NH), 7.47 (d, 1H, C6-H), 7.30 (m, 2H, o - aromatic), 7.26-7.18 ( m, 3H, m,p -aromatic), 6.18 (br d,1H,C1'-H), 5.70 (d,1H,C5-H), 5.02 (sept,C H -(CH 3 ) 2 ), 4.53 (m, 2H, C-5'-H 2 ), 4.11 (d, 1H, C3'-H), 3.97 (m, 3H, C3'-OH, C4'-H, ala-C H -CH 3 ), 3.77 (br s, 1H, ala-NH), 1.39 (d, 3H, C2'-CH 3 ), 1.37 (d, 3H, ala-CH 3 ), 1.24 (d, 6H, CH-(C H 3 ) 2 ).

Method 2: Oil from crude 4 : Phenyldichlorophosphate (14.9 mL, 100 mmol) was added to isopropyl L-propyl propylamine hydrochloride (20.6 g) in dichloromethane (200 mL). , 123 mmol, azeotropically dried (75 times each time with a total of 75 mL of toluene) in a stirred solution. The mixture was cooled to -10 ° C then a solution of NMI (61.3 mL, 769 mmol) in 60 mL dichloromethane. After the addition was completed, the mixture was stirred at -10 and -15 ° C for 1 hour. A batch of 2'-deoxy-2'-fluoro-2'-C-methyluridine ( 3 ) (20 g, 76.9 mmol) was added to the above mixture and the mixture was stirred at below -10 °C for 3 hours. Then slowly warm it to 20 ° C (6 hours). The mixture was stirred at this temperature overnight (15 hours) and quenched again with 10 mL of methanol. The solvent was evaporated and the residue was crystallised from EtOAc EtOAc. Water (200mL), 1N HCl (3 × 100mL), 2% NaHCO 3 solution (100 mL) and brine (50mL) rinsing the EtOAc layer. Through the organic layer dried over Na 2 SO 4, filtered and concentrated. The residue was dried under high vacuum for 2 hours to afford a white foam (43 g). The above foam was dissolved in 86 mL of EtOAc in a two-necked round bottom flask containing a mechanical stirrer. While stirring, 100 mL of heptane was slowly added and the suspension was stirred for 1 hour. The supernatant was decanted and the residue was stirred with 50 mL of 2:3 EtOAc /Heptane for 10 min then decanted. The residue was dried under high vacuum to afford a white foam (31 g).

The above foam was dissolved in 46 mL of DCM and then 95 mL of IPE was added to give a saturated solution. Through a small pad of diatomaceous earth was filtered and the solution, at room temperature and S P - 4 seeding the filtrate was stirred for 72 hours. The white solid was filtered to IPE (30mL) washed and dried to provide 7.33 g (as measured by 31 P NMR, and were ~ 85: S 15 of P - 4: R P - 4 mixture) as a white powder. The above solid was suspended in 36 mL of DCM and then refluxed for 3 hr. The mixture was cooled to room temperature and stirred for 15 hours. The white solid was filtered, rinsed with cold 7.5mL of DCM and the height of 45 ℃ dried under vacuum to provide> 99% pure S P - 4 (4.78g, 11.6 % from the uridine).

Method 3: Crude 4 loading of the gum: in the same manner as the mixture of non-image isomers, just before the column chromatography step, with approximately 2.5 g of 2'-deoxy-2'-fluoro-2' Starting from -C-methyluridine ( 3 ), 5.0 g of crude 4 was produced. The crude material was dissolved in 10 mL of DCM and 10 g of silica gel was added to the solution. The solvent was evaporated to give a cement free slurry. The slurry was stirred with 40 mL of 50% EtOAc / hexanes for 15 min then filtered. The tannin was rinsed with an additional 10 mL of 50% EtOAc in hexanes. Then with 15% MeOH/DCM

The gel was rinsed (100 mL) and collected separately. The solvent was evaporated and dried under high vacuum to provide 4.0 g of residue (foam). The residue was dissolved in DCM (6 mL) and then &lt;~&gt; The mixture was then gently stirred with S P - 4 seeds overnight at room temperature. The white solid was filtered and washed with EtOAc (5 mL) to afford 1.28 g. 31 P NMR showed the above product to contain a mixture of S P - 4 : R P - 4 of 77:23, respectively. This was recrystallized from 20mL of DCM to obtain 0.75g,> 99% purity of the S P - 4 (12% from the uridine). This S P - 4 Preparation of a silicide step is accomplished without the mixture, so that the entire reaction sequence as shown above. The aspects of the single crystal and polymorphic form of S P - 4 are as follows.

Method 4: 40.0g, 1: 1 mixture of 4 dissolved in 90mL of dichloromethane. Diisopropyl ether (70 mL) was added to the above solution to provide a saturated solution. (The amount of diisopropyl ether may vary depending on the purity of the product.) The solution is seeded as pure S P -4 (>99%) and the mixture is gently stirred at room temperature for 20 hours with a stir bar (at 2 Solid formation was observed after an hour). The solid was filtered, diisopropyl ether to 40mL / dichloromethane: Flush (11) of the mixture, and dried to provide a white solid (16.6 g of, by NMR purity of 89.35% S P - 4). The solid was suspended in 83 mL of dichloromethane and refluxed for 3 hours. The suspension was cooled to room temperature and stirred overnight. The solid was filtered and rinsed with 10 mL cold DCM. The solid was dried under vacuum to afford S P - 4 (13.1 g, mp. 11 g of this solid was redissolved in 330 mL of DCM under hot conditions. The solution was cooled to room temperature and left at this temperature overnight. The crystallized product was filtered and dried to give 10.5 g of S P - 4 (from HPLC 99.74%).

Compounds S P -4 and R P - 4 may alternatively be prepared, via a nucleoside (protected or unprotected) 3 via an isopropyl-propylamine thiol group, according to the ninth or tenth embodiment. Amino phosphate (mixture of C and C' , C or C' ), as shown in the following equation.

PD Howes et al. Nucleosides, Nucleotides & Nucleic Acids 2003, Vol. 22, Nos. 5-8, pp. 687-689 ("Howes") discloses 2'- and 5'- obtained via reaction with tert-butylmagnesium chloride. Amino phosphate. Here, Howes discloses the reaction of 3'-deoxy-cytidine with methyl (S)-2-[chloro-phenoxy-phosphonamido]propionate, which is equivalent to 1.2 equivalent tert-butyl Selective phosphorylation occurs at the 2'-position in the presence of magnesium chloride, but with additional equivalent tert-butylmagnesium chloride, selective phosphorylation occurs at the 5'-position. This disclosure should be compared with those disclosed in Option 1.

Example 5-1. Preparation of (S)-2-[(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester

A solution of one of phenol and triethylamine (7.7 mL, 55 mmol) in dichloromethane (100 mL) was added at -78 ° C over 4 min. A stirred solution of chlorophosphate (12.8 g, 50 mmol). The mixture was stirred at this temperature for 30 minutes and then transferred to a EtOAc EtOAc EtOAc (EtOAc) A second crop of triethylamine (14.6 mL, 105 mmol) was added to the mixture over 15 min. The mixture was stirred at 0 ° C for 1 hour and then the solvent was evaporated. The residue was triturated with ethyl acetate (150 mL) and then filtered. The filtrate was concentrated under reduced pressure to give a pale yellow oil. The crude compound was chromatographed using a gradient of 0-20% ethyl acetate/hexanes to afford product (17 g, yield 83%) as a mixture. 31 P NMR (162MHz, DMSO- d6): δ -0.31, -0.47; 1 H NMR (400MHz, DMSO-d6): δ 8.31-8.27 (m, 2H), 7.51-7.37 (m, 4H), 7.27- 7.19 (m, 3H), 6.70-6.63 (m, 1H), 4.85-4.78 (m, 1H), 3.97-3.86 (m, 1H), 1.21-1.19 (m, 3H), 1.11-1.09 (m, 6H) MS (ESI) m/z 407 (M-1) + . 31 P NMR (162 MHz, CDCl 3 ): δ -2.05, -2.10; 1 H NMR (400 MHz, CDCl 3 ) : δ 8.22 (d, J = 9.2 Hz, 2H), 7.41 - 7.33 (m, 4H), 7.26-7.18 (m, 3H), 5.05-4.96 (m, 1H), 4.14 - 4.05 (m, 1H), 3.93 - 3.88 (m, 1H) ), 1.38 (d, J = 6.8 Hz, 3H), 1.22 (dd, J = 6.2 & 3.0 Hz, 6H); MS (ESI) m/z 407 (M-1).

Example 5-2. S P -4/ R P -4 preparation

1.0 M solution of tert-butylmagnesium chloride (1.05 mL, 1.05 mmol, 2.1 equivalent) was added to 1-((2R,3R,4R,5R) in anhydrous THF (1.5 mL) at room temperature over 5 min. a stirred solution of 3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione (130 mg, 0.5 mmol) in. After 30 minutes, (S)-2-[(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropylate (1:1) in THF (1.5 mL) A solution of the mixture of isomers, 408 mg, 1 mmol) was added dropwise over 5 minutes. The mixture was stirred for 48 hours at room temperature and then subsided saturated aqueous NH 4 Cl (20ml). The mixture was partitioned between ethyl acetate (50 mL) and water (20 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered and evaporatedEtOAc. The residue was purified using a gradient of 0-2% MeOH / methylene chloride column chromatography to provide of a white foamy solid (125 mg of, 47% yield, ratio of about 3.05: 1.0 S P -4 / R P -4 mixture).

Example 6. Preparation and non-chromatographic separation of (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester

L-alanine isopropyl ester hydrochloride (330 g, 1.97 mol) was pre-dried under reduced pressure via co-evaporation with toluene (2 x 400 mL), and then in a vacuum oven (50 ° C, 0.2 mm Hg, 17 hours) dry. A solution of phenol (183.8 g, 1.953 mol) and triethylamine (300 mL, 2.15 mol) in dichloromethane (900 mL) was added to dry methylene chloride (3.0) over EtOAc. A stirred solution of 4-nitrophenyl dichlorophosphate (500.0 g, 1.953 mol) in L). The mixture was stirred at this temperature for an additional 30 minutes and then allowed to warm to -5 °C over 2.5 hours. The pre-dried amino acid ester was added in a nitrogen atmosphere at -5 to 0 ° C for 10 minutes. The residue of the amine ester salt in an additional flask was transferred to the reaction mixture by rinsing with dichloromethane (2 x 100 mL). The mixture was stirred at 0 ° C for 40 minutes and a second portion of triethylamine (571 mL, 4.10 mol) was added over a period of 40 min. The mixture was stirred at 0 to 10 ° C for 3 hours, then a white solid (triethylamine hydrochloride) was removed by filtration and rinsed with dichloromethane (3×300mL). The filtrate was concentrated under reduced pressure and the residue was triturated with methyl tert-butyl ether (MTBE, 4L). The thus formed additional solid salt was removed by filtration and rinsed with MTBE (3×150 mL). The filtrate was concentrated under reduced pressure to give a clear brown oil. The residue was co-evaporated with hexane (2 x 140 mL) to remove any residual MTBE and further dried under vacuum at 40 °C for 2 hours. The dried residue was mixed with diisopropyl ether (IPE, 1.1 L) and stirred in an ice water bath at 5 °C. A small amount of the desired S P -isomer of the product was added to the solution and the mixture was stirred at 5 ° C for more than 22 hours to form a medium thickness slurry. It was placed in a freezer (-10 ° C) for 44 hours. The precipitated product was collected by filtration and rinsed with a mixture of pre-cooled IPE and hexane (1:1, 3×190 mL). The solid was dried under vacuum at room temperature (0.5 mmHg) until a constant weight was obtained to afford 227.23 g (yield: 28.5%) as a white powder. The ratio of the two non-image isomers S P : R P was 9.65/1 according to 31 P NMR (162 MHz, DMSO-d 6 , δ -0.31 ( S P ), -0.47). The product was recrystallized by dissolving in IPE (840 mL) while heating in a 60 ° C water bath. The solution was stirred at room temperature for 1 hour, and then seed crystals of a small amount of crystalline Sp isomer were added. A white powder solid was formed over 2 hours and the flask was stored in a freezer (-10 ° C) for 16 hours. The obtained white and fine crystalline solid was filtered, washed with pre-cooled IPE (3×50 mL) and dried under vacuum (room temperature, 0.5 mmHg) to a constant weight to afford a white fluffy solid (177.7 g, According to the theoretical yield of the S P isomer, the total yield was 22% or 44%), with a ratio of 48/1 according to the 31 P-NMR non-image isomer. Melting point 62-66 ° C.

31 P NMR (162MHz, DMSO- d6): δ -0.31; 1 H NMR (400MHz, DMSO-d6): δ 8.30-8.27 (m, 2H), 7.49 (d, J = 8.8Hz, 2H), 7.41- 7.37 (m, 2H), 7.23-7.19 (m, 3H), 6.66 (dd, J = 13.6, 10.0 Hz, 1H), 4.86-4.78 (m, 1H), 3.97-3.86 (m, 1H), 1.19 ( d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.4 Hz, 6H); 31 P NMR (162 MHz, CDCl 3 ): δ -2.05; (162 MHz, DMSO-d6): δ -0.31; 1 H NMR (400MHz, CDCl 3 ): δ 8.22 (d, J = 9.2 Hz, 2H), 7.41-7.33 (m, 4H), 7.26-7.18 (m, 3H), 5.05-4.96 (m, 1H), 4.14 4.05 (m, 1H), 3.93-3.88 (m, 1H), 1.38 (d, J = 6.8 Hz, 3H), 1.22 (dd, J = 6.2 & 3.0 Hz, 6H); 1 H NMR (400 MHz, DMSO- D6): δ 8.30-8.27 (m, 2H), 7.49 (d, J = 8.8 Hz, 2H), 7.41-7.37 (m, 2H), 7.23-7.19 (m, 3H), 6.66 (dd, J = 13.6) , 10.0 Hz, 1H), 4.86-4.78 (m, 1H), 3.97-3.86 (m, 1H), 1.19 (d, J = 7.2 Hz, 3H), 1.10 (d, J = 6.4 Hz, 6H)

MS (ESI) m / z 407 (M-1) +.

The stereochemistry of 8 ( S P -isomer) has been confirmed by single crystal X-ray crystallography, see details provided below.

Example 7. Separation of non-Spiegelmer mixture via SFC (S)-2-[(4-Nitro-phenoxy)-phenoxy-phosphonium] isopropyl propionate

A sample (4.8 g) of a mixture of non-image isomers amplified with R P -isomer was used for SFC using a ChiralPak AD-H (2 x 15 cm) column and 35% in carbon dioxide at 100 bar Isopropyl alcohol is extracted. Injection loading of a 4 mL sample of methanol at a concentration of 17 mg/mL. The R P -isomer [(S)-2-[(R)-(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl] was first flushed out. Suitable fractions were combined and the multiple operations in a case where concentrated under reduced pressure to provide a pale yellow viscous oil, 2.9 g of the R P - isomer [(S) -2 - [( R) - (4 -Nitro-phenoxy)-phenoxy-phosphonium]propionic acid propionate], and provided as a white solid, 1.9 g of S P -isomer [(S)-2-[(S )-(4-Nitro-phenoxy)-phenoxy-phosphonium] isopropyl propionate]. The analytical data of the R P -isomer is similar to the product isolated by the above crystallization method.

Analytical data of (S)-2-[(R)-(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester (8, R P -isomer): 31 P NMR (162 MHz, DMSO-d6): δ -0.47; 1 H NMR (400 MHz, DMSO-d6): δ 8.30-8.27 (m, 2H), 7.46-7.38 (m, 4H), 7.27-7.20 (m) , 3H), 6.68 (dd, J = 13.8, 10.2 Hz, 1H), 4.86-4.77 (m, 1H), 3.97-3.86 (m, 1H), 1.20 (d, J = 7.2 Hz, 3H), 1.10 ( dd, J = 6.2,2.2Hz, 6H) ; MS (ESI) m / z 407 (m-1) +.

Example 8-1. Preparation of racemic 2-[(4-chloro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester (±):

A solution of phenol (0.94 g, 10 mmol) and triethylamine (1.56 mL, 11 mmol) in dichloromethane (20 mL) was added in dichloromethane (20 mL) A stirred solution of chloro-phenyl dichlorophosphate (2.45 g, 10.0 mmol). The mixture was stirred at this temperature for 30 min then transferred to EtOAc EtOAc (EtOAc) A second crop of triethylamine (2.92 mL, 21 mmol) was added to the mixture over 15 min. The mixture was stirred at 0 ° C for 1 hour and then the solvent was evaporated. The residue was triturated with ethyl acetate (30 mL) and the white solid was filtered. The filtrate was concentrated under reduced pressure to give a pale yellow oil. The crude compound was chromatographed using a 10-20% gradient of ethyl acetate /hexane to afford product (2.0 g, yield 50%) 31 P NMR (162 MHz, CDCl 3 ): δ -1.58, -1.62; 1 H NMR (400 MHz, CDCl 3 ) : δ 7.06-7.51 (m, 8H), 7.15-7.28 (m, 2H), 7.29-7.47 ( m, 2H), 4.0-4.10 (m, 1H), 3.82-3.88 (m, 3H), 1.35-1.36 (dd, 6H); 1.19-1.22 (m, 3H). MS (ESI) m/z 398 ( M-1) + . The resulting product is purified by extraction, crystallization or chromatography as described above.

Example 8-2. (S)-Isopropyl 2-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) Preparation of -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)(phenoxy)-phosphoniumamine)propionic acid (4)

A solution of 1.7 M tert-butylmagnesium chloride (12.4 mL, 21 mmol, 2.1 equivalent) was added to 1-((2R,3R,4R,5R)-3 in anhydrous THF (50 mL) over 15 min. a stirred solution of -fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione ( 3 , 2.6 g, 10 mmol) in. After 30 minutes, racemic ( 2-[(4-chloro-phenoxy)-phenoxy-phosphonamido]propionic acid isopropyl ester was added dropwise in THF (15 mL) over 10 min. (4.08 g, 10 mmol). The mixture was stirred at room temperature for 72 hours. The TLC co-point with the real product showed about 5% of the desired product compared to the starting nucleoside.

Example 9-1. Preparation of racemic 2-[(2-chloro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester (±)

A solution of phenol (3.76 g, 40 mmol) in trichloromethane (80 mL) and triethylamine (6.16 mL, 44 mmol) was added at -78 ° C for 20 min in dichloromethane (80 mL) A stirred solution of chloro-phenyl dichlorophosphate (9.8 g, 40 mmol). The mixture was stirred at this temperature for 30 min and then transferred to EtOAc EtOAc (EtOAc) A second crop of triethylamine (11.6 mL, 84 mmol) was added to the mixture over 15 min. The mixture was stirred at 0 ° C for 1 hour and then the solvent was evaporated. The residue was triturated with ethyl acetate (100 mL) and the white solid was filtered. The filtrate was concentrated under reduced pressure to give a pale yellow oil. The crude compound was chromatographed using a 10-20% gradient of ethyl acetate /hexane to afford product (11.3 g, yield 72%). 31 P NMR (162 MHz, CDCl 3 ): δ -1.58, -1.61; 1 H NMR (400 MHz, CDCl 3 ) : δ 7.06-7.51 (m, 8H), 5.02-5.94 (m, 1H), 4.10-4.16 ( m, 1H), 3.31-3.94 (m , 1H), 1.18-1.35 (m, 3H), 1.38-1.40 (dd, 6H); MS (ESI) m / z 398 (m-1) +. The resulting product is purified by extraction, crystallization or chromatography as described above.

Example 9-2. (S)-Isopropyl 2-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) Preparation of -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)(phenoxy)-phosphoniumamine)propionic acid

A solution of 1.7 M tert-butylmagnesium chloride (12.4 mL, 21 mmol, 2.1 equivalent) was added to 1-((2R,3R,4R,5R)-3 in anhydrous THF (50 mL) over 15 min. a stirred solution of -fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione ( 3 , 2.6 g, 10 mmol) in. After 30 minutes, ( 2-[(2-chloro-phenoxy)-phenoxy-phosphonamido]propionic acid isopropyl ester ( racemic) was added dropwise in THF (15 mL) over 10 min. A solution of 4.08 g, 10 mmol) was allowed to stir at room temperature for 72 hours. The TLC co-point with the actual product showed about 5-10% of the desired product compared to the starting nucleoside.

Example 10-1. Racemic 2-[(2,3,4,5,6-pentafluoro-phenoxy)-phenoxy-phosphoniumamine Preparation of isopropyl]propionate (±)

A solution of phenol and triethylamine (3.08 mL, 22 mmol) in dichloromethane (40 mL) was added at -78 ° C over 15 min. A stirred solution of (6.0 g, 20 mmol). The mixture was stirred at this temperature for 30 minutes and then transferred to a EtOAc EtOAc EtOAc EtOAc (EtOAc) A second crop of triethylamine (5.84 mL, 42 mmol) was added to the mixture over 15 min. The mixture was stirred at 0 ° C for 1 hour and then the solvent was evaporated. The residue was triturated with ethyl acetate (60 mL) and the white solid was filtered. The filtrate was concentrated under reduced pressure to afford a pale-yellow oil as a mixture of </ br> 31 P NMR (162 MHz, CDCl 3 ): δ -0.49, -0.58. The resulting product is purified by extraction, crystallization or chromatography as described above.

Example 10-2. (S)-Isopropyl 2-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) Preparation of -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)(phenoxy)-phosphoniumamine)propionic acid

A solution of 1.7 M tert-butylmagnesium chloride (12.4 mL, 21 mmol, 2.1 equivalent) was added to 1-((2R,3R,4R,5R)-3 in anhydrous THF (50 mL) over 15 min. a stirred solution of -fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione ( 3 , 2.6 g, 10 mmol) in. After 30 minutes, the crude racemic ( 2-[(2,3,4,5,6-pentafluorophenoxy)-phenoxy-phosphorus ) was added dropwise in THF (15 mL) over 10 min. Imidyl] isopropyl propionate (4.08 g, 10 mmol). The mixture was stirred at room temperature for 72 hours. The TLC co-point with the real product showed about 40-50% compared to the starting nucleoside. The desired product.

The preparation and purification of C or C' provides a direct pathway to S P - 4 or R P - 4 as shown in the following examples.

Example 11. S P Preparation of -4 (32mg-scale):

Add 1 M tert-butylmagnesium chloride solution (0.26 mL, 0.26 mmol, 2.1 equivalent) to 1-((2R,3R,4R,5R)-3- in anhydrous THF (1 mL) at room temperature over 3 min. A stirred solution of fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 3 (32 mg, 0.12 mmol). After 30 minutes, (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphonamido] in THF (0.5 mL) was added dropwise over 3 min. A solution of isopropyl propionate ( 8 , S P - isomer). The mixture was stirred at room temperature for 42 hours, and then subsided to a saturated aqueous solution of NH 4 Cl (10mL). The mixture was partitioned between ethyl acetate and water. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated. Using a gradient of 0-4% methanol / dichloromethane The residue was chromatographed to provide a foamy solid of S P - 4 (29mg, yield 44.5%). 1 H and 31 P NMR were consistent with those disclosed herein.

Example 12. Preparation of S P - 4 (2.6 g-scale, without chromatography):

Add 1.7 M tert-butylmagnesium chloride solution (12.4 mL, 21 mmol, 2.1 equivalent) to 1-((2R,3R,4R,5R)-3- in anhydrous THF (50 mL) over 15 min. A stirred solution of fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione (2.6 g, 10 mmol). After 30 minutes, (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphonamido]propyl in THF (15 mL) was added dropwise over 10 min. acid isopropyl ester (8, S P - isomer, 4.08g, 10mmol) in a solution. The mixture was stirred at room temperature for 60 hours and then subsided to a saturated aqueous solution of NH 4 Cl (20mL). The mixture was partitioned between ethyl acetate (150 mL) and then 10% aqueous Na 2 CO 3 (3×20 mL) and water (20 mL). The combined organic extracts were dried <RTI ID=0.0></RTI><RTIID=0.0> The residue was dissolved in dichloromethane (7.6 mL) and then stirred at room temperature for 20 hr. The white solid was filtered, washed with EtOAc EtOAc EtOAc EtOAc

Example 13. Preparation of S P -4 using NaHMDS :

A solution of 2.0 M bis-trimethylammonium sulphate (NaHMDS) (12.4 mL, 21 mmol, 2.1 equivalent) in THF (270 μL, 0.54 mmol) was added to anhydrous THF (2.0 mL) at -78 ° C over 2 min. 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4 a stirred solution of diketone (71 mg, 0.27 mmol). After 30 minutes, (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphonamido]-propionic acid isopropyl ester in THF (1 mL) A solution of 8 , S P -isomer, 111 mg, 0.27 mmol) was added to the mixture. The mixture was allowed to stir at this temperature for 2 hours, then warmed to -20 ° C and stirred at this temperature for an additional 20 hours. ~30% of unreacted nucleoside starting material is indicated by TLC. Therefore, an additional 0.5 equivalent reagent (55 mg, 0.14 mmol) in THF (0.5 mL) was added to the mixture and stirred for 6 hr. The reaction mixture was quenched with saturated aqueous ammonium chloride and then partitioned between ethyl acetate and water. The combined organic extracts were dried over anhydrous sodium sulfate and concentrated to afford a pale brown residue. Using a gradient of 0-5% methanol / dichloromethane the crude product row column chromatography to provide S P - 4 (22mg, 15% yield), 3'-phosphate group (5, S P - Isomer, 11.5 mg, 16% yield) and bis-amino phosphate ( 6 , S P , S P - isomer, 12.6 mg).

Example 14. R P Preparation of -4 (260 mg-scale):

Add 1.7 M tert-butylmagnesium chloride solution (1.23 mL, 2.1 mmol, 2.1 equivalent) to 1-((2R,3R,4R,5R)-3 in anhydrous THF (6 mL) at room temperature over 5 min. A stirred solution of -fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione (260 mg, 1 mmol). After 30 minutes, (S)-2-[(R)-(4-nitro-phenoxy)-phenoxy-phosphonamido]propyl in THF (3 mL) was added dropwise over 3 min. A solution of isopropyl acid ( 8 , R P - isomer). The mixture was stirred at room temperature for 96 hours and then subsided to a saturated aqueous solution of NH 4 Cl (10mL). The mixture was partitioned between ethyl acetate (50 mL) and water (2×20 mL). The combined organic extracts were dried <RTI ID=0.0> The residue was chromatographed using EtOAc EtOAc (EtOAc)

The preparation of S P - 4 or R P - 4 can also be achieved by reacting 3'-protected 3 with a suitable reagent C or C' or a mixture comprising C and C' , as shown in the following examples.

Example 15. S P Preparation of -4 accompanied by 3a as a synthetic intermediate

Example 15-1.5'- O -tert-Butyldimethylmercapto-2'-deoxy-2'-fluoro-2'- C -methyluridine (9):

The TBDMSCl solution (103.19 g, 685.6 mmol) in anhydrous pyridine (500 mL) was added dropwise at room temperature over 2 minutes to 2'-deoxy-2'-fluoro-2' in anhydrous pyridine (750 mL). - a stirred solution of C -methyluridine ( 3 , 81.1 g, 312 mmol). The reaction was allowed to stir at room temperature for 24 hours. Methanol (85 mL) was added to the reaction mixture and allowed to stir for 10 minutes, then the solvent was distilled off under reduced pressure. Hot water (45 ° C) (1 L) was added to the reaction mixture and the mixture was extracted with ethyl acetate (2×500 mL) and rinsed with water (1×500 mL). The organic layer was dried over anhydrous sodium sulfate. The ethyl acetate was distilled off and the obtained residue with toluene (2 × 500mL) was co-evaporated to provide a white foam of the crude 9. Yield = 116.9 g (quantitative). 1 H NMR (CDCl 3 , 300 MHz): δ 0.1 (s, 6H), 0.91 (s, 9H), 1.22 (d, 3H, J = 21 Hz), 2.50 (s, 2H), 3.75-4.05 (m, 4H) ), 5.54 (d, 1H, J = 9 Hz), 5.73 (s, 1H), 6.0 (d, 1H, J = 18 Hz), 7.81 (d, 1H, J = 9 Hz), 8.57 (br, s, 1H) , 11.1 (s, 1H).

Examples 15-2.5'- O - (t-butyldimethylsilyl silicon based) -3'- O - acetyl propyl (levulinyl) -2'- deoxy-2'-fluoro-2'- C - methyl - Synthesis of uridine (10):

DMAP (30.5 g, 249.7 mmol) was added to a stirred solution of nucleoside 9 (116.9 g, 312.1 mmol) in DCM (1 L) and allowed to stand at room temperature for 20 min. A solution of acetamidine anhydride (133.6 g, 642.3 mmol) in DCM (200 mL) was added and stirred for 24h. This mixed TLC indicates the completion of the reaction. Cold water (500 mL) was added and the mixture was stirred for 20 minutes. The organic layer was washed with aq. EtOAc (EtOAc)EtOAc. Crude yield: 197.6 g (135%). This material is used in the next step. 1 H NMR (CDCl 3, 300MHz ) δ 0.11 (s, 6H), 0.94 (s, 9H), 1.34 (d, 3H, J = 21Hz), 2.22 (s, 3H), 2.6-2.89 (m, 4H) , 3.72 (m, 1H), 4.01 (d, 1H, J = 12 Hz), 4.23 (d, 1H, J = 9 Hz), 5.33 (dd, 1H, J = 15 Hz), 5.73 (d, 1H, J = 6 Hz) ), 6.26 (d, 1H, J = 15 Hz), 8.12 (d, 1H, J = 12 Hz), 8.72 (br, s, 1H).

Example 15-3.3'- O -Ethylpropyl-2'-deoxy-2'-fluoro 2'- C -methyl-uridine (3a) synthesis:

The crude 10 (197.6 g, ~312.1 mmol) was dissolved in DCM (1L). TLC of the mixture indicated that the reaction was about 50% complete. Another equivalent of TEA.3HF (50.3 g, 312.1 mmol) was added and the reaction mixture was stirred for 6 h. At this point TLC indicated about 10% of unreacted starting material. An additional 0.25 equivalent of TEA.3HF (12.5 g, 78.0 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was concentrated to dryness to afford a yellow oil. All batches of crude product were purified via hydrazine column chromatography (0-2% MeOH in DCM) to afford 124.1 g, as a white foam solid, 3'- acetalic acid (from 2'-deoxy The purification yield in the three steps of -2'-fluoro-2'-C-methyluridine was 90%). 1 H NMR: (CDCl 3 , 400 MHz) δ 1.55 (d, 3H, CH3, J = 20 Hz), 2.36 (s, 3H, CH3), 2.8-3.03 (m, 5H, CH2CH3), 3.91-3.96 (dd, 1H, CH"), 4.2-4.25 (m, 1H, CH'), 4.34 (dd, 1H, CH, J = 8 Hz), 5.25 (dd, 1H, J = 16 Hz), 5.93 (d, 1H, J = 8 Hz), 8.20 (d, 1H, J = 8 Hz), 9.18 (s, 1H).

Example 15-4. (S)-2-{[(1R,4R,5R)-5-(2,4-Dioxy 3,4-dihydro-2H-pyrimidin-1-yl)-4-(R -Fluoro-3-(4-oxopentenyl)-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphonium}-propionic acid (S)- Stereoselective synthesis of isopropyl ester (11):

A solution of nucleoside ( 3a , 1.00 mmol, 358 mg) in 5 mL of dry THF cooled to 0 ° C was added to a solution of t-butylmagnesium chloride (1.7M in THF, 2 equivalent) and allowed to warm to room temperature. Stir for half an hour. Reagent (ca.97% to palm purity) (S)-2-[(S)-(4-nitro-phenoxy)-phenoxy-phosphonium]propionic acid isopropyl ester ( 8 , S P -isomer) (408 mg, 1.00 mmol, 1.00 equivalent) was added to the mixture in one portion and allowed to stir at room temperature. After 16 hours, ~30% of the starting material remained. The reaction mixture with saturated NH 4 Cl solution 10mL subsided, and ethyl acetate (3 × 25mL) and extracted the aqueous phase. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate and evaporated to dryness It was purified by gel chromatography using 2-5% methanol in dimethyl chloride to provide about 97% P to palm purity, a white foam product (275 mg) and unreacted starting material (162 mg). . The yield was 76% based on the starting material consumed. 31 P NMR (CDCl 3 , 162 MHz): 3.7 ppm; 1 H NMR (CDCl 3 , 400 MHz): δ 1.22 (dd, 6H, J = 6.4 Hz), 1.37 (s, 3H), 1.58 (s, 3H), 2.18(s,3H),2.63-2.9(m,4H),4.0(d,1H,J=8Hz),4.2-4.33(m,1H),4.57(d,1H,J=8Hz),4.96-5.00 (sept, 1H), 5.2 (dd, 1H, J = 9 Hz), 5.42 (d, 1H, J = 8 Hz), 6.19 (d, 1H, J = 18 Hz), 7.15 - 7.35 (m, 5H), 7.5 ( d, 1H, J = 5.6 Hz), 8.2 (br, s, 1H).

Example 15-5. (S)-2-{[(1R,4R,5R)-5-(2,4-Dioxy-3,4-dihydro-2H-pyrimidine Pyridin-1-yl)-4-(R)-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphonamido}-propionic acid ( S)-isopropyl ester ( S P -4) Synthesis

A sodium sulfite solution was prepared via the addition of Na 2 S 2 O 3 (1.51 g) and Na 2 S 2 O 5 (0.57 g) in water (25 mL). The 1.OML solution of this sodium sulfite was added to a solution of acetalic acid ( 11 , 250 mg, 0.40 mmol) in anhydrous THF (2.5 mL). It was allowed to stir at room temperature for 4 hours. The reaction mixture was poured into water (15 mL) and extracted with ethyl acetate (3×25 mL), dried and evaporated to give a white solid product of about 97% P to palm purity, which The physical and optical properties of the protected nucleoside directly generated by S P - 4 are commensurate.

Example 16. Preparation of S from 3a P -4 alternative program

1.7 M tert-butylmagnesium chloride solution (1.07 mL, 1.82 mmol) was added to 4-oxopentanoic acid (2R, 3R, 4R, 5R) in anhydrous THF (1.5 mL) at room temperature over 2 min. 5-(2,4-Dioxy-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-2-hydroxymethyl-4-methyl-tetrahydro-furan-3-yl ester A stirred solution of ( 3a , 210 mg, 0.59 mmol). Initially, a white precipitate was observed and the reaction mixture turned to a dark yellow solution after 10 minutes. After 30 minutes, (S)-2-[(S)-(4-nitrophenoxy)-phenoxy-phosphonamido]-propionic acid isopropyl ester in THF (1.5 mL) A solution of ( 8 ( S P -isomer), 382 mg, 0.94 mmol) was added dropwise over 3 min. When TLC and 1 H NMR indicated less than 2% of the unreacted starting material, the mixture was heated at 40 ° C for 5 hours. The reaction was quenched with saturated aqueous ammonium chloride and then partitioned between ethyl acetate and water. The combined organic layer was washed with 10% aq. Na 2 CO 3 (3×10 mL) then water. The organic layer was dried over anhydrous sodium s This crude product was dissolved in tetrahydrofuran (1.0 mL), and then a mixed aqueous solution of sodium sulfite (37 mg, 0.295 mmol) and sodium metabisulfite (224 mg, 1.18 mmol) in 1 mL of water was added. At a stage where only about 10% conversion was observed at TLC, the mixture was heated at 45 °C for 20 hours, so additional sodium sulfite (74 mg) and sodium metabisulfite (448 mg) were added and heating was continued for an additional 52 hours. At this time, approximately 40% conversion was observed via TLC. The reaction mixture was partitioned between water and ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give a brown material. The residue was purified using a gradient of 0-5% MeOH / DCM column chromatography, the unreacted starting materials to provide (89 mg of) and S P - 4 (57mg, yield 18%, 24% recycled material according to the starting ).

Example 17. Preparation of S from 3c as a synthetic intermediate P -4

Example 17-1.1-[(2R,3R,4R,5R)-4-(tert-Butyldimethylmethylalkoxy)-3-fluoro-5-hydroxymethyl-3-methyl-tetrahydro-furan- Preparation of 2-yl]-1H-pyrimidine-2,4-dione, 12

Dichloromethane (50 mL) was added to a solution of 3 (10.0 g, 38.43 mmol) in pyridine (50 mL). The solution was cooled to 0 °C. 4,4'-Dimethoxytrityl chloride (14.32 g, 42.27 mmol) was added to the solution, and the solution was stirred at 0 ° C for 5 hours. Methanol (5 mL) was added to quench the reaction and the mixture was evaporated to dryness. The organic solution was washed with brine (50 mL) and dried (MgSO4, 4 g). The solvent was removed under reduced pressure and the residue was dissolved in dichloromethane (100 mL). Imidazole (7.83 g, 115 mmol) and tert-butyldimethylmethyl chloride (8.68 g, 57.6 mmol) were added to the solution. The solution was stirred at room temperature for 16 hours. Methanol (5 mL) was added to quench the reaction and the solvent was evaporated and evaporated. The organic solution was dried (sodium sulfate, 4 g) and evaporated in vacuo. The residue was purified by column chromatography (10-40%EtOAcEtOAcEtOAc) elute It was the turn to be treated with 1% trifluoroacetic acid in dichloromethane (200 mL). The solution was stirred at room temperature for 1 hour. Water (20 mL) was added and the solution was stirred at room temperature for another one hour. Methanol (5 mL) was added slowly and the solution was stirred at room temperature for another one hour. Ammonium hydroxide was added to adjust the pH of the solution to 7. The organic solution was separated, dried (sodium sulfate, 4 g) and evaporated to dryness under reduced pressure. The residue in 50% yield three steps of 12 purified by silica gel column chromatography (in the 1-5% methanol in dichloromethane) to provide a white solid, 7.5g,. 1 H NMR (DMSO-d6) δ (ppm) 11.48 (br s, 1H, N H ), 7.94 (d, 1H, H-6), 6.00 (d, 1H, H-1 '), 5.69 (d, 1H, H-5), 4.06 (dd, 1H, 3'-H), 3.85 (m, 2H, H-5'a, H-4'), 3.58 (br d, 1H, H-5'b) , 1.27 (d, 3 H, 2-C H 3 ), 0.89 (s, 9H, C (C H 3 ) 3 ), 0.12 (s, 6H, Si(C H 3 ) 2 ).

Example 17-2. Using 1-[(2R,3R,4R,5R)-4-(tert-butyldimethylsilyloxy)-3-fluoro-5-hydroxymethyl-3-methyl-tetrahydro - furan-2-yl] -1H- pyrimidine-2,4-dione (3c) to prepare a S P -4

Add 1.7 M tert-butylmagnesium chloride solution (1.8 mL, 3.1 mmol) to 1-[(2R,3R,4R,5R) in anhydrous THF (3 mL) at room temperature over 2 min.

-4-(tert-Butyldimethylhydrazinyloxy)-3-fluoro-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl]-1H-pyrimidine-2,4-dione A stirred solution of ( 12 , 374 mg, 1 mmol). Initially, a white precipitate was observed and after 10 minutes the reaction mixture turned to a clear dark yellow solution. After 30 minutes, (S)-2-[(S)-(4-nitrophenoxy)-phenoxy-phosphonamido]-propionic acid isopropyl ester in THF (2.5 mL) A solution of ( 8 , S P -isomer, 653 mg, 1.6 mmol) was added dropwise over 3 minutes. When TLC and 1 H NMR indicated less than 5% of unreacted starting material, the mixture was heated at 40 ° C for 20 hours. The reaction was quenched with saturated aqueous ammonium chloride and then partitioned between ethyl acetate and water. At 10% 2 CO 3 solution (3 × 10mL) Na followed by water (20mL) the organic layer was washed. Via the organic layer was dried over anhydrous sodium sulfate and concentrated to provide a brown residue (850 mg of) comprises the 3c. The crude product was dissolved in tetrahydrofuran (2 mL) and then was then applied. The reaction mixture was heated at 50 °C for 96 hours. Approximately 70% conversion was observed at TLC. The reaction mixture was poured into a cold saturated aqueous solution of sodium bicarbonate and then partitioned between ethyl acetate and water. The combined organic layers were dried over anhydrous sodium s The residue was purified using a gradient of 0-5% MeOH / DCM of column chromatography, to provide the starting material (21mg), and unreacted S P - 4 (77mg, 35% yield, 39% yield according to the recovered Starting material).

Example 18. Preparation of S from 3d as a synthetic intermediate P -4

Preparation of Examples 18-1.3d

TIPDS-Cl was added dropwise to a stirred solution of 3 in pyridine (20 Ml) over 15 minutes. The mixture was slowly warmed to room temperature and stirred at this temperature for 16 hours. Evaporation to remove its pyridine and the residue was co-evaporated with toluene (50 mL). The residue was then triturated with hexane and the white precipitate was removed by filtration using a pad of Celite. The filtrate was concentrated under reduced pressure to give a foamy solid (12.97 g). The crude product ( 13 ) was re-dissolved in tetrahydrofuran (75 mL) and aqueous TFA (75 mL, 1:1 TFA / water) The mixture was stirred at this temperature for 6 hours. TLC indicates ~5% of starting material. With saturated aqueous NaHCO 3 subsided the reaction mixture until pH 8, then extracted with ethyl acetate. The combined organic extracts were rinsed with water, dried and concentrated to provide a white crystalline solid. The solid was further triturated with hexanes (30 mL) to afford a white solid, which was filtered and dried under high vacuum to afford 3d (10.1 g, yield 84% in two steps). 1 H NMR (400 MHz, CDCl 3 ) : δ 8.83 (bs, 1H), 7.94 (bd, J = 6.0 Hz, 1H), 6.10 (bd, J = 18.4 Hz, 1H), 5.71 (d, J = 8.2 Hz) , 1H), 4.43 (bs, 1H), 4.36 (dd, J = 22.6, 9.0 Hz, 1H), 4.27 (bs, 1H), 4.10 (d, J = 13.2 Hz, 1H), 4.03 (d, J = 9.2 Hz, 1H), 3.92 (d, J = 13.2 Hz, 1H), 1.39 (d, J = 22.0 Hz, 3H), 1.11 - 0.92 (m, 28H).

Example 18-2. S P -4 preparation

A stirred solution of 1.7 M tert-butylmagnesium chloride solution (1.8 mL, 3.1 mmol, 3.1 equivalent) was added to a stirred solution of 3d (520 mg, 1 mmol) in anhydrous THF (5 mL) over 15 min. After 30 minutes, (S)-2-[(S)-(4-nitro-phenoxy)-phenoxyphosphonium]propionic acid isopropylate ( 8 ) in THF (1 mL) A solution of S P -isomer, 653 mg, 1.6 mmol) was added dropwise over 3 minutes. The mixture was allowed to stir at room temperature for 60 hours. The 1 H and 31 P NMR of the crude sample indicated a mixture of non-image isomers of about 1:0.76. The reaction mixture with saturated aqueous NH 4 Cl (20mL) subsided. The mixture was partitioned between ethyl acetate (150 mL) and then 10% aqueous Na 2 CO 3 (3×20 mL) and water (20 mL). Dried over anhydrous sodium sulfate via the combined organic extracts were filtered and concentrated under reduced pressure to provide a pale yellow residue (14, 878mg).

The above compound 14 was re-dissolved in tetrahydrofuran (3 mL), followed by the addition of 80% aqueous formic acid. The mixture was heated at 55 ° C for 20 hours. The reaction mixture was cooled to 0 ° C then quenched with saturated aqueous sodium bicarbonate (pH 7.0). The reaction mixture was then partitioned between ethyl acetate and water. The combined organic layers were dried over sodium sulfate and concentrated to afford 560 mg of residue. The residue was chromatographed using 0-5% methanol / methylene chloride gradient to provide the starting material (14, 242mg) and the unreacted as a white solid of S P - 4 (80mg, 15 % yield) .

Example 19. Isotope Labeling S P -4 preparation

Example 19-1.1-((6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro Preparation of -6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)pyrimidine-2,4(1H,3H)-dione, 16

The uridine ( 15 , 100.0 g, 409.5 mmol) was co-evaporated with anhydrous pyridine (600 mL) to dryness and resuspended in anhydrous pyridine (700 mL). 1,3-Dichloro-1,1,3,3-tetraisopropyldioxane (135.7 g, 482.5 mmol) was added to the stirred fine suspension at room temperature over 60 minutes. After stirring the fine suspension at room temperature for 17 hours, methanol (20 mL) was added to quench the reaction and then concentrated under reduced pressure. The residue was partitioned between ethyl acetate (1.5 L) and water (2L). The organic layer was further washed with EtOAc EtOAc (EtOAc) (EtOAc) The residue was placed on a filter column using EtOAc (1. Combine with the homogeneous TLC as the component of the purified product (Rf 0.55 in 1:1 hexane-ethyl acetate), and concentrate under reduced pressure and dry (40 ° C, 0.2 mmHg, 24 hours) to Provided as a white foam solid, 145.5 g of 16 (76%). At the same time, an additional slightly impure 16 component (35 g) was collected. 1 H NMR (DMSO- d 6 ) δ (ppm) 11.35 (s, 1H, N H ), 7.66 (d, 1H, J = 7.6 Hz, H -6), 5.57 (d, 1H, J = 4.8 Hz, 2'-O H ), 5.50-5.49 (m, 2H, 1'- H and H -5), 4.14 - 4.18 (m, 3H, 2', 3', 4'- H ), 3.97-3.87 (m , 2H, 5'- H a and H b), 1.02-0.95 (m, 28H, C H (C H 3) 2).

Example 19-2.1-((6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxo-tetrahydro-6H-furo[3,2-f][1,3, Preparation of 5,2,4]trioxadisilocin-8-ylpyrimidine-2,4(1H,3H)-dione, 17

Anhydrous DCM (600 mL) and DMSO (30.82 g, 394.5 mmol) were placed in a dry three-necked flask. The solution was cooled to -78 °C in a dry ice/acetone bath under nitrogen. Trifluoroacetic anhydride (anhydrous, 77.7 g, 369.8 mmol) was added via a syringe over 40 minutes to give a cloudy mixture. A solution of the uridine derivative 16 in DCM (600 mL) was added dropwise to the mixture at -78 ° C over 75 minutes via an additional funnel. The heterogeneous mixture was stirred at -78 to -65 °C for 2 hours, then anhydrous triethylamine (92 mL) was quickly added via a syringe to give a clear pale yellow solution. After 1 hour at low temperature, the reaction was completed via TLC (30%EtOAc in hexanes). The cold bath was removed and the reaction mixture was slowly warmed to room temperature over 1 hour. Saturated NH 4 Cl (180mL) to the reaction subsided. Water (200 mL) was added and the organic layer was separated. The aqueous layer was extracted again with DCM (300 mL). The combined organic layers were washed with water (3×400 mL), brine (150 mL) and dried over Na 2 SO 4 . The solvent is removed to form a viscous brown residue.

The crude oily residue (containing a small amount of DCM) was stored in a freezer overnight. Some crystalline solids were observed in the oil after overnight. The oil was dissolved in 500 mL of hexane at room temperature. The solution was stored in a freezer for 24 hours and more solids were formed. The solid was collected by filtration and rinsed with cold 10% DCM (1L) in hexane to remove most of the orange. The solid ( 17 ) was dried under vacuum for 2 hours and then dried in air for 24 hours. After drying under vacuum at 50 ° C, the solid weighed 21 g. The filtrate was concentrated and purified by column chromatography (10-70% ethyl acetate in hexanes) to afford to afford to afford a pale brown solid, 37 g (yield 97%) 17 .

Example 19-3.1-((2R,3S,4R,5R)-3,4-Dihydro-5-(hydroxymethyl)-3- 13 Preparation of C-over-deuterated methyltetrahydrofuran-2-ylpyrimidine-2,4(1H,3H)-dione, 18

Magnesium (3.53 g, 147 mmol), which was washed with a 5% hydrochloric acid solution and dried (50 ° C, 0.2 mmHg, 24 hours), was placed in a two-necked round bottom flask equipped with a magnetic stirrer and a condenser. The flask was filled with argon and then anhydrous ether (80 mL) was added. The deuterated- 13 C methyl iodide (15.06 g, 110.3 mmol) was slowly added to the magnesium in the ether which produced an exothermic reaction. After the reaction mixture was cooled, the suspension was transferred to dry compound 17 (50 ° C, 0.2 mmHg, 15 hr) (10.0 g, 20.63 mmol) in anhydrous THF (1 L) at -50 °C. In the solution. The temperature was raised to -40 ° C and the mixture was stirred between -40 and -25 ° C for 4 hours. Upon completion of the reaction, the mixture was diluted with EtOAc (1 L) at -50 ° C, then brine (300 mL) was slowly added. The organic layer was separated and washed with a saturated aqueous ammonium chloride solution (300 mL×2) and dried over sodium sulfate. After filtration and concentration under reduced pressure, the residue was crystallised from MeOH (250 <RTIgt; Ammonium fluoride (12 g) and TBAF (400 mg) were added. The resulting mixture was stirred at 90 ° C for 7 hours and then concentrated under reduced pressure with EtOAc (20 g). After drying via vacuum to flash silica gel column chromatography (MeOH: CH 2 Cl 2 = 1: 20 to 1:10) to give the obtained residue was generated as a white solid of compound 18 (5g, 46%) . 1 H NMR (DMSO- d 6 ) δ (ppm) 11.26 (s, 1H, NH), 7.65 (d, 1H, J = 8.4 Hz, H-6), 5.77 (d, 1H, J = 2.4 Hz, H -1'), 5.57 (d, 1H, J = 8.0 Hz, H-5), 5.46 (d, 1H, J = 5.2 Hz, HO-3'), 5.24 (d, 1H, J = 2.4 Hz, HO -2'), 5.14 (t, 1H, J = 5.6 Hz, HO-5'), 3.74 - 3.56 (m, 4H, H-3', 4', 5', 5").

Example 19-4. ((2R,3R,4S,5R)-3-Ethyloxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4 -hydroxy-4- 13 Preparation of methyl C-(deuterated methyltetrahydrofuran-2-yl)acetate, 19

A solution of compound 18 (5.00 g, 19.1 mmol) in anhydrous pyrimidine (100 mL) was added to acetic anhydride (3 mL). The resulting mixture was stirred at room temperature for 15 hr then diluted with EtOAc (250 <RTIgt; After filtration and concentration, by flash column chromatography (at 0-5% MeOH CH 2 Cl 2 in the) purifying the residue, to provide a gray solid of compound 19 (4.0g, 68%).

Example 19-5. ((2R,3R,4R,5R)-3-Ethyloxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4 -fluoro-4- 13 Preparation of C-over-deuterated methyltetrahydrofuran-2-yl)acetate, 20

Compound DAST (1.33mL, 10.1mmol) was slowly added at -78 deg.] C in dry CH 2 Cl 2 (60mL) of 19 (2.33g, 6.73mmol) in a solution. After the resulting mixture was exposed to room temperature, it was stirred for 30 minutes. An additional two 2.33 g scale reactions and a 1.00 g scale reaction were performed in exactly the same manner. All four reaction mixtures were combined, diluted with CH 2 Cl 2 (300mL) and ice water (100mL × 2) and then rinsed with cold aqueous NaHCO 3 (100mL × 2). After drying, filtration, and concentrating, the residue was purified by flash column chromatography (0-% 50%EtOAc in hexanes 20 (2.0 g, from a total of 7.99 g of compound 19 of 24%). 1 H NMR (CDCl 3 ) δ (ppm) 8.27 (s, 1H, NH), 7.55 (d, 1H, J = 8.4 Hz, H-6), 6.17 (d, 1H, J = 18.8 Hz, H-1 '), 5.78 (dd, 1H, J = 1.2, 8.4 Hz, H-5), 5.12 (dd, 1H, J = 9.6, 21.6 Hz, H-3'), 4.40-4.31 (m, 3H, H- 4 ', 5', 5 " ), 2.19 (s, 3H, CH 3), 2.15 (s, 3H, CH 3).

Example 19-6.1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3- 13 Preparation of C-per-deuterated methyltetrahydrofuran-2-ylpyrimidine-2,4(1H,3H)-dione, 21

A solution of compound 20 (2 g, 5.74 mmol) in methanol (20 mL) was added n-butylamine (6 mL). The resulting mixture was stirred at room temperature for 15 hr and concentrated in vacuo. To flash silica gel column chromatography (in CH 2 Cl 2 in the 0-10% MeOH) to afford the residue, to provide a white solid of compound 21 (1.3g, 85%). 1 H NMR (CD 3 OD) δ (ppm) 8.08 (d, 1H, J = 8.0 Hz, H-6), 6.13 (d, 1H, J = 18.4 Hz, H-1 '), 5.70 (d, 1H) , J = 8.0 Hz, H-5), 3.99 (d, 1H, J = 13.6 Hz, H-5'), 3.97-3.91 (m, 2H, H-3', 4'), 3.80 (dd, 1H) , J = 2.0, 12.8 Hz, H-5"), ESMS (M + 1) is estimated to be 265, and 265 is observed.

Example 19-7. (S)-Isopropyl 2-((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-) 4-fluoro-3-hydroxy-4- 13 Preparation of C-over-deuterated methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoniumamino)propionic acid, 22

The previously prepared chlorophosphoric acid in THF (1.0 M, 2.35 mL, 2.35 mmol) was added dropwise at 0 ° C to unprotected nucleoside 21 (207 mg, 0.783 mmol) and N -A in THF (4 mL) A solution of imidazole (0.4 mL, 5 mmol). The reaction was slowly warmed to room temperature over 1 h then water (1 mL) and EtOAc (5 mL). With saturated citric acid solution (monovalent alkali, 2 × 2mL), saturated NaHCO 3 solution (1 × 2mL) rinsing the organic solution was dried (MgSO 4) and concentrated under a reduced pressure. The crude was used in order to CH 2 Cl 0 of 5% CO2 in i PrOH was purified by silica gel column chromatography was eluted solution of, to provide the amine as a white solid phosphoric ester 22 (216mg, 52%, P - 1:1 mixture of non-Spiegelmers): 1 H NMR ((400MHz, DMSO- d 6 ) δ 11.54 (s, 1H), 7.56 (d, J = 6.8 Hz, 1H), 7.40-7.35 (m , 2H), 7.23-7.18 (m, 3H), 6.14-5.96 (m, 2H), 5.89 (dd, J = 5.6, 25.6 Hz, 1H), 5.55 (t, J = 8.4 Hz, 1H), 4.85 ( Dq, J = 1.6, 6.0 Hz, 1H), 4.44 - 4.32 (m, 1H), 4.25 (m, 1H), 4.06-3.98 (m, 1H), 3.86-3.70 (m, 2H), 1.30-1.08 ( m, 9H); 31 P NMR (162MHz, DMSO- d 6) δ 4.90,4.77; calculated for C 21 13 CH 27 D 3 FN 3 O 9 P 534.5 LRMS (ESI) [m + H] +, found 534.4.

Example 19-8. (2S)-2-(((((2(R)))))) -4-fluoro-3-hydroxy-4- 13 Preparation of C-over-deuterated methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryloxy)amino)propionic acid, 23

Aminophosphate 22 (147 mg, 0.276 mmol) was suspended in triethylamine (2 mL) and water (0.5 mL), and then evaporated. The volatile component is then evaporated under reduced pressure. The crude product was purified by silica gel column chromatography, eluting with 50-70% of i PrOH in CH 2 Cl 2 and then with 0 to 20% of NH 4 OH in i PrOH. Provided as a white solid 23 (95 mg, 83%): 1 H NMR (400 MHz, DMSO - d 6 ) δ 8.00 (d, J = 8.4 Hz, 1H), 5.98 (d, J = 19.2 Hz, 1H) , 5.52 (d, J = 8.4 Hz, 1H), 4.02-3.81 (m, 4H), 1.10 (d, J = 6.8 Hz, 3H); 31 P NMR (162 MHz, DMSO- d 6 ) δ 8.12; 12 13 CH 17 D 3 FN 3 O 9 P 416.3 Calculated LRMS (ESI) [M+H] + found 416.4.

R P - 4 , 4 , and S P - Preparation of 4 samples

X-ray powder diffraction (XRPD), nuclear magnetic resonance (NMR) spectroscopy, Fourier transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), weight vapour Samples of R P - 4 , 4 , and S P - 4 were analyzed by adsorption method (GVS), thermodynamics of solution solubility, and high performance liquid chromatography (HPLC).

Example 20. X-ray powder diffraction

Samples of R P - 4 , 4 , and S P - 4 were analyzed via X-ray powder diffraction (XRPD) according to the following protocol.

a. Bruker AXS/Siemens D5000

The X-ray powder diffraction pattern was collected on a Siemens D5000 diffractometer using Cu Ka radiation (40 kV, 40 mA), θ-θ direction finder, V20 divergence and receiving slits, graphite secondary single light, and scintillation counter. The instrument was certified using the certified Corundum standard (NIST 1976). The software used to collect the data is Diffrac Plus XRPD Commander v2.3.1 and uses Diffrac Plus EVA v 11.0.0.2 or v 13.0.0.2 to analyze and present the data.

Environmental conditions

The sample processed was prepared as a flat sample using the received powder under ambient conditions. Approximately 35 mg of the sample was lightly loaded into a wafer that was cut into a polished, zero background (510). The sample is rotated in its own plane during the analysis period. The details of this data collection are: angle range: 2 to 42 ° 2θ; step size: 0.05 ° 2θ; and collection time: 4 s. step -1 .

b. Bruker AXS C2 GADDS

X-ray powder diffraction pattern was collected on a Bruker AXS C2 GADDS diffractometer using Cu Kα radiation (40 kV, 40 mA), automated XYZ stage, laser photographic microscope for automatic sample positioning, and HiStar 2D area detector . The X-ray optics consists of a single Göbel multilayer mirror coupled to a 0.3 mm pinhole collimator.

The divergence angle, i.e., the effective size of the X-ray beam on the sample, is about 4 mm. The θ-θ continuous scan mode is used for a sample-detector distance of 20 cm, which provides an effective 2θ range of 3.2° - 29.7°. Typically the sample will be exposed to an X-ray beam for 120 seconds. The software used to collect data is GADDS for WNT 4.1.16 and uses Diffrac Plus EVA v 9.0.0.2 or v 13.0.0.2 to analyze and present data.

Environmental conditions

The sample being manipulated was prepared as a flat sample using the received and unground powder under ambient conditions. Approximately 1-2 mg of the sample was lightly pressed onto the slide to obtain a flat surface.

X-ray powder diffraction (XRPD)

It was found by XRPD that 4 was amorphous (see Fig. 1 ). The high-resolution XRPD analysis of R P - 4 prepared according to Example 3 was confirmed to be a high-resolution XRPD analysis of a crystalline solid material exhibiting a diffraction powder pattern, S P - 4 (prepared according to Method 4 of Example 4), It was confirmed as a crystalline solid substance. The XRPD results table for R P - 4 and S P - 4 is shown in Table 1, which excludes performance intensity. 5% ( R P - 4 ) and All peaks of 3% ( S P - 4 ).

The sample of S P - 4 was ground in a mortar and pestle, and then continuously passed through a sieve of 500 and 250 μm to produce a sample of the fine powder. The sample was reanalyzed via high resolution XRPD to confirm that no shape change occurred.

Example 21. S P -4 crystallographic study

The crystal S P - 4 exhibited polymorphism. Thus, on the one hand, it is directed to the crystal S P - 4 and its individual polymorphic forms. S P -4 may exist in at least five polymorphic forms, designated Forms 1-5. In addition, amorphous S P - 4 can also be prepared. A typical crystallization provides dissolution of about 100 mg of S P - 4 in a suitable volume of crystallization solvent (acetonitrile (5 vol), chloroform (5 vol), n-butyl acetate (7 vol), dichloromethane (50 vol) Anisole (7 vol) and 1:1 MTBE/hexane (50 vol)) and the solution was evaporated at 5 °C. A variety of crystal forms are obtained, but each form provides Form 1 via filtration and/or drying.

As confirmed by single crystal X-ray and XRPD analysis, Forms 1, 2, and 3 were an unsolvated form, a 1:1 DCM solvate, and a 1:1 chloroform solvate, respectively. Forms 4 and 5 obtained by crystallization of S P - 4 were derived from acetonitrile and anisole solutions, respectively. Since no single crystal of sufficient quality was obtained, sufficient data could not be collected to determine whether Forms 4 and 5 were unsolvates, hydrates or solvates. Forms 4 and 5 were converted to Form 1 by filtration. Crystallization of S P -4 from a solution of n-butyl acetate ( n BuAc) and a solution containing methyl n-butyl ether (MTBE) and heptane yields two additional crystalline forms; this two crystalline forms are transformed by filtration For form 1. Forms 2 and 3 are also separated into Form 1 upon separation. Form 1 is an unsolvated form which exhibits a broad melting endotherm with an onset temperature of 94.3 ° C and a ΔH fus of 24.0 kJ mol -1 . An additional S P - 4 Form 1 XRPD pattern is depicted in Figure 4 .

Example 21-1. S P -4 form 1

Example 21-2. S P -4 form 2

The XRPD pattern of S P -4 Form 2 is depicted in Figure 5 .

Example 21-3. S P -4 form 3

The XRPD pattern of S P -4 Form 3 is depicted in Figure 6 .

Range 21-4. S P -5 form 4

The XRPD pattern of S P -4 Form 4 is depicted in Figure 7 .

Example 21-5. S P -4 form 5

The XRPD pattern of S P -4 Form 5 is depicted in Figure 8 .

Example 21-6. S P -4 (amorphous)

The XRPD pattern of amorphous S P - 4 is depicted in Figure 9 .

Example 22. S P Single crystal X-ray crystallography of -4 and its solvates Example 22. S P Single crystal X-ray crystallography of -4 and its solvates

Figure 10 shows the X-ray crystal structure of Form 3 of S P - 4 . Among them, the figure shows the viewpoint of the molecule of Form 1 by showing the crystal structure using the numbering scheme. The anisotropic atomic displacement elliptical surface of a non-hydrogen atom is shown in the 50% probability layer. Hydrogen atoms are shown to have any small radius.

The structural analysis system is obtained via the direct method, precise method of least squares of the F full matrix 2 of, with weights w -1 = σ 2 (F o 2) + (0.0592 P) 2 + (0.6950 P), where P =( F o 2 +2 F c 2 )/3, anisotropic displacement parameters, empirical absorbance correction using spherical harmonics, scaling algorithm implemented in SCALE3 ABSPACK. Finally, for all data, wR 2 ={Σ[ w ( F o 2 - F c 2 ) 2 ]/Σ[ w ( F o 2 ) 2 ] 1/2 }=0.0871, the traditional R 1 =0.0329 The 7090 reflections of the F value have F o >4σ( F o ), S = 1.016 for all data, and 870 parameters. The final Δ / σ (maximum) 0.001, Δ / σ (average value), 0.000. The final difference map is between +0.534 and -0.36e Å -3 .

Example 22-2. S P -4 (form 2) single crystal X-ray crystallography

Figure 11 shows the X-ray crystal structure of Form 2 of S P - 4 . Among them, the figure shows the molecular view of Form 2 by showing the crystal structure using the numbering scheme. Due to very weak data, heteroatoms are resolved by isotropic. Hydrogen atoms are not shown.

The structural analysis system is obtained via the direct method, precise method of least squares of the F full matrix 2 of, with weights w -1 = σ 2 (F o 2) + (0.0975 P) 2 + (10.6969 P), where P =( F o 2 +2 F c 2 )/3, anisotropic displacement parameters, empirical absorbance correction using spherical harmonics, scaling algorithm implemented in SCALE3 ABSPACK. For all data, the final wR 2 ={Σ( w ( F o 2 - F c 2 ) 2 ]/Σ[ w ( F o 2 ) 2 ] 1/2 }=0.1883, the traditional R 1 =0.0741 The 2525 reflections at F have F o >4σ( F o ), S = 1.05 for all data, and 158 parameters. The last Δ / σ (maximum) 0.000, △ / σ (average value), 0.000. The final difference map is between +1.388 and -0.967e Å -3 .

Example 22-3. S P -4 (form 2) single crystal X-ray crystallography

Figure 12 depicts the S P - 4 (form 2) X-ray crystal structure (ORTEP-anisotropic). The crystal structure of the dichloromethane solvate of S P - 4 (form 2), C 23 H 31 N 3 PO 9 FCl 2 , produces a monoclinic space group P2 1 (system lacks 0k0:k=odd), which has a= 12.8822(14)Å, b=6.1690(7)Å, c=17.733(2)Å, β=92.045(3)°, V=1408.4(3)Å 3 , Z=2 and d calc =1.449g/cm 3 . X-ray intensity data was collected on a Rigaku Mercury CCD area detector using graphite monochromatic Mo-Kα radiation (λ=0.71073 Å) at a temperature of 143K. Preliminary index editing was performed from a series of 12 0.5° rotated images with 30 second exposure. A total of 648 rotated images were collected with a 35mm crystal to detector distance, a θ angle of -12°, a rotation width of 0.5°, and a 30 second exposure: scan number 1 is at ω=10° and χ=20 ° φ scan from 315 ° to 525 °; scan number 2 is ω scan at χ = -90 ° and Φ = 315 ° from -20 ° to 5 °; scan number 3 is at χ = -90 ° and Φ = ω scan of 135° from -20° to 4°; scan number 4 is ω scan at χ=-90° and Φ=225° from -20° to 5°; scan number 5 is at χ=-90° and Φ=45° ω scan from -20° to 20°. Use CrystalClear (CrystalClear: Rigaku Corporation, 1999 ) rotation of the image processing, generates a list and does not mean F 2 [sigma] (F 2) values, this does not mean, and [sigma] F 2 (F 2) value is then passed to the packet CrystalStructure program ( CrystalStructure : Crystal Structure Analysis Package, Rigaku Corp. Rigaku/MSC (2002)) for further processing and answering the structure on a Dell Pentium III computer. At 5.48 50.04°, -14 h 15, -7 k 6, -19 1 A total of 7707 reflections were measured in the range of 21, yielding 4253 unique reflections (Rint = 0.0180). The intensity data was corrected for Lorentz and polarization effects and absorbance using REQAB (minimum and maximum transfer of 0.824, 1.000).

By direct method (SIR97; SIR97 : Altomare, A., M. Burla, M. Camalli, G. Cascarano, C. Giacovazzo, A. Guagliardi, A. Moliterni, G. Polidori & R. Spagna (1999). J. Appl. Cryst., 32 , 115-119) solves this structure. Accuracy was performed by the full matrix least squares method based on F 2 using SHELXL-97 ( SHELXL-97 : Sheldrick, GM (2008) Acta Cryst., A64 , 112-122). Use all reflections during the refinement. The weighting scheme used is w=1/[σ 2 ( ) +0.0472P 2 +0.4960P], where P=( +2 ) /3. Non-hydrogen atoms are anisotropically refined and a "riding model" is used to refine the hydrogen atoms. For 4046 reflections, the precision is pooled to R1=0.0328 and wR2=0.0817, where for all 4253 unique, non-zero reflections and 358 variables, F>4σ(F) and R 1 =0.0348, wR 2 =0.0838 and GOF =1.056(R 1 =Σ ∥F o |-|F c ∥/Σ |F o |;wR 2 ={Σw( - ) 2 /Σw( ) 2 } 1/2 ; GOF={Σw( - ) 2 /(np)} 1/2 , where n = number of reflections and p = number of precision parameters). The maximum Δ/σ in the last cycle of the least square is 0.000, and the two most significant peaks in the last differential Fourier are +0.312 and -0.389e/Å 3 . The absolute structural parameters of Flack were refined to -0.06 (6) to confirm the stereochemistry of the title compound.

Table 1 lists the unit cell information, data collection parameters, and precision data. The final position and equal isotropic thermal parameters are provided in Table 2. Anisotropic thermal parameters are given in Table 3 ("ORTEP-II: A Fortran The Thermal Ellipsoid Plot Program for Crystal Structure Illustrations ". C. K. Johnson (1976) ORNL-5138) represents the molecule in a enthalpy circle showing a 30% probability.

Example 22-4. S P -4 (Form 3) single crystal X-ray crystallography

Figure 13 shows the X-ray crystal structure of Form 3 of S P - 4 . Among them, the figure shows the molecular view of Form 3 by showing the crystal structure using the numbering scheme. The anisotropic atomic displacement elliptical surface of a non-hydrogen atom is shown in the 50% probability layer. Hydrogen atoms are shown to have any small radius.

The structural analysis system is obtained via the direct method, precise method of least squares of the F full matrix 2 of, with weights w -1 = σ 2 (F o 2) + (0.0512 P) 2 + (0.6810 P), where P =( F o 2 +2 F c 2 )/3, anisotropic displacement parameters, empirical absorbance correction using spherical harmonics, scaling algorithm implemented in SCALE3 ABSPACK. For all data, the final wR 2 ={Σ( w ( F o 2 - F c 2 ) 2 ]/Σ[ w ( F o 2 ) 2 ] 1/2 }=0.0796, the traditional R 1 =0.0294 The 2486 reflections at F have F o >4σ( F o ), S = 1.068, and 377 parameters for all data. The final Δ/σ (maximum) 0.001, Δ/σ (average value), 0.000. The final difference map is between +0.211 and -0.334e Å -3 .

Example 23. Stability at elevated temperature and relative humidity

The R P -4 sample was stored in a humidity chamber at 40 ° C and 75% relative humidity for one week, and the sample was reanalyzed via XRPD. The obtained R P - 4 powder map showed no significant change during the course of the experiment, meaning that no change in solid form was observed. This result should be compared to a sample of 4 which deliquesces in about 16 hours at 40 ° C and 75% relative humidity. Specifically, an example of the deliquescent property of 4 is explained below. A sample of 4 was passed through a 250 μm mesh, and the sample was stored at 40 ° C / 75% RH and 25 ° C / 53% relative humidity, and visually observed in regular intervals. The results are provided in Table 4 .

The sample of S P - 4 was deliquescent within 16 hours after storage at 40 ° C and 75% relative humidity. For example, the S P -4 sample was ground with a honing and honing, and then continuously passed through a 500 and 250 μm mesh to produce a sample of the fine powder. Samples of this material were stored at 40 ° C with 75% relative humidity and 25 ° C and 53% RH and visually observed in regular intervals. The results are provided in Table 5 .

XRPD analysis of the samples after storage for 104 hours at 25 ° C and 53% RH showed no significant change in the resulting diffraction pattern, meaning that no change in form occurred.

Example 24. Fourier Transform-Infrared (FT-IR) Spectroscopy

Data was collected on an infrared spectroscopy analyzer (Perkin-Elmer Spectrum One) equipped with a universal attenuated total reflection (ATR) sampling accessory. Collect and analyze this data using Spectrum v5.0.1 software.

The IR spectra of the obtained 4 , R P - 4 and S P - 4 are shown in Figures 5-7, respectively. The selected peaks are listed as wave numbers (cm -1 ) as follows: 4 :~1680, ~1454, ~1376, ~1205, ~1092, ~1023 (Fig. 14); R P - 4 :~1742, ~1713 , ~1679, ~1460, ~1377, ~1259, ~1157, ~1079 (figure 15); and S P - 4 (form 1): ~1743, ~1713, ~1688, ~1454, ~1378, ~ 1208, ~1082 (Figure 16).

Example 25. Differential Scanning Thermal Method (DSC) Thermogravimetric Analysis (TGA)

DSC data was collected on a TA Instruments Q2000 equipped with a 50-position autosampler. The heat capacity value is calibrated using sapphire and the energy and temperature calibration is performed using certified indium.

The temperature-amplified DSC is typically carried out in 0.8-1.2 mg of each sample in a pinhole aluminum pan using a lower heating rate of 2 ° C.min -1 and a temperature adjustment parameter of ± 0.2 ° C. min -1 and 40 seconds. The sample was maintained with a dry nitrogen purge of 50 mL.min -1 .

The software for the control instrument is Advantage for Q Series V2.8.0.392 and Thermal Advantage v4.8.3, and using Universal Analysis v4.3A analysis data.

DSC data was collected on a Mettler DSC 823e equipped with a 34-position autosampler. Calibrate the energy and temperature of the instrument using certified indium. Typically, for each sample of 0.8-1.2 mg, it is heated from 25 ° C to 250 ° C at 10 ° C.min -1 in a pinhole aluminum pan. The sample was maintained purged with nitrogen at 50 mL.min -1 . The software for controlling instruments and analyzing data is STARe v9.20.

TGA data was collected on a Mettler TGA/SDTA 851e equipped with a 34-position autosampler. Calibrate the temperature of the instrument using certified indium. Typically, each sample of 8-12 mg was loaded into a pre-weighed aluminum crucible and heated from room temperature to 350 °C at 10 ° C.min -1 . The sample was maintained purged with nitrogen at 50 mL.min -1 . The software for controlling instruments and analyzing data is STARe v9.20.

DSC analysis of 4 showed a single broad endothermic peak with an onset temperature of 58.7 ° C (ΔH 14 J.g -1 ), which was confirmed to be molecular relaxation during glass transfer due to further amplitude modulated DSC analysis (Fig. 17). A TGA analysis of 4 showed no weight loss prior to dissociation above 240 °C, confirming that the material was unsolvated. As XRPD analysis of 4 confirmed that the material was amorphous, an amplitude modulated DSC analysis was performed in an attempt to calculate the glass transition temperature, which was found to be 57 °C.

DSC analysis of R P - 4 showed that a single sharp endothermic peak was confirmed to be melted by a high temperature stage microscope with an initial temperature of 136.2 ° C (ΔH 76 J.g -1 ). See picture 18. TGA analysis of R P -4 showed no weight loss prior to dissociation above 240 ° C, confirming that the material was unsolvated.

DSC analysis of S P - 4 showed that a single broad endothermic peak was confirmed to be melted by a high temperature stage microscope with an onset temperature of 93.9 ° C (ΔH 43 J.g -1 ). See picture 19. TGA analysis of S P -4 showed no weight loss prior to dissociation above 240 ° C, confirming that the material was unsolvated.

Example 26. Gravity Vapor Sorption (GVS) SMS DVS Intrinsic

The SMS DVS Intrinsic Moisture Absorption Analyzer was used to obtain adsorption isotherms, which were controlled via the SMS Analysis Suite software. The sample temperature was maintained at 25 °C via instrument control. The humidity was controlled by mixing dry and wet nitrogen vapor with a total flow rate of 200 mL.min -1 . The relative humidity is measured from a calibrated Rotronic probe (dynamic range 1.0-100% RH) near the sample. The weight change (mass slack) of the sample is a function of % RH continuously monitored via microbalance (accuracy ± 0.005 mg).

Typically, 5-20 mg of the sample is placed in a stainless steel basket that has been measured for tare weight at room temperature. The samples were loaded and removed at 40% RH and 25 ° C (typical room conditions). The humidity adsorption isotherm is operated as outlined below (2 scans provide 1 full cycle). The standard isotherm was operated at intervals of 10% RH at 25 ° C, 0.5-90% RH.

GVS analysis showed that R P - 4 was non-hygroscopic and exhibited reversible uptake of about 0.2 weight percent (wt%) water from 0 to 90% relative humidity. After the GVS experiment, the sample was reanalyzed via XRPD showing no shape change.

The S P -4 sample was ground with a honing and honing, and then continuously passed through a 500 and 250 μm mesh to produce a sample of the fine powder, which was then analyzed using a modified single cycle method. Samples were taken from 40% RH (approximately room temperature) to 60% RH, replacing 90% of the standard method, then cycled to 0% and back to 40% RH. This analysis shows that S P - 4 is not hygroscopic until 60% RH, with a reversible uptake of ~0.2% by weight of water from 0 to 60% RH.

Example 27. Thermodynamics of Solubility of Aqueous Solutions

Suspension of a sufficient amount of the compound in water to produce the final concentration of the maximum amount of the parent free form of the compound 10 mg.mL -1 to determine the solubility of the aqueous solution. The suspension was equilibrated at 25 ° C for 24 hours and its pH was measured. The suspension was then filtered through a glass fiber C filter into a 96 well plate. The filtrate was further diluted by a factor of 101. Quantitative by reference to a standard solution of about 0.1 mg.mL -1 in DMSO by HPLC. Inject different volumes of standard, diluted and undiluted sample solutions. The solubility was calculated by using the peak found at the same residence time as the main peak in the standard injection, and measuring the peak area thereof by integration.

The analysis was carried out according to the conditions mentioned above for the Agilent HP1100 series system equipped with a diode array detector and using ChemStation software vB.02.01-SR1.

Example 28. Determination of Chemical Purity by HPLC

A variety of HPLC conditions can be used to determine the chemical purity of the compounds disclosed herein. One such example is disclosed above in the thermodynamic study of solution solubility. Another example is disclosed below.

HPLC conditions:

LC: Waters Alliance 2695 Separation Module, Waters 2996 PDA Detector and Waters Empower 2 Software (Version 6.00)

Column: Phenomenex Luna C18(2); 4.6×50mm; 3μm

Flow rate: 1.2mL/min

Injection volume: 10μL

Mobile phase: Solvent A: 95% water with 5% methanol and 10 mM acetic acid

Ammonium; pH~5.3

Solvent B: MeOH with 10 mM ammonium acetate

Gradient: kept at 0% B 3min

0-47%B 3-4min

Maintain at 47% B 4-10min

47%-74%B 10-11min

Maintain at 74% B 11-13.5min

Reply to 0%B 13.5-13.6min

Keep at 0% B 13.6-15.5min

Under these conditions, measured 4, R P - 4 and S P - 4 ~ purity were 99.6% to 99% and to 99.5%. It should be noted that higher purity can be achieved by optimizing the methods disclosed above.

A review of the XRPD diffraction pattern shows that the two crystalline single non-image isomers provide significantly different XRPD patterns. Additionally, crystallization of the two diastereomers have distinct melting points, R P - 4 compared to S P - 4 having a high starting point of considerable (136 deg.] C for 94 ℃).

Example 29. Additional separation method

The following SFC separations (conditions listed below) produced sufficient separation of the non-image isomers, R P - 4 and S P - 4 mixture.

The following SFC separations (conditions listed below) produced sufficient separation of the non-image isomers, R P - 4 and S P - 4 mixture.

Example 30. 8 ( S P -isomer) X-ray crystallography

Compound 8 ( S P -isomer), C 18 H 21 N 2 PO 7 , crystallized in a monoclinic space group P2 1 (system lacks 0k0:k=odd), which has a=5.3312(4)Å,b =15.3388 (8) Å, c = 23.7807 (13) Å, β = 92.891 (3) °, V = 1942.2 (2) Å 3 , Z = 4, and d calc = 1.397 g/cm 3 . X-ray intensity data were collected on a Bruker APEXII CCD area detector using a graphite monochromatic Mo-Kα radiation line (λ=0.71073 Å) at a temperature of 100 (1) K. Figures 20A and 20B show the asymmetric units of numerator numbers 1 and 2, respectively.

Perform preliminary index editing from a series of 36 0.5° rotation frames with 30 second exposure. A total of 3608 boxes were collected with a 70.00 mm crystal to detector distance, a 0.5° rotation width, and a 20 second exposure:

Integrating the spin box using SAINT (Bruker (2009) SAINT. Bruker AXS Inc., Madison, Wisconsin, USA) produces a list of unaveraged F 2 and σ(F 2 ) values, which are not averaged F 2 and σ(F 2 ) The value is then passed to the SHELXTL (Bruker (2009) SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA.) program package for further processing and resolution of the structure on a Dell Pentium 4 computer. At 1.58 θ 25.09°, -6 h 6, -18 k 18,-28 l A total of 6909 reflections were measured in the range of 28, yielding 6909 unique reflections (Rint = 0.0581). The intensity is corrected for Lorentz and polarization effects and absorbance using SADABS (Sheldrick, GM (2007) SADABS. University of Gottingen, Germany.) (minimum and maximum transmissions are 0.6093, 0.7452) data.

This structure was solved by a direct method (SHELXS-97) (SHELXS-97: Sheldrick, GM (2008) Acta Cryst. A64, 112-122.). Accuracy was performed by the full matrix least squares method based on F 2 using SHELXL-97 (SHELXL-97: Sheldrick, GM (2008) Acta Cryst., A64, 112-122). Use all reflections during the refinement. The weighting scheme used is w = 1 / [σ 2 (F 0 2 ) + (0.0000P) 2 +14.0738P], where P = (F 0 2 + 2F c 2 ) / 3. Non-hydrogen atoms are anisotropically refined and a riding model is used to refine the hydrogen atoms. For the 6173 observed reflections, the precision is pooled to R1=0.0847 and wR2=0.1899, where for all 6909 unique, non-zero reflections and 512 variables, F>4σ(F) and R1=0.0963 and wR2=0.1963 and GOF=1.119(R1=Σ∥F 0 |-|F c ∥/Σ|F 0 |; wR2=[Σw(F 0 2 -F c 2 ) 2 /Σw(F 0 2 ) 2 ] 1⁄2 ;GOF= [Σw(F 0 2 -F c 2 ) 2 /(np)] 1⁄2 ; where n = the number of reflections and p = the number of precision parameters). The maximum Δ/σ in the last cycle of the least square is 0.000, and the two most significant peaks in the last differential Fourier are +0.402 and -0.559e/Å 3 .

Example 31. Biological activity

The cell-containing replication unit was seeded at 3,000 cells/well (50 Ml) in a 96-well white/opaque plate or at 1500 cells/well (25 μL) on a 384-well white/opaque plate. 50 μL of the 2X compound was added to a 96-well plate or 25 μL of the 2X compound was added to a 384-well plate. The plate was incubated for 4 days at 37 ° C in a humidified 5% CO 2 atmosphere. After the incubation, Bright-Glo reagent (50 μL in a 96-well plate or 25 μL in a 384-well plate) was added to measure the HCV-replicating luciferase reporter gene. The percent inhibition was calculated for the untreated control group.

R P - 4 and S P - 4 have been validated to have a wide range of genotypes. For example, both show activity against hepatitis C virus genotypes 1-4.

US Patent Application No. 12/053, 015, and U.S. Provisional Patent Application No. 61/179,923, filed on May 20, 2009, and U.S. Provisional Patent Application No. 61/319,513, filed on March 31, 2010 The subject matter, which is incorporated herein by reference in its entirety. The subject matter of all of the cited references is hereby incorporated by reference. If the meaning of the incorporated term conflicts with the meaning of the term as defined herein, then the terminology encompassed by the present disclosure is preferred over the term incorporated.

Claims (3)

  1. a compound represented by the following structural formula, Wherein LG' is p-nitrophenoxy, p-chlorophenoxy, o-chlorophenoxy, 2,4-dinitrophenoxy or pentafluorophenoxy.
  2. The compound of claim 1, wherein the compound is
  3. The compound of claim 1, wherein the compound is
TW104102544A 2009-05-20 2010-05-19 Nucleoside phosphoramidates TWI583692B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17992309P true 2009-05-20 2009-05-20
US31951310P true 2010-03-31 2010-03-31

Publications (2)

Publication Number Publication Date
TW201518313A TW201518313A (en) 2015-05-16
TWI583692B true TWI583692B (en) 2017-05-21

Family

ID=42310683

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105132248A TWI598358B (en) 2009-05-20 2010-05-19 Nucleoside phosphoramidates
TW104102544A TWI583692B (en) 2009-05-20 2010-05-19 Nucleoside phosphoramidates
TW099115937A TWI576352B (en) 2009-05-20 2010-05-19 Nucleoside phosphoramidates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105132248A TWI598358B (en) 2009-05-20 2010-05-19 Nucleoside phosphoramidates

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW099115937A TWI576352B (en) 2009-05-20 2010-05-19 Nucleoside phosphoramidates

Country Status (31)

Country Link
US (6) US8642756B2 (en)
EP (5) EP2610264A3 (en)
JP (3) JP5885659B2 (en)
KR (3) KR101603817B1 (en)
CN (4) CN102459299B (en)
AR (1) AR082937A1 (en)
AU (1) AU2010249481B2 (en)
BR (1) BRPI1012781A2 (en)
CA (4) CA2915187C (en)
CL (1) CL2010000520A1 (en)
CO (1) CO6470789A2 (en)
CY (1) CY1118045T1 (en)
DK (1) DK2432792T3 (en)
EA (3) EA028742B1 (en)
ES (2) ES2648803T3 (en)
HK (5) HK1169414A1 (en)
HR (1) HRP20160958T1 (en)
HU (1) HUE031637T2 (en)
IL (3) IL216492A (en)
LT (1) LT2432792T (en)
MX (1) MX2011012417A (en)
NZ (3) NZ709926A (en)
PH (2) PH12014502684B1 (en)
PL (1) PL2432792T3 (en)
PT (2) PT2913337T (en)
SG (4) SG10201708263SA (en)
SI (1) SI2432792T1 (en)
SM (1) SMT201600316B (en)
TW (3) TWI598358B (en)
WO (1) WO2010135569A1 (en)
ZA (1) ZA201108749B (en)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Idenix (Cayman) Ltd Methods and compositions for treating hepatitis c virus
EP2345661A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2398684T3 (en) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Carbanucleoside analogues for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
PL2609923T4 (en) * 2010-03-31 2017-11-30 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2552931B1 (en) * 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
PE20130807A1 (en) * 2010-07-19 2013-07-27 Gilead Sciences Inc Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
AU2011280910B2 (en) 2010-07-22 2015-07-09 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
WO2012048013A2 (en) * 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
JP6069215B2 (en) * 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
CA2832459A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2832449A1 (en) 2011-04-13 2012-10-18 Vinay GIRIJAVALLABHAN 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en) * 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CN104039319B (en) 2011-11-29 2017-12-29 吉利德制药有限责任公司 For treating HCV composition and method
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013066748A1 (en) 2011-10-31 2013-05-10 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
ES2659216T3 (en) 2011-09-16 2018-03-14 Gilead Pharmasset Llc Methods for the treatment of HCV
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
BR112014006314A2 (en) * 2011-10-21 2017-04-11 Abbvie Inc methods for treating hepatitis c virus (hcv) comprising at least two direct acting antiviral agents, ribavirin, without interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AU2013265194B2 (en) 2012-05-25 2018-01-04 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
WO2014078427A1 (en) * 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) * 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
SG11201503750YA (en) * 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
UA118256C2 (en) * 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Combination formulation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137929A1 (en) 2013-03-04 2014-09-12 Gilead Pharmasset Llc Methods for treating hepatitis c virus
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014169280A2 (en) * 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
CN103408624A (en) * 2013-07-08 2013-11-27 江西科技师范大学 Method for synthesizing nucleotide phosphoramidate and nucleotide thio-phosphoramidate
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US8889701B1 (en) * 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (en) * 2013-12-23 2016-03-16 吉李德製藥公司 Solid forms of an antiviral compound
CN104761582B (en) * 2014-01-08 2018-09-28 上海创诺医药集团有限公司 A method of preparing N- [(S)-(2,3,4,5,6- phenyl-pentafluorides oxygroup) phenoxy group phosphoryl]-l-Alanine isopropyl ester
US20170015696A1 (en) 2014-02-20 2017-01-19 Ratiopharm Gmbh Solid state forms of sofosbuvir
CN103804446A (en) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 Preparation method of 3,5-dibenzoyl-2-deoxy-2-fluoro-2-methyl-D-ribo-gamma-lactone
EP3113762A1 (en) * 2014-03-05 2017-01-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
EP3125868A2 (en) * 2014-04-03 2017-02-08 Sandoz AG Solid composition comprising amorphous sofosbuvir
CZ307789B6 (en) 2014-04-15 2019-05-09 Zentiva, K.S. Method of producing biologically active phosphoramidate medicaments
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN105153257B (en) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 The preparation method of Suo Feibuwei
EP3154526B1 (en) 2014-06-13 2019-03-06 ratiopharm GmbH Solid state forms of sofosbuvir
WO2015197549A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
EP2959901A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
EA201692514A1 (en) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Pharmaceutical compositions on the basis of sofosbuvir and ribavirin with modified freedom
CN105254694B (en) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 Deuterated nucleoside derivates
CZ2014502A3 (en) 2014-07-17 2016-01-27 Zentiva, K.S. Sofosbuvir novel form and process for preparing thereof
CN104130302B (en) * 2014-08-08 2017-02-15 乳源东阳光药业有限公司 Crystal form of nucleotide medicines and preparation method of crystal form
WO2016023905A1 (en) * 2014-08-13 2016-02-18 Sandoz Ag New and efficient process for the preparation of crystalline form 6 of sofosbuvir
WO2016023906A1 (en) * 2014-08-13 2016-02-18 Sandoz Ag A crystalline form of sofosbuvir
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
CN104230985B (en) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 Preparation method of (s)-2-[(s)-(4-nitro-phenoxy)-phenoxy-phosphoryl amino] isopropyl propionate
WO2016038542A2 (en) 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
EP3194414A1 (en) * 2014-09-15 2017-07-26 Medivir Ab Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104327138B (en) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Preparation method of PSI-7977 intermediate compound
CN104277088A (en) * 2014-10-29 2015-01-14 汤律进 Sofosbuvir monocrystal M and preparation method and applications of sofosbuvir monocrystal M
TW201630925A (en) 2014-10-29 2016-09-01 吉李德科學股份有限公司 Methods for the preparation of ribosides
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN104327137A (en) * 2014-11-07 2015-02-04 王彩琴 Deuterated Sofosbuvir and application thereof
CN106083964B (en) * 2014-11-07 2018-12-18 南京旗昌医药科技有限公司 The crystal form H2 and preparation method thereof of rope fluorine cloth Wei
CN105254695B (en) * 2014-11-10 2019-01-18 南京曼杰生物科技有限公司 Nucleoside phosphoramidate derivative and its application
CN104478976A (en) * 2014-11-12 2015-04-01 苏州明锐医药科技有限公司 Preparation method for sofosbuvir
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105732751A (en) * 2014-12-09 2016-07-06 北京万生药业有限责任公司 Novel sofosbuvir crystal
CA2969733A1 (en) * 2014-12-10 2016-06-16 Solstice Biologics, Ltd. Mononucleotides having a bioreversible disulfide group
CN104546783A (en) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 Sofosbuvir film coating tablet preparation and preparation method thereof
CN105801645B (en) * 2014-12-29 2019-01-04 浙江海正药业股份有限公司 The method for preparing Suo Feibuwei crystal form 6
CN104610404B (en) * 2015-01-16 2016-04-06 南通常佑药业科技有限公司 A kind of preparation method of ribofuranose phosphate derivative
CA2975813A1 (en) 2015-02-13 2016-08-18 Sandoz Ag Pharmaceutical compositions comprising ledipasvir and sofosbuvir
MX2017011386A (en) 2015-03-06 2018-04-26 Atea Pharmaceuticals Inc ß-D-2'-DEOXY-2'A-FLUORO-2'-ß-C-SUBSTITUTED-2-MODIFIED-N6 -SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT.
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106146588A (en) * 2015-03-26 2016-11-23 常州制药厂有限公司 A kind of preparation method of Suo Feibuwei
WO2016156512A1 (en) 2015-04-01 2016-10-06 Sandoz Ag A process for preparing a crystalline form of sofosbuvir
US20180111954A1 (en) * 2015-04-02 2018-04-26 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
WO2016181313A1 (en) 2015-05-11 2016-11-17 Lupin Limited A process for the preparation of sofosbuvir intermediates & its polymorph
CN104829668B (en) * 2015-05-19 2017-05-31 江苏福瑞生物医药有限公司 A kind of method that nucleoside phosphoramidate class mother liquid medicine is reclaimed
WO2016191079A1 (en) * 2015-05-26 2016-12-01 Boropharm, Inc. Improved process for preparing boryl 7-azaindole compounds
EP3303360A1 (en) 2015-05-26 2018-04-11 Sandoz AG Selective process for synthesis of nucleoside phosphoramidates
WO2016196735A2 (en) 2015-06-03 2016-12-08 Teva Pharmaceuticals International Gmbh Improved processes for the preparation of sofosbuvir and intermediates thereof
WO2016207194A1 (en) * 2015-06-22 2016-12-29 Sandoz Ag Synthesis of phosphoramidates
CZ2015443A3 (en) 2015-06-26 2017-01-04 Zentiva, K.S. Sofosbuvir pharmaceutical formulation
CN105017359A (en) * 2015-07-08 2015-11-04 苏州晶云药物科技有限公司 Preparation method of Sofosbuvir crystal form
CN106366146A (en) * 2015-07-13 2017-02-01 中科云和(北京)生物医药科技有限公司 2-dialkyl substituted nucleoside analogue and uses thereof
WO2017019581A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Process for making phosphorus-containing nucleoside prodrug compounds
EP3133062A1 (en) 2015-08-19 2017-02-22 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of a pharmaceutical agent
WO2017029408A1 (en) 2015-08-20 2017-02-23 Ratiopharm Gmbh Solid state forms of sofosbuvir
CA2997170A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral tetrahydrofurane derivatives
AU2016323604A1 (en) 2015-09-16 2018-03-29 Gilead Sciences, Inc. Methods for treating Arenaviridae and Coronaviridae virus infections
CN108136033A (en) 2015-10-07 2018-06-08 桑多斯股份公司 Include the solid composite medicament of amorphous Suo Feibuwei
CN105461775B (en) * 2015-12-24 2018-03-13 江苏阿尔法药业有限公司 A kind of Suo Feibuwei preparation method
WO2017158624A1 (en) 2016-03-17 2017-09-21 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CN105669804B (en) * 2016-03-28 2018-08-17 南通常佑药业科技有限公司 The preparation method of Suo Feibuwei
WO2017184670A2 (en) * 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CZ2016257A3 (en) 2016-05-05 2017-11-15 Zentiva, K.S. The amorphous form of sofosbuvir, the method of its preparation and its stabilization
AU2017271990A1 (en) 2016-05-27 2018-11-29 Gilead Sciences, Inc. Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
BR102017011025A2 (en) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
KR20190038881A (en) 2016-08-12 2019-04-09 산도즈 아게 Solid pharmaceutical compositions comprising amorphous Sophos bubir
EP3500584A1 (en) 2016-08-19 2019-06-26 Sandoz AG Sofosbuvir derivatives for the treatment of hepatitis c
CN106432328B (en) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 A kind of preparation method of Suo Feibuwei intermediate
CN106432327A (en) * 2016-09-14 2017-02-22 江苏福瑞生物医药有限公司 Method for preparing sofosbuvir key intermediate
WO2018049534A1 (en) * 2016-09-16 2018-03-22 Lcb Pharma Inc. Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2' position and methods of use as a cardioprotective agent
WO2018093717A1 (en) * 2016-11-17 2018-05-24 Abbvie Inc. Compositions and methods for treating hcv infection
US20190276481A1 (en) * 2016-11-18 2019-09-12 Neurovive Pharmaceutical Ab Liver Prodrugs of Mitochondrial Proton Ionophores
RU2656228C9 (en) * 2017-06-13 2019-04-16 Олег Ростиславович Михайлов WEAKLY CRYSTALLISED β-MODIFICATION OF (S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)-(PHENOXY)PHOSPHORYLAMINO)PROPANOATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON
WO2019025600A1 (en) 2017-08-03 2019-02-07 Sandoz Ag Sofosbuvir hydrate
WO2019030387A1 (en) 2017-08-11 2019-02-14 Sandoz Ag Solid composition comprising amorphous sofosbuvir and amorphous daclatasvir
WO2019134971A1 (en) 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904453A (en) * 2007-03-30 2009-02-01 Pharmasset Inc Nucleoside phosphoramidate prodrugs

Family Cites Families (341)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007275A (en) 1933-01-09 1935-07-09 Elizabeth Q Kendall Ingot stripper
US2759300A (en) 1954-08-11 1956-08-21 Pest Control Ltd Method and means for introducing a predetermined amount of a poisonous material beneath the surface of the soil
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
NL8403224A (en) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxaphosphorinanes, the preparation thereof and the use for the splitting of optically active compounds.
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
JPH03501253A (en) 1987-09-22 1991-03-22
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5277914A (en) 1989-03-31 1994-01-11 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE69132332D1 (en) 1990-04-06 2000-08-24 Genelabs Tech Inc Hepatitis c-virus-epitope
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
JP3347723B2 (en) 1990-06-13 2002-11-20 グラツィエル,アーノルド Phosphorus-containing prodrugs
US6060080A (en) 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
JP2599492B2 (en) 1990-08-21 1997-04-09 第一製薬株式会社 Process for the preparation of a liposomal formulation
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
HU9202318D0 (en) 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (en) 1991-09-13 1994-05-21 Paul B Chretien
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
DE4200821A1 (en) 1992-01-15 1993-07-22 Bayer Ag A taste masked pharmaceutical agent
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5405598A (en) 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
JP3102945B2 (en) 1992-02-27 2000-10-23 キッコーマン株式会社 Hepatitis treatment agent
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5256798A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
DK0576231T3 (en) 1992-06-22 1997-08-25 Lilly Co Eli Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2, 2-difluoro-D-ribofuranosyl derivatives
CA2105112C (en) 1992-09-01 2005-08-02 Thomas C. Britton A process for anomerizing nucleosides
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
EP0686043B1 (en) 1993-02-24 1999-06-23 WANG, Jui, H. Compositions and methods of application of reactive antiviral polymers
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
AU701574B2 (en) 1993-05-12 1999-02-04 Karl Y. Hostetler Acyclovir derivatives for topical use
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US7375198B2 (en) 1993-10-26 2008-05-20 Affymetrix, Inc. Modified nucleic acid probes
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1995024185A1 (en) 1994-03-11 1995-09-14 Isis Pharmaceuticals, Inc. Novel pyrimidine nucleosides
DE4415539C2 (en) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Plants with virustatic and antiviral effects
CA2192950A1 (en) 1994-06-22 1995-12-28 Danny P.C. Mcgee Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
DE4432623A1 (en) 1994-09-14 1996-03-21 Huels Chemische Werke Ag A process for the bleaching of aqueous surfactant
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE19514523A1 (en) 1995-04-12 1996-10-17 Schering Ag New cytosine and cytidine derivatives
AT318896T (en) 1995-09-27 2006-03-15 Univ Emory Recombinant rna replicase of hepatitis c virus
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
EP0914421A2 (en) 1996-02-29 1999-05-12 Immusol,Inc. Hepatitis c virus ribozymes
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998016184A2 (en) 1996-10-16 1998-04-23 Icn Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
US6455690B1 (en) 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
PT1132393E (en) 1996-10-16 2003-08-29 Ribapharm Inc L-ribavirin and uses of the same
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
PT932617E (en) 1996-10-18 2002-06-28 Vertex Pharma Series protease inhibitors particularly protease ns3 hepatitis c virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
HU226110B1 (en) 1997-06-30 2008-04-28 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing and their use
ES2234144T3 (en) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogs of inhibiting peptides of hepatitis c.
ES2186660T3 (en) 1997-09-21 2003-05-16 Schering Corp Combination therapy to eradicate detectable HCV-RNA in patients with chronic hepatitis C infection.
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
EP1045897B1 (en) 1998-01-23 2002-01-30 Newbiotics Inc. Enzyme catalyzed therapeutic agents
JP2002504558A (en) 1998-02-25 2002-02-12 エモリー ユニバーシテイ 2'-fluoro nucleoside
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
CZ300540B6 (en) 1998-05-15 2009-06-10 Schering Corporation Pharmaceutical composition comprising ribavirin combined with alpha interferon for treating patients with chronic infection of hepatitis C of genotype 1
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
AT307597T (en) 1998-06-08 2005-11-15 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DE69925918T2 (en) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketic acid derivatives as polymerases inhibitors
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ES2579903T3 (en) 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
AU750738B2 (en) 1998-10-16 2002-07-25 Microbiopharm Japan Co., Ltd. Crystallization of doxorubicin hydrochloride
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
WO2000037110A2 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
AU5905400A (en) 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
PL354144A1 (en) 1999-07-30 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg 2-pyrazolin-5-ones
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CN1423654A (en) 1999-11-12 2003-06-11 法玛赛特有限公司 Synthesis of 2'-deoxy-L-nucleosides
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
AU3527801A (en) 2000-02-18 2001-08-27 Iaf Biochem Int Method for the treatment or prevention of flavivirus infections using nucleoside analogues
CA2404639A1 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
AU5549501A (en) 2000-04-20 2001-11-07 Schering Corp Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis infection
MY164523A (en) 2000-05-23 2017-12-29 Idenix (Cayman) Ltd Methods and compositions for treating hepatitis c virus
AU2001263484B2 (en) 2000-05-26 2006-12-14 Novartis Ag Methods of treating hepatitis delta virus infection with beta-l-2'- deoxy-nucleosides
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP5230052B2 (en) 2000-05-26 2013-07-10 イデニクス(ケイマン)リミテツド Methods and compositions for the treatment of flaviviruses and pestiviruses
FR2810322B1 (en) 2000-06-14 2006-11-10 Pasteur Institut COMBINATORY PRODUCTION OF NUCLEOTIDE AND NUCLEOTIDE ANALOGUES (XiTP)
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
AR034127A1 (en) 2000-07-21 2004-02-04 Schering Corp Imidazolidinones as inhibitors of NS3-serine protease of hepatitis C virus, pharmaceutical composition, a method for its preparation, and use thereof for the manufacture of a medicament
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (en) 2000-07-21 2003-07-16 Dendreon Corp New peptides as inhibitors of NS3-serine protease hepatitis c virus
IL153669D0 (en) 2000-07-21 2003-07-06 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
AR039558A1 (en) 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Compositions and method for treating glaucoma or ocular hypertension
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2002228749B2 (en) 2000-10-18 2008-04-24 Pharmasset Inc Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP1326594A2 (en) 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
BR0115447A (en) 2000-11-20 2005-10-18 Squibb Bristol Myers Co Hepatitis C Tripeptide Inhibitors
CN1301994C (en) 2000-12-12 2007-02-28 先灵公司 Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU3076302A (en) 2000-12-13 2002-06-24 Bristol Myers Squibb Pharma Co Inhibitors of hepatitis c virus ns3 protease
AU3076402A (en) 2000-12-13 2002-06-24 Bristol Myers Squibb Pharma Co Imidazolidinones and their related derivatives as hepatitis virus ns3 proteaseinhibitors
BR0116221A (en) 2000-12-15 2005-09-13 Pharmasset Ltd Antiviral agents for treatment of flaviviridae infections
PL207405B1 (en) 2001-01-22 2010-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
MY129350A (en) 2001-04-25 2007-03-30 Squibb Bristol Myers Co Aripiprazole oral solution
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
JP4455056B2 (en) 2001-07-11 2010-04-21 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cross-linked bicyclic serine protease inhibitor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
PL209765B1 (en) * 2001-08-14 2011-10-31 Toyama Chemical Co., Ltd. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
EP1432721A4 (en) 2001-09-13 2008-02-20 Squibb Bristol Myers Co Process for the preparation of rebeccamycin and analogs thereof
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
DE60221875T2 (en) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4- (6-low) heteroaryl acyl-pyrrolidine derivatives as hcv inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
GB0129945D0 (en) 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
BR0214944A (en) 2001-12-14 2005-06-07 Pharmasset Ltd N4-Acylcytosine Nucleosides for the Treatment of Viral Infections
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
JP2005514401A (en) 2001-12-21 2005-05-19 マイクロロジックス バイオテック,インコーポレイテッドMicrologix Biotech,Inc Antiviral 7-deaza l- nucleoside
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2002341942A1 (en) * 2002-01-17 2003-09-02 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
US7070801B2 (en) 2002-01-30 2006-07-04 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
JP2005524662A (en) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド 5'-monophosphate mimetics and prodrugs thereof
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
EA200401437A1 (en) 2002-04-26 2005-04-28 Джилид Сайэнс, Инк. Nucleoside reverse transcriptase inhibitors for treatment of HIV infection, PROCESS FOR THEIR PREPARATION (VARIANTS) AND A METHOD OF INCREASING half-life of non-nucleoside compounds active against retroviruses, and methods of preparing a pharmaceutical composition having specificity for leukocytes
US20040014108A1 (en) 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
ES2304511T3 (en) 2002-06-04 2008-10-16 Schering Corporation Pirazolo compounds (1,5-a) pyrimidine as antiviral agents.
CA2488611C (en) 2002-06-07 2011-11-15 Kylix, B.V. Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
AU2003251524A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
WO2004000858A2 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1572945A2 (en) 2002-06-27 2005-09-14 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
KR20050035194A (en) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AP200503211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2469569T3 (en) 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. 2 'and 3' modified nucleoside prodrugs for the treatment of Flaviviridae infections
CA2490950A1 (en) 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
US6973905B2 (en) 2002-07-01 2005-12-13 Cinetic Automation Corporation Valve lash adjustment apparatus and method
US7041690B2 (en) 2002-07-01 2006-05-09 Pharmacia & Upjohn Company, Llc Inhibitors of HCV NS5B polymerase
US20060264389A1 (en) 2002-07-16 2006-11-23 Balkrishen Bhat Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7323449B2 (en) 2002-07-24 2008-01-29 Merck & Co., Inc. Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1572709A3 (en) 2002-07-24 2005-11-23 PTC Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004011478A2 (en) 2002-07-25 2004-02-05 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
KR100855907B1 (en) 2002-09-13 2008-09-02 노파르티스 아게 BETA;-L-2'-Deoxynucleosides for the treatment of resistant HBV strains and combination therapies
CA2501547A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2003290584B2 (en) 2002-11-01 2009-07-16 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP2319853B1 (en) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
PL378368A1 (en) 2003-01-14 2006-04-03 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
CN101415719A (en) 2003-03-20 2009-04-22 微生物化学及药品有限公司 Methods of manufacture of 2 -deoxy-beta-L-nucleosides
JP4733023B2 (en) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Macrocyclic isoquinoline peptide inhibitor of hepatitis C virus
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
AU2004233989A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
EA200501676A1 (en) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Phosphonate-containing kinase inhibitors (options), method for their receiving, pharmaceutical composition, pharmaceutical form on their basis and method for inhibing kinase in molopytic treatment them
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
MXPA05011297A (en) 2003-04-25 2006-05-25 Gilead Sciences Inc Antiviral phosphonate analogs.
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP2345661A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005007810A2 (en) 2003-06-16 2005-01-27 Grinstaff Mark W Functional synthetic molecules and macromolecules for gene delivery
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE602004028841D1 (en) 2003-07-25 2010-10-07 Centre Nat Rech Scient Purin nucleoside for the treatment of flavividraic diseases, including hepatitis c
KR20060123707A (en) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 Novel trinucleosides or nucleotides as therapeutic agents
AR045769A1 (en) 2003-09-18 2005-11-09 Vertex Pharma Serine protease inhibitors, particularly the NS3-NS4A protease of HCV (hepatitis C virus)
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
BRPI0415373A (en) 2003-10-14 2006-12-12 Intermune Inc macrocyclic carboxylic acids and acylsulfonamides as hcv replication inhibitors
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
JP2007519734A (en) 2004-01-28 2007-07-19 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Aminocyclopentylpyridopyrazinone chemokine receptor activity modulator
CA2557075A1 (en) 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf Methylation inhibitor compounds
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
EA012389B1 (en) 2004-03-30 2009-10-30 Интермун, Инк. Macrocyclic compounds as inhibitors of viral replication
GB0408995D0 (en) 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
EP1912643A2 (en) 2004-06-23 2008-04-23 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
EP1773355B1 (en) 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7217523B2 (en) 2004-07-02 2007-05-15 Regents Of The University Of Minnesota Nucleoside phosphoramidates and nucleoside phosphoramidases
MX2007000803A (en) 2004-07-21 2007-04-02 Pharmasset Inc Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives.
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
RS58600B1 (en) 2004-07-27 2019-05-31 Gilead Sciences Inc Phosphonate analogs of hiv inhibitor compounds
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1794172B1 (en) 2004-08-23 2009-07-15 F.Hoffmann-La Roche Ag Antiviral 4'-azido-nucleosides
WO2006021340A1 (en) 2004-08-23 2006-03-02 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
RU2433124C2 (en) 2004-09-14 2011-11-10 Фармассет, Инк. Methods of producing 2'-fluoro-2'-alkyl-substituted or other substituted ribofuranosyl pyrimidines and purines and derivatives thereof
KR20070073805A (en) 2004-09-24 2007-07-10 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄 (쎄엔알에스) Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
JP5046942B2 (en) 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズTibotec Pharmaceuticals HCV-inhibiting bicyclic pyrimidines
US20080280842A1 (en) 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
KR20070100237A (en) 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Therapeutic furopyrimidines and thienopyrimidines
JP2008523082A (en) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Nucleotides having antibacterial and anticancer activities
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
WO2006093986A1 (en) 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside prodrugs for treating viral infections
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
AR056347A1 (en) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Use of pteridine compounds for producing medicaments and pharmaceutical compositions
AR054122A1 (en) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pyrido [2,3-d] pyrimides useful as HCV inhibitors, and methods for preparation thereof
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
US20060293752A1 (en) 2005-06-27 2006-12-28 Missoum Moumene Intervertebral disc prosthesis and associated methods
BRPI0613962A2 (en) 2005-07-25 2009-03-24 Intermune Inc innovative macrocyclic hepatitis c virus replication inhibitors
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
CN101273030B (en) 2005-07-29 2012-07-18 泰博特克药品有限公司 Macrocyclic inhibitors of hepatitis C virus
WO2007013047A2 (en) 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
DE602006019883D1 (en) 2005-07-29 2011-03-10 Medivir Ab Macrocyclic inhibitors of hepatitis c virus
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
ES2389964T3 (en) 2005-07-29 2012-11-05 Janssen R&D Ireland Hepatitis C virus macrocyclic inhibitors
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab Macrocyclic compounds as inhibitors of hepatitis C virus
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0519488D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
CN101331116A (en) 2005-12-12 2008-12-24 健亚生物科技公司 N-(6-membered aromatic ring)-amido anti-viral compounds
AT541844T (en) 2005-12-21 2012-02-15 Abbott Lab Antiviral connections
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7879815B2 (en) 2006-02-14 2011-02-01 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ES2374455T3 (en) 2006-02-17 2012-02-16 Pfizer Limited Derivatives of 3-deazapurinza as modulators of tlr7.
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007140254A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
PT2487165T (en) 2006-07-07 2016-11-18 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
US20080014228A1 (en) 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
EP1881001A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
JP5252459B2 (en) 2006-10-10 2013-07-31 ギリアド ファーマセット エルエルシー Preparation of ribofuranosylpyrimidine nucleosides
PL216525B1 (en) 2006-10-17 2014-04-30 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk 5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN101108870A (en) 2007-08-03 2008-01-23 冷一欣 Process for preparation of nucleoside phosphoric acid ester compound and application thereof
US20100256098A1 (en) 2007-08-31 2010-10-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2009142822A2 (en) 2008-03-26 2009-11-26 Alnylam Pharmaceuticals, Inc. 2-f modified rna interference agents
CA2722308A1 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
ES2398684T3 (en) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Carbanucleoside analogues for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011000060A (en) 2008-07-10 2011-02-22 Prosidion Ltd Piperidinyl gpcr agonists.
ES2435799T3 (en) 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis C virus by combining a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
EA019341B1 (en) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
US20100227801A1 (en) 2009-01-07 2010-09-09 Scynexis, Inc. Pharmaceutical compositions
KR20110120886A (en) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
PL2609923T4 (en) * 2010-03-31 2017-11-30 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
LT2480552T (en) 2009-09-21 2017-02-10 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2552931B1 (en) * 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130109647A1 (en) 2011-10-31 2013-05-02 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904453A (en) * 2007-03-30 2009-02-01 Pharmasset Inc Nucleoside phosphoramidate prodrugs

Also Published As

Publication number Publication date
EA028742B1 (en) 2017-12-29
JP2012527477A (en) 2012-11-08
CN105198949A (en) 2015-12-30
EP2910562A1 (en) 2015-08-26
PH12014502684B1 (en) 2016-02-10
EP2913337A1 (en) 2015-09-02
EP2913337B1 (en) 2017-09-06
PH12015502237B1 (en) 2016-11-14
EA201370186A1 (en) 2015-02-27
KR20120034662A (en) 2012-04-12
US9206217B2 (en) 2015-12-08
CA2915187A1 (en) 2010-11-25
EP2432792A1 (en) 2012-03-28
HK1213572A1 (en) 2016-07-08
SG176197A1 (en) 2011-12-29
US20130165644A1 (en) 2013-06-27
HRP20160958T1 (en) 2016-10-07
CY1118045T1 (en) 2017-05-17
CN102459299A (en) 2012-05-16
CA2915187C (en) 2018-01-23
SG10201500835WA (en) 2015-04-29
DK2432792T3 (en) 2016-10-03
IL239115A (en) 2016-07-31
PT2913337T (en) 2017-11-28
WO2010135569A1 (en) 2010-11-25
KR20140147144A (en) 2014-12-29
CO6470789A2 (en) 2012-06-29
US20100298257A1 (en) 2010-11-25
TWI576352B (en) 2017-04-01
CA2763151A1 (en) 2010-11-25
HUE031637T2 (en) 2017-07-28
US8629263B2 (en) 2014-01-14
NZ596635A (en) 2014-05-30
JP2016053045A (en) 2016-04-14
SG10201702294QA (en) 2017-05-30
JP2015028060A (en) 2015-02-12
US8633309B2 (en) 2014-01-21
HK1213571A1 (en) 2016-07-08
AU2010249481B2 (en) 2015-01-22
IL216492A (en) 2015-06-30
EA201171417A1 (en) 2012-05-30
TW201704249A (en) 2017-02-01
IL237471D0 (en) 2015-04-30
EP2610264A3 (en) 2014-01-22
MX2011012417A (en) 2012-01-25
CA2819700C (en) 2016-03-22
US20130165401A1 (en) 2013-06-27
JP6355605B2 (en) 2018-07-11
HK1219106A1 (en) 2017-03-24
CA2988217A1 (en) 2010-11-25
EA026731B1 (en) 2017-05-31
TW201107341A (en) 2011-03-01
PH12015502237A1 (en) 2016-11-14
ES2648803T3 (en) 2018-01-08
SI2432792T1 (en) 2016-09-30
CN105085592A (en) 2015-11-25
NZ709926A (en) 2016-11-25
LT2432792T (en) 2016-09-26
AU2010249481A1 (en) 2011-12-15
US20130137654A1 (en) 2013-05-30
TW201518313A (en) 2015-05-16
EP2432792B1 (en) 2016-07-06
EP2610264A2 (en) 2013-07-03
AR082937A1 (en) 2013-01-23
CL2010000520A1 (en) 2011-05-06
CA2819700A1 (en) 2010-11-25
US9637512B2 (en) 2017-05-02
CN104292256A (en) 2015-01-21
IL239115D0 (en) 2015-07-30
KR20150043553A (en) 2015-04-22
KR101603817B1 (en) 2016-03-16
IL216492D0 (en) 2012-01-31
PL2432792T3 (en) 2017-06-30
US20140121366A1 (en) 2014-05-01
SMT201600316B (en) 2016-11-10
EA028709B1 (en) 2017-12-29
PT2432792T (en) 2016-08-18
IL237471A (en) 2016-10-31
BRPI1012781A2 (en) 2016-07-12
JP5909535B2 (en) 2016-04-26
EA201592101A1 (en) 2016-05-31
US8642756B2 (en) 2014-02-04
HK1169414A1 (en) 2016-07-29
TWI598358B (en) 2017-09-11
ZA201108749B (en) 2013-05-29
PH12014502684A1 (en) 2016-02-10
SG10201708263SA (en) 2017-11-29
JP5885659B2 (en) 2016-03-15
CN102459299B (en) 2015-09-30
ES2586821T3 (en) 2016-10-19
KR101599183B1 (en) 2016-03-03
US20180044367A1 (en) 2018-02-15
NZ623602A (en) 2015-10-30
EP3321275A1 (en) 2018-05-16
HK1217494A1 (en) 2017-01-13

Similar Documents

Publication Publication Date Title
JP5492785B2 (en) 2 &#39;, 4&#39;-substituted nucleosides as antiviral agents
DE60217465T2 (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CA2804375C (en) Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
TWI357332B (en) Nucleoside phosphoramidate prodrugs
TWI412368B (en) Compounds and pharmaceutical compositions for the treatment of viral infections
EP1758453B1 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
ES2726998T3 (en) Modified fluorinated nucleoside analogs
ES2708570T3 (en) Chemical compounds
US7323449B2 (en) Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2009329872B2 (en) Synthesis of purine nucleosides
US20040186283A1 (en) Synthesis of 5-azacytidine
CA2794671C (en) Stereoselective synthesis of phosphorus containing actives
EP1284741B1 (en) 3&#39;-or 2&#39;-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
US20060264389A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20120052046A1 (en) Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections
CN100434079C (en) Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
JP5271913B2 (en) Compound
KR20110115601A (en) Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
EP1928475B1 (en) Antiviral phosphoramidates of 4&#39;-c-azido-substituted pronucleotides
US20040266996A1 (en) Methods of manufacture of 2&#39;-deoxy-beta-L-nucleosides
JP5080973B2 (en) Nucleoside aryl phosphoramidates for treating RNA-dependent RNA virus infection
ES2536727T3 (en) nucleoside cyclophosphates
US20040002476A1 (en) Modified fluorinated nucleoside analogues
ES2623016T3 (en) 6-O-substituted 2-amino purine nucleoside phosphoramidates
EP2120565B1 (en) Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection